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Abstract  
Introduction 
According to the World Health Organisation, antimicrobial resistance (AMR) is one of 
the major threats to human health in the twenty-first century. Many of the advances of 
modern medicine, such as cancer treatments and complex surgeries, are being threatened 
by the development of AMR. Antimicrobial overuse has been associated with the 
development of AMR. This has resulted in a situation where previously treatable 
infections can now become life-threatening. To address these risks, antimicrobial 
stewardship (AMS) has been developed as an important strategy for improving the use of 
antimicrobials. AMS aims to improve patient outcomes, reduce adverse effects, and 
alleviate AMR. Most of the available literature on AMS has been derived from single site, 
metropolitan teaching hospitals with on-site infectious diseases, pharmacy and 
microbiology support. There remains an evidence gap for AMS strategies that are 
applicable to non-metropolitan and multisite hospital settings.  
 
The aims of this thesis were threefold: (1) to develop and evaluate educational strategies 
for improving antimicrobial use in different clinical settings, such as infection prevention, 
treatment of infection, and side effects of antimicrobial use; (2) to develop methods for 
AMS education and evaluation that are applicable to non-metropolitan and multisite 
settings, and; (3) to develop, apply and evaluate technology in AMS, including the role of 
clinical decision support software and innovative educational tools such as interactive e-
learning for health professional education.  
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Methods 
This research project consisted of a series of interconnected studies that addressed AMS 
education and evaluation strategies at the individual, departmental, hospital and health 
district level. Quantitative and qualitative approaches were used to evaluate the impact of 
the interventions. A focus was placed on measurement of patient outcomes related to 
antimicrobial use, such as length of hospital stay, readmission rate and mortality. An 
interactive e-learning tool for health professional education on the antibiotic vancomycin 
was also developed and evaluated. 
 
Results 
Improvements in antimicrobial use supported by timely audit and feedback methods were 
demonstrated, without evident harm to patients. Those included discontinuation of the 
antibiotic gentamicin for prophylaxis around hip and knee replacement surgeries, a 
reduction in the duration of therapy for community-acquired pneumonia, and a reduction 
in broad spectrum antimicrobial use across multiple hospitals sites resulting from 
implementation of AMS. A clinical decision support system was shown to be a successful 
tool for supporting implementation of AMS across multiple sites. A novel web-based e-
learning tool that adopted serious game design concepts was also developed for education 
of health professionals. Successful change to the culture of antimicrobial use from the 
individual to the health district level was demonstrated. 
 
Discussion 
The results suggest that educational strategies, supported by technology and antimicrobial 
restriction, can be effective in improving antimicrobial use in a network of hospitals with 
17 
 
disparate geography and resources. The application of similar techniques across different 
settings created economies of scale, which allowed support of smaller sites by larger, 
better resourced hospitals. Future research aims to demonstrate the effect of changes to 
antimicrobial use patterns on AMR, and to further elaborate novel educational strategies 
for improving antimicrobial use. 
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List of key acronyms and definitions 
 
ACSQHC Australian Commission on Safety and Quality in Health Care 
AIHW Australian Institute for Health and Welfare 
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AMO Attending medical officer 
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AMS Antimicrobial stewardship 
ASP Antimicrobial stewardship program 
AU$ Australian dollar 
CAP Community-acquired pneumonia 
CDI Clostridium difficile infection 
CDSS (Computerised) Clinical decision support system 
CI Confidence interval 
COPD Chronic obstructive pulmonary disease 
CORB Confusion, oxygen saturation, respiratory rate, blood pressure 
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CNS Central nervous system 
DDD Defined daily dose 
DRG Diagnosis-related group 
ED Emergency Department 
eMR Electronic medical record 
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1 General introduction  
1.1 Preamble 
The World Health Organisation (WHO) has described antimicrobial resistance (AMR) as 
one of the main threats to human health in the twenty-first century (World Health 
Organisation, 2014). Governments around the world have recognised that an international 
effort is required to curb AMR, whereby overuse of antimicrobials has led to a situation 
where previously treatable infections can now become life-threatening. In Australia, 
management of infections in hospitals forms a key component of the strategy for 
addressing AMR (Australian Government, 2015). In 2010, the first edition of 
Antimicrobial Stewardship in Australian Hospitals was published by the Australian 
Commission on Safety and Quality in Health Care (ACSQHC), which offered a 
framework for improving the treatment and prevention of infections through more 
judicious use of antimicrobials (Duguid and Cruickshank, 2010).  
 
This introductory chapter provides a brief background on strategies for improving 
antimicrobial use, with a focus on evaluating strategies for education at the individual, 
department, hospital and health district level. It identifies that there is limited published 
evidence for these strategies in the non-metropolitan setting where health care facilities 
experience geographic and resource disparities. The specific aims of the research and an 
outline of the thesis structure are also provided. 
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1.2 Background 
Antimicrobial stewardship (AMS), or antibiotic stewardship, is defined as a set of 
strategies intended to improve the use of antimicrobials (Duguid and Cruickshank, 2010). 
Antimicrobial stewardship programs (ASPs) are a required component for accreditation 
according to ACSQHC standards, which have been introduced to drive safety and quality 
in public and private health care organisations in Australia (Australian Commission on 
Safety and Quality in Health Care, 2011). ASPs are implemented with the goals of 
treating and preventing infections more effectively, while curbing AMR and reducing 
adverse outcomes for patients (Ashiru-Oredope et al., 2012). Previously reported patient-
related outcome measures used to evaluate AMS include mortality, length of hospital stay 
(LOS) and readmission rates (Khadem et al., 2012). Various approaches for establishing, 
maintaining and measuring the success of ASPs include: implementation of clinical 
guidelines; formulary restriction and approval systems; education on appropriate 
prescribing of antimicrobials; and audit with intervention and feedback to the prescriber 
(Dellit et al., 2007; Duguid and Cruickshank, 2010). 
 
High rates of inappropriate antimicrobial prescribing in Australian hospitals have been 
described in the literature (Robertson et al., 1999; Robertson et al., 2002; Radford et al., 
1999; To et al., 1999). Improving appropriateness of prescribing according to accepted 
antimicrobial guidelines is a key strategy for ASPs (Dellit et al., 2007). Furthermore, 
ASPs have been effective in reducing AMR in selected settings (Yong et al., 2010; 
Khadem et al., 2012). Organisms commonly targeted as part of these programs include 
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methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci 
(VRE) and multidrug resistant Gram-negative species (Khadem et al., 2012). 
 
Improvements in the quality of antimicrobial prescribing have been associated with: 
improved cure rates, reduced adverse events, Clostridium difficile infection (CDI), 
reduced LOS and reduced infection-related mortality (Davey et al., 2013). Some ASPs 
have demonstrated reduced costs without causing harm to patients (Dellit et al., 2007; 
Carling et al., 2003). A common limitation of many AMS studies is their uncontrolled 
before-and-after design, with some studies not accounting for external factors such as 
changes in drug-acquisition costs and infection control practices (Vettese et al., 2013; 
McGowan, 2012). To compensate for the potential methodological shortcomings of 
pragmatic clinical research, interrupted time series (ITS) analysis, or analysis of change in 
trend attributable to an intervention, has been used as an effective evaluation tool (van 
Kasteren et al., 2005).  
1.3 Evaluating educational strategies 
A number of methods have been developed for improving antimicrobial prescribing. A 
Cochrane review of interventions to improve antimicrobial prescribing for hospital 
inpatients categorised interventions into three groups: persuasive (or educational), 
restrictive and structural (Davey et al., 2013). Examples of persuasive interventions 
include printed educational material, reminders, audit and feedback, and educational 
outreach in the form of academic detailing and recommending change. Restrictive 
interventions include compulsory order forms, requirement for expert approval, stock 
restriction (removal of antimicrobials from clinical areas), and “review and make change” 
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strategies. Restrictive interventions have demonstrated greater initial effects on 
antimicrobial use whereas educational interventions may be more durable over time. 
Structural interventions include computerised clinical decision support systems (CDSSs) 
and introduction of quality monitoring mechanisms (Davey et al., 2013). The updated 
Cochrane review by Davey and colleagues (2017) identifies “enabling” interventions as 
audit and feedback, educational outreach and reminders. Evaluation of educational 
interventions forms the main theoretical framework for this research, whereby education 
is supported by restrictive and structural interventions. 
 
When developing educational AMS strategies, it is necessary to recognise concepts such 
as medical hierarchy, targeting of opinion leaders and unwillingness of prescribers to alter 
prescriptions started by medical colleagues (Charani et al., 2011). Study designs for 
improving antimicrobial use should include multiple quality improvement methods, 
developing an understanding of the target audience’s motivations (Charani et al., 2011; 
Gaynes et al., 2009; Antoine et al., 2006). It is also necessary to recognise differences in 
learning styles between junior and senior medical staff (Gaynes et al., 2009). Prospective 
audit with educational feedback is an important component of AMS education (Duguid 
and Cruickshank, 2010). Timely feedback allows for meaningful changes to the therapy 
of the individual patient, in addition to providing quality improvement data (Griffith et 
al., 2012).  
 
It has been proposed that a strategy for health care quality improvement should include 
the following: measurement that is practical and goal-oriented; gathering baseline data on 
small numbers initially  and checking findings; improving the delivery process while 
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gathering data; and following these up with graphical representation of data and 
measurement of key outcomes over time (Nelson et al., 1998). Emphasis on usefulness 
rather than perfection is readily applicable to AMS methodology as the focus should be 
on making measurable improvements to processes and outcomes that are relevant to 
patient care. Outcome measures for ASPs should include balancing measures, or 
unintended consequences of changes to antimicrobial use (Davey et al., 2013; Davey et 
al., 2017).  
 
This research project employs a series of Plan-Do-Study-Act (PDSA) cycles as a 
pragmatic methodological approach to improving antimicrobial prescribing practices 
(National Health Service Institute for Innovation and Improvement, 2008). ITS analysis is 
used as a pragmatic quasi-experimental technique to evaluate the impact of AMS 
interventions (Fowler et al., 2007), where the immediate clinical need for change may 
hamper the application of more robust research methodologies. 
1.4 Rural and regional hospitals 
Much of the literature supporting AMS has been produced in metropolitan teaching 
hospitals with on-site access to infectious diseases (ID), microbiology and pharmacy 
expertise (Dellit et al., 2007). There is little primary evidence on ASPs in small, rural or 
regional hospitals. Approaches to AMS in those settings have included education, clinical 
review, and implementation of clinical guidelines (LaRocco, 2003). Antimicrobial 
restriction has typically been reported in response to infection outbreaks such as CDI 
(Kuntz et al., 2007; Schabas et al., 2012). Barriers to successful implementation and 
evaluation of ASPs in those sites include a lack of human resources for education and 
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research, large distances from AMS experts and microbiology laboratories, and the 
potential for small numbers to limit conclusions about any interventions. It is necessary 
for hospitals to tailor approaches to their specific needs and level of resources (Patel, 
2010). Of the 1345 hospitals in Australia, 753 are public hospitals, comprising 80 
principal referral hospitals, 40 large hospitals and 589 hospitals defined as medium-sized 
or smaller (Australian Institute of Health and Welfare, 2013). With such a large number 
of smaller Australian hospitals, there is a need to address the evidence gap on pragmatic 
approaches to improving antimicrobial use in these settings. 
1.5 Use of technology to support AMS education  
Use of computerised clinical decision support systems (CDSSs) 
CDSSs are software tools that bring together patient-specific data and knowledge bases 
(Thursky, 2006). In the setting of AMS, this commonly refers to provision of evidence-
based guidelines for selection and dosing of antimicrobials for a specific infection. As 
prescribing is a complex task that involves integrating information (often incomplete) 
from a variety of sources, and potential time pressure, a CDSS may be employed to 
reduce the cognitive effort required to prescribe (Sintchenko and Coiera, 2003). A CDSS 
also offers improved potential for education through provision of links to guidelines, and 
improved monitoring and reporting of antimicrobial use (Baysari et al., 2016). 
 
Use of email as a communication strategy in clinical research 
Given the geographic disparity of some hospital locations within the health districts 
studied (Australian Institute of Health and Welfare, 2016), provision of timely clinical 
audit feedback using face-to-face methods can be challenging. Email is described as a 
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tool to report research findings at an individual and department level, and to provide links 
to knowledge and attitude surveys. However, low response rates have been reported in the 
literature, with lack of time and survey burden described as the main reasons for non-
response (Cunningham et al., 2015). An investigation into the utility of email as a 
communication method for clinical quality improvement is explored in this research 
project. 
 
Novel strategies for health professional education 
The use of internet-based learning (IBL), or web-based learning, for health professional 
education is an emerging field (Cook et al., 2008). As an educational approach, IBL can 
overcome some of the barriers that are experienced by traditional educational methods, 
such as increased clinical demands preventing face-to-face teaching (Cook et al., 2010). 
Web-based e-learning tools that adopt serious game concepts such as interactivity and 
entertainment have the potential to improve health professional education (Graafland et 
al., 2012). In AMS, smartphone availability may also drive novel educational approaches 
for health professionals (Goff, 2012). Novel IBL approaches also provide opportunities 
for AMS research. 
1.6 Aims 
This research project aims to contribute new knowledge regarding the best methods of 
education and evaluation to improve antimicrobial use in a multisite hospital setting, and 
to inform future AMS research. 
The specific aims of this research are:   
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1. To develop and evaluate educational strategies for improving antimicrobial use in 
different clinical settings: 
 prevention of infection (surgical prophylaxis; Chapter 2) 
 treatment of infection (community-acquired pneumonia [CAP]; Chapter 3) 
 adverse effects of antimicrobial overuse (CDI; Chapters 4 and 5) 
 dosing, administration and therapeutic drug monitoring (TDM; 
vancomycin; Chapters 6 and 7) 
2. To develop methods for AMS education and evaluation that are applicable to non-
metropolitan and multisite settings, including: 
 use of timely audit and feedback (Chapters 2, 3 and 4) 
 appropriate evaluation of outcome measures such as mortality, LOS, 
duration of therapy, and health costs (Chapters 3, 4 and 5)  
 use of ITS methodology for evaluation of AMS research (Chapters 4 and 
5) 
3. To develop, apply and evaluate technology for improving antimicrobial use, 
including: 
 the role of a CDSS as a tool for implementing an ASP and supporting 
quality improvement initiatives (Chapters 3, 4 and 5) 
 the utility of email as a method of feedback and education for clinicians 
(Chapters 2, 3, 4 and 7) 
 innovative methods for health professional education such as a web-based 
e-learning tool (Chapters 6 and 7) 
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1.7 Structure of the thesis  
This thesis has been prepared in the format of journal article compilation. This was 
considered to be the most appropriate style for the thesis content due to the common 
education and evaluation themes between chapters. Chapters 2 through 7 comprise six 
articles; five have been published or are in press, one has been submitted for editorial 
review. Although the articles are formatted according to the guidelines of each journal, 
the referencing style has been changed to Harvard style for consistency throughout the 
thesis, with references placed at the end of each chapter. In order to enhance the 
coherence of this thesis by compilation, a brief summary of each chapter is provided 
below. 
 
Chapter 2 reports on an initiative to improve antimicrobial use for prevention of 
infections related to prosthetic hip and knee replacements. Quality improvement 
methodology is employed, using the combination of departmental education with timely 
audit and feedback to individual prescribers. Use of email to overcome communication 
barriers with senior doctors is described. The article was written by the candidate with co-
authors Craig Boutlis, Stuart Jansen and Spiros Miyakis, and was published in the 
Australian New Zealand Journal of Surgery (Bond et al., 2016a). 
 
Chapter 3 provides a model for improving the antimicrobial treatment  of community-
acquired pneumonia (CAP), one of the most common and serious infections. A similar 
educational framework as used in Chapter 2 is described, including the use of timely 
email feedback of audit results. Education for decision makers (senior medical staff) and 
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at the departmental level on appropriate use of antimicrobials was central to the 
improvement methodology. The CDSS was used as a tool to assist the data collection 
process. The article was written by the candidate with co-authors Craig Boutlis, Wilf Yeo 
and Spiros Miyakis, and was published as a brief communication in Internal Medicine 
Journal in 2017 (in press) (Bond et al., 2017a).  
 
Chapter 4 describes a research project on an adverse effect from inappropriate 
antimicrobial use, CDI. A multisite methodology for reducing inappropriate use of 
causative antimicrobials is described, including use of timely email feedback to senior 
clinicians and a CDSS for monitoring of antimicrobial use. The chapter also reports 
hospital costs and LOS as key AMS outcome measures. The article was written by the 
candidate with co-authors Craig Boutlis, Wilf Yeo, William Pratt, Megan Orr, and Spiros 
Miyakis. It was published in the Journal of Hospital Infection in 2016 (Epub ahead of 
print) (Bond et al., 2016b). 
 
Chapter 5 provides an overview of implementation and evaluation of an ASP across 
multiple hospital sites, with antimicrobial use, CDI, antimicrobial costs, LOS and 
mortality as indicators of improvement. Hospitals from two health districts and a 
specialist children’s hospital are included in the report. A centrally deployed CDSS and 
various educational strategies are explored as tools for implementing and evaluating a 
multisite ASP across hospitals with varying resources, including those in regional and 
rural areas. The article was written by the candidate with co-authors Adriana Chubaty, 
Suman Adhikari, Spiros Miyakis, Craig Boutlis, Wilf Yeo, Marijka Batterham, Cara 
Dickson, Brendan McMullan, Mona Mostaghim, Samantha Li-Yan Hui, Kate Clezy, and 
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Pamela Konecny. The article was published in the Journal of Antimicrobial 
Chemotherapy in 2017 (in press) (Bond et al., 2017b). 
 
Chapter 6 reports on the design and implementation of a novel web-based e-learning tool 
for health professional education on antimicrobial use. The specific antimicrobial tested is 
vancomycin, used for treatment of serious infections caused by MRSA. The Vancomycin 
Interactive (VI) is proposed as a useful approach where the multiple hospitals within a 
health district are spread across a large geographic area, thereby addressing a barrier to 
ongoing education. Through its hosting on an open website, the game can also be easily 
used in smaller rural and regional hospitals. Qualitative survey methodology is employed 
to report on knowledge and attitudes related to the intervention. The article was written 
by the candidate with co-authors Shelley Crowther, Suman Adhikari, Adriana Chubaty, 
Ping Yu, Jay Borchard, Craig Boutlis, Wilf Yeo, and Spiros Miyakis. The article was 
published in Journal of Medical Internet Research in 2017 (in press) (Bond et al., 2017c). 
 
Chapter 7 further explores the use of the VI for health professional education, through 
comparison with a standard email intervention. As in Chapters 3, 4 and 5, the CDSS is 
used to support evaluation of the initiative. Further research on evaluation of the e-
learning tool is also described. The article was written by the candidate with co-authors 
Shelley Crowther, Suman Adhikari, Adriana Chubaty, Ping Yu, Jay Borchard, Craig 
Boutlis, Wilf Yeo, and Spiros Miyakis. The article was under review in Journal of 
Medical Internet Research: Medical Education in March 2017. 
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Chapter 8 provides a summary of project findings followed by a discussion on the 
implications, strengths and limitations of the research. Suggestions for future research and 
thesis conclusions are also presented. 
 
A full list of collaborators, their roles and areas of expertise are provided in Table 1.1 
below. 
Table 1.1: Research collaborators for this thesis 
Research 
collaborator 
Site Position Areas of expertise 
Wilf Yeo Wollongong 
Hospital; 
UOW 
Professor of Medicine; 
thesis supervisor 
Research planning, 
data analysis, critical 
review 
Craig Boutlis Wollongong 
Hospital; 
UOW 
ID physician;  
thesis supervisor 
AMS, data collection 
and analysis, 
scientific writing 
Spiros Miyakis Wollongong 
Hospital; 
UOW 
ID physician; 
Associate Professor of 
Medicine; thesis 
supervisor 
AMS, research 
planning, manuscript 
review and 
submission 
Stuart Jansen Wollongong 
Hospital 
Wollongong Hospital 
Orthopaedic surgeon 
Project 
implementation, 
manuscript review 
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William Pratt Shoalhaven 
Hospitals; 
UOW 
General/ ID physician; 
health district lead for 
AMS 
AMS, project design 
and implementation, 
manuscript review 
Megan Orr Shoalhaven 
Hospitals 
AMS pharmacist AMS, data collection, 
manuscript review 
Adriana Chubaty Prince of 
Wales 
Hospital 
AMS pharmacist AMS, project design, 
data collection and 
analysis, manuscript 
review 
Suman Adhikari St George 
Hospital 
AMS pharmacist AMS, data collection 
and review, project 
implementation; 
critical review 
Marijka Batterham UOW Associate Professor of 
applied statistics 
Project design, 
statistics 
Cara Dickson St George 
Hospital 
Performance analyst Data collection and 
analysis 
Brendan McMullan Sydney 
Children’s 
Hospital 
Paediatric ID 
physician 
AMS, project 
implementation, 
manuscript review 
Mona Mostaghim Sydney 
Children’s 
Hospital 
Paediatric AMS 
pharmacist 
AMS, project 
implementation, 
manuscript review 
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Samantha Li-Yan 
Hui 
Prince of 
Wales 
Hospital 
CDSS administrator 
pharmacist 
AMS, CDSS support, 
coordination of data 
collection 
Kate Clezy Prince of 
Wales 
Hospital 
ID physician AMS, project design 
and implementation, 
manuscript review 
Pamela Konecny St George 
Hospital 
ID physician AMS, literature 
review, manuscript 
review 
Shelley Crowther Wollongong 
Hospital 
District educator 
pharmacist 
Survey design, project 
design and 
implementation, 
manuscript review 
Ping Yu UOW Associate Professor of 
Health Informatics 
Survey design, study 
design, manuscript 
review 
Jay Borchard Wollongong 
Hospital 
Clinical researcher Statistical analysis, 
manuscript review 
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2 Discontinuation of peri-operative gentamicin use for 
indwelling urinary catheter manipulation in orthopaedic 
surgery 
Article published in ANZ Journal of Surgery (2016). 
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surgery’, ANZ Journal of Surgery, doi: 10.1111/ans.13642 (Epub ahead of print). 
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2.1 Summary statement 
This chapter offers a model for improving antimicrobial use related to prevention of 
infection around orthopaedic surgery. Educational themes explored as part of this project 
include: use of timely audit and feedback, departmental education with subsequent 
reporting of post-intervention results by email, and tailoring of an educational strategy to 
senior surgical staff through the use of peer education. Those themes are further explored 
in Chapters 3 and 4. 
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2.2 Abstract 
2.2.1 Background 
Gentamicin has historically been used prior to insertion and removal of indwelling 
urinary catheters (IDCs) around elective joint replacement surgery to prevent infection; 
however, this indication is not recognised in the Australian Therapeutic Guidelines: 
Antibiotic and the paradigm for safe use of gentamicin has shifted.  
2.2.2 Methods 
The AMS team of a 500 bed tertiary regional hospital performed a retrospective clinical 
study of gentamicin IDC prophylaxis around total hip and knee arthroplasties. Results 
were presented to the orthopaedic surgeons. A literature review identified no guidelines to 
support gentamicin prophylaxis and only a very low risk of bacteraemia associated with 
IDC insertion/removal in patients with established bacteriuria. Consensus was reached 
with the surgeons to discontinue this practice. Subsequent prospective data collection was 
commenced to determine effectiveness, with weekly feedback to the Department Head of 
Orthopaedics.  
2.2.3 Results 
Data from 137 operations pre-intervention (6 months) were compared with 205 
operations post-intervention (12 months). The median patient age was 72 years in both 
groups.  Following the intervention, reductions in gentamicin use were demonstrated for 
IDC insertion (59/137 [42%] to 4/205 [2%], p<0.01) and removal (39/137 [28%] to 6/205 
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[6%], p<0.01). No gentamicin use was observed during the final 40 weeks of the post-
intervention period. There were no significant differences between the groups for pre-
operative bacteriuria, surgical site infections (SSIs) or acute kidney injury (AKI). 
2.2.4 Conclusions 
A collaborative approach using quality improvement methodology can lead to an 
evidence based reappraisal of established practice. Regular rolling audits and timely 
feedback were useful in sustaining change. 
 
2.2.5 Keywords 
Antibiotic prophylaxis, gentamicin, arthroplasty, in-dwelling catheters, surgical site 
infection 
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2.3 Introduction 
Urinary catheterisation is common during the peri-operative period and is associated with 
increased risk of bacteriuria and symptomatic urinary tract infection (UTI) (Marschall et 
al., 2013). In contrast, bacteraemia from IDC manipulation is rare, even when indwelling 
times are longer (Polastri et al., 1990; Jewes et al., 1988; Bregenzer et al., 1997). A causal 
link has not been established between peri-operative asymptomatic bacteriuria, 
bacteraemia and subsequent haematogenous seeding of the prosthetic joint (Sousa et al., 
2014). Studies have reported either no effect (Britt et al., 1977) or modest reduction (Jaffe 
et al., 1985; Mountokalakis et al., 1985; Romanelli et al., 1990; Esposito et al., 2006; 
Pfefferkorn et al., 2009; Petronella et al., 2012; van der Wall et al., 1992) in rates of 
bacteriuria and UTIs from antibiotic prophylaxis around short term IDC use. Several 
limitations applied: small sample sizes, none examined aminoglycosides, and the effect 
on antibiotic resistance was not routinely examined. In addition, the studies were not 
performed in the setting of orthopaedic surgery, and did not examine the impact on SSIs.  
 
Gentamicin is an aminoglycoside antibiotic administered intravenously for the treatment 
of Gram-negative infections (Leong et al., 2006). Gentamicin is also recommended as 
prophylaxis for surgery with high risk of Gram-negative infections, such as urological 
procedures (Antibiotic Expert Group, 2010). Due to concerns over side effects such as 
ototoxicity and nephrotoxicity, even after a single dose (Ahmed et al., 2012; Coroners 
Court of Victoria, 2012), there has been a shift in the paradigm of safe gentamicin use 
(Australian Commission on Safety and Quality in Health Care, 2015). Two recent studies 
examining the combination of gentamicin with a beta-lactam antibiotic for orthopaedic 
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surgical prophylaxis gave conflicting results on the risk of AKI (Bell et al., 2014; Craig et 
al., 2012). Both highlighted the presence of additional potentially nephrotoxic factors 
(e.g. older age, fractures, volume loss, anti-hypertensive medications and analgesics).  
  
The Australian Therapeutic Guidelines: Antibiotic (Antibiotic Expert Group, 2010) 
recommend against the routine use of gentamicin in the setting of peri-operative IDC 
insertion and removal and this recommendation has not changed in the latest update 
(Antibiotic Expert Groups, 2014). Despite guideline recommendations, gentamicin had 
been used as peri-operative prophylaxis in around one third of orthopaedic patients in our 
hospital. Some surgeons were initially reluctant to abandon gentamicin use, due to 
concerns about a potential increase in SSI rates and medico-legal considerations related to 
not following an established historical practice.  
 
Education and quality improvement are fundamental aspects of AMS in hospitals (Davey 
et al., 2013). Recent evidence suggests that feedback as a component of the change 
management process is more effective when it is: frequently presented; delivered by a 
peer; and aims to decrease a specific behaviour (Ivers et al., 2014). Our study analysed 
the effect of education with rapid-cycle audit and feedback, a method that may be 
effective where clinicians have previously agreed to review their practice (Ivers et al., 
2012). The importance of engaging with stable staff groups such as consultant surgeons 
and anaesthetists became evident. We assessed the impact of a group of interventions that 
aimed to reduce prophylactic gentamicin use during IDC insertion and removal in 
orthopaedic surgery, without increasing SSI rates. This quality improvement initiative 
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could constitute an effective model for management of change in the setting of limited 
background data. 
 
2.4 Methods 
2.4.1 Setting 
We initially performed a retrospective clinical study at Wollongong Hospital, a regional 
500 bed university teaching hospital in New South Wales (NSW), Australia. The AMS 
team (pharmacist and ID physician) identified the use of gentamicin as prophylaxis for 
IDC insertion and removal during a routine retrospective audit of systemic antibiotic 
prophylaxis around total hip and knee arthroplasties and revisions. IDC use was routine in 
this setting. The decision to administer gentamicin and its dose were at the discretion of 
the surgeon and there was not a departmental policy. 
2.4.2 Intervention 
This study employed PDSA quality improvement methodology (National Health Service 
Institute for Innovation and Improvement, 2008). The timeline of observations and 
interventions is shown in Figure 2.1. The guideline recommendations for routine surgical 
prophylaxis were the same for both the pre- and post-intervention groups (cephazolin 
routinely, with or without vancomycin following risk assessment for MRSA) (Antibiotic 
Expert Group, 2010). Notably, there was discussion with the surgeons and anaesthetists 
around guideline-concordant prescribing during the time interval (March 2012 to January 
2013) from the presentation of initial findings until the main intervention point. 
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Discussion also occurred at the AMS committee meetings (which included a surgeon 
representative) during this time. 
2.4.3 Definitions 
SSIs were defined according to standard definitions (Australian Council on Healthcare 
Standards, 2014) and reported by mandate to the NSW Ministry of Health. AKI was 
defined by the Kidney Disease Improving Global Outcomes criteria as a >50% rise above 
baseline serum creatinine (Kidney Disease Improving Global Outcomes, 2012). 
Assessment for vestibular toxicity was available, as dictated by patient symptoms. 
2.4.4 Outcomes 
The effect of the intervention was assessed using the following measures: prevalence of 
gentamicin use for insertion and removal of IDCs; comparative SSI rates; proportion of 
patients with AKI 48-72 hours post-operation. 
2.4.5 Data sources 
A retrospective dataset of total hip and total knee arthroplasties was obtained from 
medical records for the period 1 January to 30 June 2011. Gentamicin use was assessed 
from anaesthetic and medication charts, and serum creatinine measurements were 
retrieved from the electronic medical record (eMR; Cerner Powerchart™). Arthroplasty 
data were collected prospectively during the post-intervention period (February 2013 to 
February 2014) from the eMR and ward list. The infection control service provided SSI 
rates.  
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Figure 2.1: Timeline of study observations and interventions 
2.4.6 Statistical analyses 
Statistical analyses were performed using Stata statistical software: Release 14 (Statacorp 
LP, College Station, TX, USA). Chi-square and Fisher’s exact tests were used as 
appropriate. A Shapiro-Wilk test was used to check for normal distribution, and Mann-
Whitney U-test was used for continuous variables. Statistical significance was accepted as 
p<0.05.  
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2.4.7 Ethics 
This study was approved by the University of Wollongong (UOW) and Illawarra 
Shoalhaven Local Health District (ISLHD) Human Research Ethics Committee: 
HE11/103 (Appendix B). 
 
2.5 Results 
Data from 137 operations pre-intervention (6 months, retrospective) were compared with 
205 operations post-intervention (12 months, prospective; Table 2.1). Patient age and 
weight were similar in both groups; however, there were marginally more males in the 
post-intervention sample (31% vs. 42%, p=0.048). There were more positive pre-
operative MRSA screening cultures in the pre-intervention group (3% vs. 0.5%, 
p=0.047). No differences were observed in the number of positive pre-operative urine 
samples (Table 2.1). Gentamicin doses ranged from 80mg to 240mg. 
A significant reduction in gentamicin use was demonstrated post-intervention (Table 2.2). 
From week 12 of the post-intervention period (Figure 2.2), no further doses of gentamicin 
were administered for IDC manipulation.  
 
No significant differences were found between the numbers of superficial hip, deep hip, 
superficial knee, or deep knee infections (Table 2.2). There were no significant changes in 
the rates of AKI (Table 2.2), and no reports of vestibular toxicity following gentamicin 
use. 
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Table 2.1: Patient characteristics and pre-operative screening 
 Pre-intervention Post-intervention p value 
Median age, yrs 
(range) 
72 (40-91) 72 (35-87) 0.79 
Male, n (%) 43 (31) 86 (42) 0.048 
Median weight†, kg 
(range) 
82 (40-142) 
 
82 (44-143) 
 
0.79 
Cephazolin as skin 
prophylaxis‡, n (%) 
116/137 (87) 188/205 (92) 0.13 
Hip arthroplasty§, n 
(%) 
58/137 (42) 70/205 (34) 0.13 
MRSA screening 
swab positive 
4/122 (3) 1/204 (0.5) 0.047 
Pathogen isolated in 
pre-operative urine 
sample║, n (%) 
25/123 (20) 28/198 (14) 0.15 
Pre-op positive urines 
treated with 
antibiotics║, n (%) 
11/25 (44) 8/28 (29) 0.24 
†Data available from 133 patients pre-intervention; 202 post-intervention; ‡Data available from 134 patients 
pre-intervention, 205 post-intervention; §Includes revisions; ║Includes mixed and single pathogen growth. 
The remainder of the urine samples were reported as “no growth” or “no significant growth”. 
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Table 2.2: Gentamicin use, surgical site infections and acute kidney injury, n (%) 
 Pre-
intervention 
 (6 months) 
n = 137 
Discussion and 
planning 
period 
(20 months) 
n = 605 
Post-intervention 
 (12 months) 
n = 205 
p value 
Gentamicin for 
IDC insertion  
59 (42) N/A 4 (2) <0.01 
Gentamicin for 
IDC removal†  
39 (28) N/A 6 (3) <0.01 
Surgical site 
infections, deep  
0 (0) 7 (1.2) 1 (0.5) 0.59 
Surgical site 
infections, 
superficial 
1 (0.7) 3 (0.5) 0 (0) 0.45 
Post-operative 
acute kidney 
injury‡ 
2 (2) N/A 1 (1) 0.35 
†Data available from 137 patients pre-intervention, 204 patients post-intervention ‡defined as >50% rise in 
baseline serum creatinine  
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Figure 2.2: The proportion of patients receiving gentamicin for catheter insertion and 
removal over the 6 month pre-intervention period and during each week post-
intervention. The discussion and planning period is shown in grey. 
 
2.6 Discussion 
Our study showed that a combined intervention of education and discussion with audit 
and timely feedback was effective in withdrawing the practice of prophylactic gentamicin 
for IDC insertion and removal in orthopaedic surgery. No significant changes were 
observed in the rates of SSI or AKI, although the study was not powered adequately to 
detect those. Most importantly, this study offers a model for a sustained quality 
improvement initiative in the setting of limited background data and contributes to 
emerging evidence on the beneficial role of AMS in improving antibiotic use. 
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The majority of infections in orthopaedic surgery are caused by Gram-positive skin flora, 
for which cephazolin and vancomycin (where appropriate) provide adequate prophylaxis 
(Antibiotic Expert Group, 2010). The potential risks and lack of clinical benefit from 
gentamicin in this setting formed the basis of our intervention. Rates of gentamicin use 
were reducing during the planning and discussion period, highlighting that the ongoing 
interaction resulted in gradual practice change. This was consolidated to a withdrawal of 
gentamicin prescribing in the study sample. The importance of directly addressing 
medico-legal concerns and providing written support for practice change was also 
recognised.  
 
To our knowledge, this is the first study that has examined the impact of a change to IDC 
prophylaxis on clinical outcomes for orthopaedic surgery patients. A Cochrane review of 
antibiotic prophylaxis for short term IDC bladder drainage in adults showed that the 
primary outcome of bacteriuria was lower in the prophylaxis group (Lusardi et al., 2013). 
There is no evidence linking insertion and/or removal of an IDC with Gram-negative 
bacteraemia and seeding of a newly implanted prosthesis. Although a recent study has 
demonstrated that asymptomatic bacteriuria was an independent risk factor for prosthetic 
joint infection, preoperative antibiotic treatment did not show any benefit and infecting 
organisms were frequently different to those isolated prior to surgery (Sousa et al., 2014). 
Studies reporting bacteraemia from IDCs in the setting of chronic catheterisation reported 
low rates of established infection (Polastri et al., 1990; Jewes et al., 1988; Bregenzer et 
al., 1997).  
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There were no deep SSIs during the pre-intervention period and only one (0.5%) post-
intervention. During the intervening period the SSI rate was low at 1.1%, comparable 
with existing literature (Kurtz et al., 2008; Havelin et al., 2000). These differences were 
not statistically significant. Studies powered to detect changes in rare outcomes such as 
SSI rates typically require larger sample sizes (Havelin et al., 2000; Kurtz et al., 2008; Al-
Mulhim et al., 2014). 
 
The rate of peri-operative AKI in our study was 1-2%. Rates have been previously 
reported at 11% for orthopaedic surgeries with routine gentamicin prophylaxis, but with 
different gentamicin doses (Bell et al., 2014). The lower rate in our study may be due to 
the lower doses of gentamicin for IDC prophylaxis than for routine skin prophylaxis.  
 
A focus on immediate clinical outcomes (gentamicin toxicity) rather than parameters that 
appear later (antibiotic resistance) may have stronger influence on prescribing behaviour 
(Broom et al., 2014). Other strategies to reduce the risk of IDC-related UTI in the peri-
operative setting include: intermittent or no catheterisation, early mobilisation (that 
shortens the period when the IDC needs to remain in place), training for insertion 
techniques, good IDC care and consideration of IDC materials (Gould et al., 2010). Male 
patients receiving epidural anaesthesia may be at greater risk of urinary retention in the 
setting of orthopaedic surgery (Griesdale et al., 2011; Hollman et al., 2015; Lingaraj et 
al., 2007). 
 
There were several limitations to our study. These included confounding factors that may 
influence SSI rates (skin preparation, surgical technique, patient comorbidities) and the 
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significantly larger proportion of male patients in the post-intervention sample (probably 
resulting from variation in data collection methods). The study was not powered to detect 
changes in SSI rates and those were not followed up long term, meaning that late deep 
infections may have been missed. The indication for gentamicin use was not routinely 
documented on the anaesthetic records and drug charts. The study did not follow the 
prescribing habits of individual surgeons, so some of the change in gentamicin use may 
have been due to changes in staff. There were; however, minimal staff changes at a senior 
level during the study period. We believe that interpersonal interactions, the prevailing 
local culture of quality improvement and strong leadership of the units involved have 
contributed to the successful outcomes of this study. Those features were furthermore 
strengthened during the interactive audit and feedback process; generalisability to other 
settings needs to be tested. Audiometry was not available on site to test for gentamicin 
toxicity. Although we used a methodology common in pragmatic AMS research, 
introduction of bias may be inherent, outside a randomised controlled environment. 
2.6.1 Conclusions 
We have shown that a group of robust multi-disciplinary AMS interventions effected 
durable practice change without obvious evidence of harm. Further studies are required to 
demonstrate validity in other settings, as well as the impact of gentamicin prophylaxis on 
renal function in other types of surgery. 
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3.1 Summary statement 
This chapter addresses treatment of a common infection, CAP, using an educational 
strategy with common links to Chapters 2 and 4. Email was used as a method for 
providing clinical feedback and education to individual prescribers, along with combined 
educational interventions at the departmental level. As CAP treatment traverses the 
emergency department and numerous medical specialties, a hospital-wide approach was 
also required. Monitoring of antimicrobial prescribing was supported by a CDSS, which 
when combined with email feedback has applicability to multiple sites within the rural 
and regional health district. The multisite and rural/regional themes are further explored 
in Chapters 4, 5, 6 and 7. 
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3.2 Abstract 
3.2.1 Background 
CAP is the second commonest indication for antibiotic use in Australian hospitals and is 
therefore a frequent target for AMS interventions. The recommended duration of 
combined intravenous and oral empiric therapy for CAP in the Australian Therapeutic 
Guidelines (2014) is seven days. The aim of this study was to improve appropriateness of 
antibiotic prescribing for CAP. 
3.2.2 Methods 
We performed a single-centre prospective study in a regional referral hospital comparing 
management of adult inpatients with presumed CAP before and after an AMS 
intervention (pre-intervention 1 June to 30 November 2013; post-intervention 1 June to 
30 November 2014). Post-intervention, individual case feedback was emailed to the 
attending medical officer (AMO). The primary outcome measure was duration of 
antibiotic therapy. Secondary outcome measures included appropriateness of therapy, 
LOS, 30 day readmission rate and in-hospital mortality. 
3.2.3 Results 
Post-intervention, median duration of therapy decreased from 11 days (n=34) to 9 days 
(n=79; p=0.04). The number of patients with non-severe CAP receiving the third 
generation cephalosporin, ceftriaxone (indicated for severe CAP) decreased from 74% 
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(14/19) to 45% (18/40; p=0.04). There were no significant differences in LOS, 30 day 
readmission rate or in-hospital mortality. 
3.2.4 Conclusions 
Our AMS intervention was successful in reducing duration of therapy and unnecessary 
exposure to ceftriaxone. The use of timely audit and feedback can foster improvement. As 
CAP therapy is responsible for a large proportion of antibiotic use in Australian hospitals, 
interventions are recommended to address initial choice and duration of therapy. 
3.2.5 Keywords 
Community-acquired pneumonia, antibiotics, duration of therapy, antimicrobial 
stewardship 
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3.3 Introduction 
CAP causes significant morbidity and mortality (Maxwell et al., 2005; Postma et al., 
2015) and is the second commonest indication for antibiotic prescribing in Australian 
hospitals, following surgical prophylaxis (Australian Commission on Safety and Quality 
in Health Care, 2015). Ceftriaxone (a third generation cephalosporin) plus azithromycin 
(a macrolide) is recommended as first-line treatment of severe CAP in non-tropical 
regions of Australia (Antibiotic Expert Group, 2010; Antibiotic Expert Groups, 2014), 
whereas benzylpenicillin plus doxycycline is recommended for moderate-severity CAP. 
These recommendations are based on susceptibility data for Streptococcus pneumoniae, 
the commonest causative pathogen of CAP in Australia (Charles et al., 2008), which is 
almost uniformly susceptible to benzylpenicillin for non-central nervous system (CNS) 
isolates (Newton, 2013).  
 
Prescribing for CAP is a common target for hospital-based ASPs, due to the potential for 
overuse of the combination of ceftriaxone plus azithromycin for treatment of non-severe 
disease (Australian Commission on Safety and Quality in Health Care, 2011; Antibiotic 
Expert Group, 2010; Maxwell et al., 2005). Unnecessary use of those antibiotics may be 
associated with increased cost; the emergence of resistant pathogens such as MRSA 
(Paterson, 2004), extended spectrum beta-lactamase (ESBL) producing 
enterobacteriaceae (Paterson, 2004), and Streptococcus pneumoniae (Musher and 
Thorner, 2014); as well as CDI (Paterson, 2004).  
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The requirement to rapidly identify and treat sepsis in emergency departments (EDs) 
(Clinical Excellence Commission, 2015; Burrell et al., 2016) may drive use of broad 
spectrum antibiotics for initial treatment of CAP. Initial antibiotic prescribing in EDs is 
often continued on the wards, possibly due to a culture of non-interference among 
medical staff (Charani et al., 2013). Clinicians may also perceive that development of 
AMR is a low priority and a distant consequence of prescribing (McCullough et al., 
2015). 
 
A number of studies have demonstrated no difference in outcomes for patients with mild 
to moderate CAP treated with up to seven days of total antibiotic therapy compared with 
prolonged courses of greater than seven days (Athanassa et al., 2008; Choudhury et al., 
2011; Li et al., 2007). Avdic et al (2012) reported a reduction of three days in median 
duration of CAP therapy using education and direct oral feedback to treating teams at a 
large metropolitan hospital. A reduction in time between measurement and feedback, and 
a high level of stakeholder buy-in (such as from senior medical staff) may result in better 
audit outcomes (Ivers et al., 2012). 
 
We evaluated whether an intervention involving education with timely audit and emailed 
feedback would lead to a more appropriate duration of antibiotic therapy and a reduction 
in the number of patients with non-severe CAP receiving a ceftriaxone-based regimen. 
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3.4 Methods 
3.4.1 Setting  
We performed a prospective pre- and post-intervention study of patients presenting to the 
ED of Wollongong Hospital, a 550-bed regional tertiary referral hospital in NSW, 
Australia. Treatment of adult (≥18 years) patients with a final diagnosis of CAP was 
compared between pre-intervention and post-intervention cohorts (1 June - 30 November 
2013 vs. 1 June - 30 November 2014).  
3.4.2 Participants 
Firstnet® ED software (Cerner, Kansas City, MO, USA) was viewed prospectively for 
admissions containing any of the following keywords in the “diagnosis” column: 
pneumonia; lower respiratory tract infection; chest infection. Patients in whom 
pneumonia was suspected were also screened where an AMO consult was requested from 
respiratory, general or geriatric medicine. Patients who received initial antibiotics directed 
at CAP were initially screened, with a final diagnosis of CAP on the discharge summary 
being required for study inclusion. Exclusion criteria were as follows: <18 years of age; 
immunosuppressed (i.e., concurrent chemo- or immunosuppressant therapy or human 
immunodeficiency virus [HIV] positive); cystic fibrosis; bronchiectasis; empyema; 
exacerbation of chronic obstructive pulmonary disease (COPD) or asthma if not involving 
pneumonia; suspected or confirmed tuberculosis; aspiration or hospital-acquired 
pneumonia; readmitted to hospital within 14 days; transferred from another hospital. 
Duration of antibiotic therapy was determined from the medication charts and pharmacy 
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dispensing data. The remaining course of oral antibiotics was supplied to the patient on 
discharge. 
 
A reference SMART-COP severity score was calculated for each patient by the AMS 
pharmacist to assess compliance with national antibiotic guidelines (Antibiotic Expert 
Group, 2010). The SMART-COP score and occasionally the CORB and CURB-65 
severity scores were used by prescribers. Regimens suggested in the antibiotic guidelines 
broadly aligned with the mild, moderate and severe categories of CAP identified by the 
severity scores. Guideline compliance was recorded as: “complete” if, after accounting 
for allergy, all drugs matched the treatment of CAP according to SMART-COP score; 
“partial” if some of the drugs given matched the score; and “not at all” if none of the 
antibiotics matched. Ongoing monitoring of broad spectrum antimicrobial use on AMS 
rounds was facilitated by a CDSS, Guidance MS® (Guidance Group, 2013). 
 
In the pre-intervention group, 42 patients were initially screened for inclusion. The use of 
a patient admissions report (i.PM, CSC, Wilmington, DE, USA) during the post-
intervention phase, resulted in a greater number of patients included (n=99). The same 
screening definitions applied in both groups. Data analysis was performed on those 
patients with a final diagnosis of CAP on discharge summary. A CAP diagnosis was 
made in 34/42 (81%) assessable patients pre-intervention and 79/99 (80%) post-
intervention (Figure 3.1). 
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Figure 3.1: Study flowchart 
 
3.4.3 Intervention 
Pre-intervention results were presented to emergency, respiratory and general medicine, 
infectious diseases, pharmacy, and nursing meetings (April - May 2014). Education 
points included: use of severity scores; initial choice of antibiotics; change of antibiotic 
regimen; duration of intravenous (IV) and total therapy; and Streptococcus pneumoniae 
antibiograms. During the post-intervention phase a summary of each case was emailed by 
the AMS pharmacist to the AMO and junior staff, typically within two weeks of 
discharge. Initial antibiotic choice, subsequent treatment and duration of therapy were 
described in the email. The response rate of AMOs was assessed and responses were 
grouped as follows: (1) containing clinical feedback, (2) basic acknowledgement, or (3) 
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defensive.  The time to collect data and send the email was approximately 30 minutes per 
patient. This was incorporated into the existing role of the AMS pharmacist. 
3.4.4 Outcomes 
The primary outcome measure was total duration of combined IV and oral antibiotic 
therapy. Secondary outcomes included proportion of non-severe CAP patients receiving a 
ceftriaxone-based regimen, documentation of severity scores; appropriateness of 
antibiotic therapy according to severity score; LOS; 30 day readmission rate; and in-
hospital mortality.  
3.4.5 Statistical analyses 
Statistical analyses were performed using Stata® statistical software (Release 14, 
Statacorp LP, College Station, TX, USA). A chi-square test was used to compare 
proportions (Fisher’s exact test was used when an expected cell value was less than 5), 
and Wilcoxon rank-sum test for comparison of continuous variables involving duration of 
antibiotic therapy and duration of IV therapy. All statistical tests were two tailed, 
differences were considered significant at p<0.05. 
3.4.6 Ethics 
Ethics approval was granted by our institutional Human Research and Ethics Committee, 
approval number HE11/377 (Appendix B). 
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3.5 Results 
Demographic characteristics were similar between the two groups (Table 3.1). Parameters 
for calculation of a SMART-COP score were available in 97/113 (86%) cases with a final 
diagnosis of pneumonia. There were no significant differences between the proportion of 
patients with mild, moderate and severe CAP according to SMART-COP score, and a 
similar number of patients received antibiotics prior to admission in both cohorts. 
Respiratory medicine and general medicine accounted for 101/113 (89%) cases. Penicillin 
allergy was slightly more common in the pre-intervention group (p=0.11).  
 
There were no significant differences in the proportion of microbiology investigations 
between the two cohorts. Streptococcus pneumoniae was the commonest organism 
identified in both groups.  
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Table 3.1: Demographic characteristics and disease severity of patients with a final 
diagnosis of community-acquired pneumonia 
Characteristic Pre-
intervention 
(2013; n=34) 
Post-
intervention 
(2014; n=79) 
p 
value 
Male, n (%) 16 (47) 48(61) 0.18  
Age, median (range), yrs 83 (20-93) 78 (18-95) 0.08 
Penicillin allergy, n (%) 9(26) 11(14) 0.11 
Antibiotics prior to ED, n (%) 9(26) 27(34) 0.42 
SMART-COP 0-2 (mild), n (%) 11(32) 27(34) 0.85 
SMART-COP 3-4 (moderate), n (%) 13(38) 29(37) 0.88 
SMART-COP 5-11 (severe), n (%) 10(29) 23(29) 0.98 
 
Abbreviations: ED, emergency department; SMART-COP, reference clinical severity score 
 
The median duration of antibiotic therapy decreased from 11 days pre-intervention to 9 
days post-intervention (p=0.04; Table 3.2). The median duration of directed therapy in 
patients with a positive microbiological test was 11 days pre-intervention and 10 days 
post-intervention. The proportion of patients with non-severe CAP treated with 
ceftriaxone-based therapy (with penicillin allergy cases excluded) decreased from 14/19 
(74%) patients pre-intervention to 18/40 (45%) post-intervention (p=0.04). Among those 
patients, ceftriaxone was continued beyond 48 hours in only 2/14 cases pre-intervention 
and in 3/18 cases post-intervention; in all other cases ceftriaxone was either deescalated 
to oral therapy or ceased (data not shown). In the pre-intervention period, therapy was 
escalated in 1/34 (3%) cases following the results of the laboratory investigations, 
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compared to 6/79 (8%) cases post-intervention (p=0.35). Where there was not a final 
diagnosis of CAP (n=28), 12 patients (3/8 pre-intervention, 9/20 post-intervention) 
received initial treatment with a ceftriaxone-based regimen. 
 
Documentation of severity scores and compliance of initial antibiotic choice with the 
guidelines (according to severity score) increased post-intervention, compared with the 
pre-intervention levels, but those differences did not reach statistical significance (Table 
3.2). Where antibiotic therapy did not match guidelines, 7/9 (78%) patients received 
ceftriaxone plus azithromycin in non-severe pneumonia pre-intervention, compared with 
11/17 (65%) post-intervention. Benzylpenicillin was administered for severe CAP once in 
each cohort, where the guidelines recommended ceftriaxone. There were no significant 
differences in LOS, 30-day readmission rate or in-hospital mortality between the two 
groups (Table 3.2). One included patient was treated by a study investigator (WY). 
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Table 3.2: Outcomes in patients with a final diagnosis of community-acquired 
pneumonia 
Variable Pre-intervention 
(2013) (n=34) 
 
Post-
intervention 
(2014) (n=79) 
p 
value 
Total duration of antibiotic therapy, median 
(IQR), days 
11 (9-13) 9 (7-10) 0.04  
Duration of intravenous antibiotic therapy, 
median (IQR), days† 
3 (2-5) 3 (2-5) 0.74 
Severity score documented, n (%) ‡ 11 (32) 35 (44) 0.22 
Mild-mod receiving initial ceftriaxone,  
n (%) –excluding penicillin allergy§ 
14 (74) 18 (45) 0.04 
Initial antibiotics guideline compliant 
(“completely”), n (%) 
11 (30) 32 (41) 0.41 
Therapy escalated by admitting team,  
n (%) ¶ 
2 (6) 12 (15) 0.22 
Length of stay, median (IQR) days 6 (3-10) 6 (3-12) 0.74 
30 day readmissions, n (%) 4 (12) 13 (16) 0.77 
In-hospital mortality 2 (6) 4 (5) 1 
 
†31 known pre-intervention, 79 post-intervention; ‡34 known pre-intervention, 78 known post-
intervention; §19 known pre-intervention, 40 known post-intervention; ¶pre-intervention, benzylpenicillin 
to ceftriaxone (n=1), ceftriaxone to meropenem (n=1); post-intervention, benzylpenicillin to ceftriaxone 
(n=6), ceftriaxone to piperacillin/tazobactam (n=4), ceftriaxone to ciprofloxacin (n=2); 30 day 
readmissions, 1 for pneumonia pre-intervention, 2 for pneumonia post-intervention. 
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Email responses were received for 20 of 99 sent emails; 6 from AMOs and 14 from junior 
medical staff. The responses either contained clinical feedback (17/20) or acknowledged 
the email (3/20); there were no defensive responses. 
 
3.6 Discussion 
Our study demonstrated that an intervention combining education with audit and email 
feedback was associated with a significant reduction in the median duration of total 
antibiotic therapy from 11 to 9 days that was driven by shorter courses of oral therapy. 
The number of patients with non-severe CAP receiving a ceftriaxone-based regimen also 
decreased significantly (74% to 45%). Increases of almost 30% in documentation of 
severity score and compliance with guidelines were observed, although these did not 
reach statistical significance. 
 
Previous AMS studies have reported similar reductions in duration of IV (Fine et al., 
2003; Carratala et al., 2012) and total antibiotic therapy (Avdic et al., 2012). Our study 
differed in that we targeted emergency medicine to address initial treatment, and 
admitting teams for ongoing therapy. We also demonstrated an approach applicable to 
rural and regional hospitals, through use of a CDSS-supported ASP, the eMR and email 
feedback. Feedback of results was provided on an individual case basis, which may be 
more effective if clinicians have previously agreed to review practice (Ivers et al., 2012). 
Emails to doctors were broadly well received.  
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Our study had several limitations, including its single-centre design and small number of 
patients. The change to data collection methodology post-intervention may have resulted 
in a change to patient demographics, even though the same screening criteria were used. 
Discharge dispensing data were obtained from pharmacy and outpatient compliance was 
not evaluated. Parameters for calculation of SMART-COP scores were not available in 
14% of cases, thus disease severity may have been underestimated in those patients. 
Patients with treatment limitations were not excluded, which may have resulted in worse 
patient outcomes; however, antibiotics are typically not withheld in those patients, and 
inclusion criteria did not change between study periods. The response rate to emails was 
low; however, email was not used as the only feedback method, with departmental 
meetings and daily AMS rounds forming part of the education strategy. 
 
The intervention demonstrated a reduction in duration of therapy that was driven by 
shorter courses of oral antibiotics. Median duration of total therapy remained long at 9 
days, indicating that further interventions are required to address both duration of therapy 
and LOS. Post-intervention, some patients still received ceftriaxone for non-severe CAP 
but the frequency was significantly reduced. Although the exact reasoning behind 
ceftriaxone overuse cannot be inferred from our data, possible reasons include its once 
daily administration, broad spectrum, lack of requirement for dose adjustment and 
existence of sepsis guidelines. Although it was recognised that therapy should be 
reviewed following discharge from ED, there may still have been some prescribing 
etiquette shown by admitting medical teams, with an unwillingness to change a therapy in 
an improving patient (Charani et al., 2013). 
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3.6.1 Conclusions 
We have demonstrated significant reductions in total duration of CAP therapy and of 
inappropriate ceftriaxone-based therapy for non-severe CAP following a targeted 
intervention that combined education with audit and feedback. This approach addressed 
initial and ongoing prescribing, and may be readily transferred to other settings. Ongoing 
education with timely feedback of audit results is recommended to foster sustainability. 
3.6.2 Acknowledgements 
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4 The burden of healthcare associated Clostridium difficile 
infection in a non-metropolitan setting 
Article published in Journal of Hospital Infection (2017). 
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burden of healthcare associated Clostridium difficile infection in a non-metropolitan 
setting’, Journal of Hospital Infection, Apr; 95(4):387-393  
© Copyright 2016. Journal of Hospital Infection – permission not required for 
reproduction in thesis format. 
4.1 Summary statement 
The themes of multisite and rural/regional applicability of AMS initiatives are explored in 
this chapter, which relates to CDI, a serious adverse effect of antimicrobial use. Using a 
multisite approach, the outcomes of patients complicated by healthcare-associated CDI 
are investigated. The widespread use of antimicrobials across the health district, and 
geographic disparity of the hospitals, necessitated the use of email feedback and 
education, which builds on those themes described in Chapters 2 and 3. The use of 
technology (CDSS and e-learning tool) to provide pragmatic AMS education is further 
explored in Chapters 5, 6 and 7. 
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4.2 Abstract 
4.2.1 Objective 
CDI is a major cause of healthcare associated (HCA) diarrhoea in industrialised countries 
and is associated with considerable morbidity and mortality. No data exist on the burden 
of HCA-CDI in multisite non-metropolitan settings. This study examined the introduction 
of an ASP in relation to HCA-CDI rates and the effect of HCA-CDI on LOS and hospital 
costs. 
4.2.2 Methods 
A before-and-after intervention comparative study of patients aged 16 years and over with 
HCA-CDI from December 2010 to April 2016 across the nine hospitals of a non-
metropolitan health district in NSW, Australia. The intervention comprised a multisite 
ASP supported by a CDSS, with subsequent introduction of email feedback of HCA-CDI 
cases to AMOs. Main outcome measures: HCA-CDI rates; comparative LOS and hospital 
costs; prior antimicrobial and proton-pump inhibitor (PPI) use; appropriateness of CDI 
treatment. 
4.2.3 Results 
HCA-CDI rates rose from 3.07 to 4.60 cases per 10,000 occupied bed days (OBDs) pre-
intervention, and remained stable at four cases per 10,000 OBDs post-intervention 
(p=0.24). Median LOS (17 vs. 6 days, p<0.01) and hospital costs (AU$19,222 vs. $7,861, 
p<0.01) were significantly greater for HCA-CDI cases (n=91) than for matched controls 
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(n=172). Half of the patients with severe HCA-CDI (4/8) did not receive initial 
appropriate treatment (oral vancomycin). 
4.2.4 Conclusions 
HCA-CDI placed a significant burden on our regional and rural health service through 
increased LOS and hospital costs. Interventions targeting HCA-CDI could be employed 
to consolidate the effects of ASPs. 
4.2.5 Keywords 
Clostridium difficile infection, antimicrobial stewardship, antibiotics, length of stay, 
hospital costs 
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4.3 Introduction 
CDI is a major cause of HCA diarrhoea in industrialised countries and is associated with 
considerable morbidity and mortality (Valiquette et al., 2007). In Australia, the annual 
incidence of hospital-identified CDI was 4.03 cases/10,000 patient days in 2012 
(Slimings et al., 2014). Risk is increased by antimicrobial use and/or immunosuppression 
(Cheng et al., 2011). Other putative risk factors include gastrointestinal surgery, gastric 
acid-suppressive therapy and prolonged hospital stay (Cheng et al., 2011). 
 
HCA-CDI has been associated with increased LOS, additional costs from hospitalisation 
(Gabriel and Beriot-Mathiot, 2014)  and antimicrobial treatment (Cheng et al., 2011), and 
indirect costs such as productivity losses (McGlone et al., 2012).  
 
Most antimicrobials have been related to occurrence of CDI, with lincosamides (e.g. 
clindamycin), third generation cephalosporins (e.g. ceftriaxone), and broad-spectrum 
penicillins (e.g. amoxycillin/clavulanic acid) showing strong associations (Slimings and 
Riley, 2014). Fluoroquinolones have been particularly associated with the hypervirulent 
NAP1/027 strain (Vardakas et al., 2012). There is probable association between PPI use 
and CDI, with the combination of PPIs and antimicrobials carrying a greater risk than 
either alone (Kwok et al., 2012). 
 
ASPs should be employed to reduce the incidence of HCA-CDI (Valiquette et al., 2007). 
Despite HCA-CDI being an outcome measure for ASPs, increasing community 
acquisition of CDI may cloud interpretation of HCA-CDI rates (Slimings et al., 2014). 
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AMS interventions targeting HCA-CDI have predominantly been conducted in 
metropolitan teaching hospitals, at single sites or within a defined clinical area (Talpaert 
et al., 2011; Feazel et al., 2014; Vonberg et al., 2008; Thomas and Riley, 2003; Brumley 
et al., 2016). Very limited data exist on the burden of HCA-CDI in Australia, particularly 
in regional and rural settings (Riley et al., 1995). To our knowledge this is the first study 
to examine a multisite ASP in relation to HCA-CDI rates in the non-metropolitan setting. 
 
The aims of our study were: to describe HCA-CDI rates before and after an ASP; to 
measure LOS and hospital costs in HCA-CDI patients across multiple hospital sites; to 
compare prior antimicrobial and PPI use in HCA-CDI patients with the background use; 
and to assess appropriateness of HCA-CDI antimicrobial treatment according to 
guidelines. 
 
4.4 Methods 
4.4.1 Setting 
From December 2010 to April 2016, a study on the burden of HCA-CDI was performed 
across the nine public hospitals (1000 total beds) of ISLHD in south eastern NSW, 
Australia. The district services 390,000 residents across a catchment that begins one hour 
south of Sydney, and extends 250km along a coastal strip. The three largest hospitals 
comprise one principal referral hospital (550 beds), a large acute hospital (150 beds) and 
a medium acute hospital (100 beds). The remaining six hospitals are either small acute or 
mixed sub- and non-acute (Australian Institute of Health and Welfare, 2015). This study 
100 
 
employed PDSA quality improvement methodology (National Health Service Institute for 
Innovation and Improvement, 2008). 
4.4.2 Antimicrobial stewardship 
In May and June 2012, an ASP supported by a CDSS (GuidanceMS®) (Guidance Group, 
2013) was uniformly implemented across the district’s nine hospitals. The CDSS enabled 
monitoring of antimicrobial use and facilitated regular AMS rounds where advice on 
appropriate antimicrobial use could be offered by an ID physician and pharmacist (post-
prescription review). In addition to the CDSS, the ASP involved a restriction policy, 
whereby broad spectrum antimicrobials were only stocked in pharmacy (with supply 
contingent on CDSS approval) or specialist areas (i.e. intensive care unit [ICU], ED, 
haematology/oncology ward). Those antimicrobials included third generation 
cephalosporins, intravenous beta/lactamase inhibitor combinations and fluoroquinolones. 
Additional restriction (prior ID/microbiology approval required) was placed on reserve 
antimicrobials such as linezolid, daptomycin, tigecycline and colistimethate sodium. An 
education campaign involved regular departmental presentations, and an intranet webpage 
was established to improve access to guidelines. In addition to regular AMS rounds at the 
three largest hospitals, and an antimicrobial advice telephone hotline was established 
across the district to support the smaller hospitals without onsite AMS clinicians. See 
Figure 4.1 for the study flowchart. There were no major changes to infection control 
policies related to either Clostridium difficile or hand hygiene during the study period. 
Patients in whom Clostridium difficile was detected were routinely isolated in single 
rooms, and personal protective equipment (disposable gown and gloves) was mandated 
by infection control policy. 
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Following a review of HCA-CDI rates, in April 2013 the AMS team (infectious diseases 
doctors and pharmacists) introduced a targeted CDI intervention. The AMS pharmacist 
audited all CDI cases for the following: patient demographics, risk factors, antimicrobial 
treatment, features indicating severe disease (Cheng et al., 2011), ICU admission, surgical 
intervention, and NAP1/027 strain. A feedback email was then sent to the attending 
medical officer (AMO) within two weeks (Figure 4.2). Qualitative analysis of email 
responses determined the level of acceptance by AMOs. Responses were categorised as 
clinical feedback, basic acknowledgement or defensive. The appropriateness of HCA-
CDI treatment (Cheng et al., 2011) was assessed during AMS rounds or retrospectively 
from medical notes. Results were presented to the AMS, drug and therapeutics, and 
infection control committees.  
4.4.3 Clostridium difficile laboratory testing 
From December 2010, our laboratory protocol subjected all diarrhoeal stools to 
Clostridium difficile testing. First line testing targeted glutamate dehydrogenase (GDH) 
antigen and toxins A and B (C. Diff Quik Chek Complete®, Techlab, Blacksburg, VA, 
USA). If those tests were discordant, then a polymerase chain reaction (PCR; 
GeneXpert®, Cepheid, Sunnyvale, CA, USA) test was employed, which could also detect 
the NAP1/027 strain. During the period June to November 2015, HCA Clostridium 
difficile stool samples were sent to a reference laboratory for molecular typing as part of a 
larger project examining HCA-CDI rates. No clonal similarities were identified, and 
molecular epidemiology was similar to other parts of NSW (data not shown). 
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Figure 4.1: Study flowchart 
Abbreviations: ASP, antimicrobial stewardship program; CDSS, clinical decision support system; HCA, 
healthcare associated; LOS, length of stay; risk factors, anti-peristaltic use, gastrointestinal surgery, 
immunosuppression; PPIs, proton pump inhibitors; HCA-CDI, healthcare associated Clostridium difficile 
infection; DRG, diagnosis-related group; background use, whole hospital prevalence data on antimicrobial 
use 
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Figure 4.2: CDI exemplar feedback email to admitting medical officer 
Dear Doctor, 
 
As part of routine antimicrobial stewardship activities we are conducting a prospective 
audit into all episodes of C. diff diarrhoea across the district. 
 
Your patient X (MRN: 111111) was diagnosed with C. diff diarrhoea on dd/mm/yyyy. 
 
Potential risk factors for your patient included: 
 
(As appropriate) 
 Proton pump inhibitor use –  
 Anti-peristaltic use –  
 Prior GI surgery –  
 Immunosuppression –  
 Antimicrobial use within one month prior to diagnosis –  
 
Details of antimicrobial treatment of CDI. 
I’ve attached a copy of the audit form for your information. Please don’t hesitate to 
contact me if you have any questions. 
 
Regards, 
AMS pharmacist 
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4.4.4 Effect of HCA-CDI on LOS and hospital costs 
LOS and hospital cost analysis was performed only for the three acute hospitals due to a 
shortage of matched controls and other confounders for LOS at smaller hospitals (e.g. 
nursing home availability, social factors). The two definitions for HCA-CDI were: HCA-
healthcare facility onset, diarrhoea onset >48 hours after admission; HCA-community 
onset, diarrhoea onset in the community or <48 hours after admission, but within four 
weeks of last discharge (Healthcare Associated Infection Technical Working Group, 
2013). Demographic data for HCA-CDI cases did not differ significantly between 
hospitals, or between the two types of HCA-CDI (data not shown), so all HCA-CDI cases 
were included for further analysis, including healthcare facility (n=103) and community 
onset (n=17; Figure 4.1). 
 
A post hoc analysis of LOS and hospital costs was conducted for those HCA-CDI cases 
identified from 1 April 2013 to 30 April 2014. Matched controls were identified from 
diagnosis-related group (DRG) data (Australian Institute of Health and Welfare, 2016) for 
HCA-CDI cases (n=103). Controls were identified from 1 January 2013 to 30 June 2014. 
Two controls were matched to each case by site, sex, age (+/- 5 years), and DRG (81 
cases). Where two matched controls were not available, one control was identified (10 
cases), resulting in 91 cases and 172 controls (Figure 4.1). DRGs were grouped and the 
most common DRGs were reported. Additional analysis was performed on those HCA-
CDI cases and controls with LOS of ≥8 days to address time-dependent biases (8 days 
equalled the median time to HCA-CDI onset). 
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4.4.5 Antimicrobial and PPI use 
Antimicrobial use within one month prior to diagnosis among HCA-CDI patients was 
compared with background antimicrobial use data, regularly collected in Australia as part 
of standard surveillance reports. Those data (defined daily doses [DDDs] per 1000 OBDs) 
from the three acute hospitals were derived from the Australian National Antimicrobial 
Utilisation Surveillance Program (NAUSP; from pharmacy software) and the Australian 
National Antimicrobial Prescribing Survey (NAPS; point prevalence survey in November 
2013, seasonally corrected, antimicrobial class use as a percentage of total use). PPI use 
was also compared with background use (point prevalence survey 2013). 
4.4.6 Statistical analyses 
ITS analysis (Linden, 2015) was used to assess HCA-CDI rates at the three large 
hospitals (due to comparability of acute OBD data). Data were included from December 
2010 (earliest time point with current CDI testing methods) to April 2016, with the 
intervention point defined as May 2012 (introduction of multisite ASP). Separate analyses 
were performed for May 2012- Mar 2013 and April 2013 onwards (targeted CDI 
intervention). Since those periods did not reveal any significant differences (data not 
shown) the post-intervention period was reported as one interval. A chi-square test was 
used for proportions or Fisher’s exact test where appropriate. A Mann-Whitney U-test 
was used to compare continuous variables such as LOS and hospital costs. Stata® 
Statistical Software Version 14 was used (Statacorp, College Station, Texas, USA). 
Significance was accepted as p<0.05. 
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4.4.7 Ethics 
Ethics approval was received from the joint UOW and ISLHD Human Research Ethics 
Committee, approval number HE13/137 (Appendix D). 
 
4.5 Results 
Figure 4.3 shows ITS analysis of monthly HCA-CDI rates. The model-predicted HCA-
CDI rate in December 2010 was 3.07 cases/10,000 OBDs. Prior to introduction of the 
ASP, the model-predicted rate was 4.6 cases/10,000 OBDs. Following the ASP’s 
introduction, and including the targeted email intervention, HCA-CDI rates remained 
stable at 4 cases/10,000 OBDs. None of those differences reached statistical significance, 
demonstrating an overall stable rate of HCA-CDI during the study period. The principal 
referral hospital accounted for two thirds of the health district’s inpatient activity, and so 
largely drove the overall HCA-CDI rate. There was larger monthly variability in HCA-
CDI rates at the smaller sites, but no significant differences in overall rates between sites. 
Detailed ITS data are provided in Table 4.1.  
 
During the targeted intervention phase from April 2013 to April 2014, 120 primary HCA-
CDI cases were identified. The median age was 73 years (IQR 63-81yrs) and 51/120 
(43%) of patients were male. Antimicrobials one month prior to HCA-CDI diagnosis 
were received by 107/120 (89%) patients.  Severe disease was identified in 8/120 (7%) 
cases; there were 8/120 (7%) ICU admissions, no surgical interventions, and no 
107 
 
NAP1/027 strains. Following a positive test for Clostridium difficile, all patients were 
isolated in single rooms according to policy. 
 
 
Figure 4.3: HCA-CDI rates for the three acute hospitals in Illawarra Shoalhaven Local 
Health District, Australia from December 2010 to April 2016 
Vertical line, implementation of antimicrobial stewardship program; HCA-CDI, healthcare associated 
Clostridium difficile infection; OBD, occupied bed day. 
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Table 4.1: HCA-CDI rates before and after implementation of an ASP 
 Pre-ASP  
(Dec 2010 to April 2012) 
Post-ASP  
(May 2012 to April 2016) 
Initial 
level 
Initial 
trend 
p 
value 
Change  
in level 
p 
value 
Change  
in trend 
p 
value 
HCA CDI per 
10,000 OBDs, n 
(LCI, UCI) 
3.07a  
(1.51-
4.65) 
0.09a  
(-0.06-
0.24) 
0.23 -0.83a 
(-2.25-
0.58) 
0.24 -0.08a  
(-0.24-
0.07) 
0.26 
 
Initial level, number of cases of HCA-CDI per 10,000 occupied bed days per month; initial trend, rate of 
increase per month; change in level, immediate difference between pre-intervention and post-intervention 
cases; change in trend, difference between pre-intervention and post-intervention trend by month; ASP, 
antimicrobial stewardship program, detail described in Methods; HCA-CDI, healthcare associated 
Clostridium difficile infection, data included for the three large acute hospitals of the health district; OBDs, 
occupied bed days; LCI, lower 95% confidence interval; UCI, upper 95% confidence interval; aadjusted for 
first order autocorrelation; 
 
Of the emails sent to AMOs for 120 HCA-CDI cases from April 2013-14, 23 responses 
were received (19% response rate). Of those responses, 10 contained clinical feedback, 13 
contained basic acknowledgement, and there were no defensive responses. Examples of 
clinical feedback responses were: “...in the setting of immune suppression and...other 
complications with chemo I am treating C diff…”; and, “the (antibiotic) was for 
aspiration… the PPI (was) longstanding…”. 
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Median LOS was 11 days greater for HCA-CDI patients (n=91; 17 days [IQR 8-27]) than 
their matched controls (n=172; 6 days [IQR 3-12]; p<0.01). Also, median hospital cost 
was estimated at AU$11,361 higher for the HCA-CDI group ($19,222 [IQR $7,817 - 
$41,337]) compared to controls ($7,861 [IQR $3,477 - $14,553]; p<0.01). The median 
time to onset of HCA-CDI was 8 days (IQR 4-14).  
 
The median hospital cost for 48 HCA-CDI patients with LOS ≥ 8 days was AU$17,832 
(IQR 9,472-28,840) vs. AU$12,563 (9,072-20,086) for 70 controls with LOS ≥ 8 days 
(p=0.17). For patients with LOS ≥ 8 days, the median LOS was 16 days (IQR 10-26) for 
HCA-CDI cases vs. 15 days (IQR 12-26) for controls. After excluding non-treated 
patients (n=6) with available controls (n=11), the difference between HCA-CDI patients 
and controls persisted for median LOS (18 vs. 7 days; p<0.01) and cost (AU$20,245 vs. 
$8,924; p<0.01). The five most common primary DRGs among 263 HCA-CDI cases and 
controls were: gastrointestinal (n=18 for cases, n=36 for controls), haematological 
malignancy (n=9, n=17), orthopaedic surgery (n=8, n=15), abdominal surgery (n=6, 
n=10), and cardiac (n=5, n=9). 
 
Antimicrobial use among the HCA-CDI group at the three acute hospitals was compared 
with background antimicrobial use (Figure 4.4). Over-represented in HCA-CDI patients 
were third generation cephalosporins (e.g. ceftriaxone; 34% of total use in HCA-CDI 
patients vs. 11% of background use; p<0.01), beta-lactamase inhibitor combinations (e.g. 
piperacillin/tazobactam; 58% vs. 36%; p=0.01), nitroimidazoles (e.g. metronidazole; 28% 
vs. 11%; p<0.01), and glycopeptides (e.g. vancomycin; 23% vs. 6%; p<0.01). Under-
represented in HCA-CDI patients were beta lactamase resistant penicillins (e.g. 
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flucloxacillin; 7% vs. 18%; p=0.02), beta lactamase sensitive penicillins (e.g. 
benzylpenicillin; 2% vs. 9%; p=0.03), extended spectrum penicillins (e.g. ampicillin; 14% 
vs. 33%; p=0.03), macrolides (e.g. azithromycin; 4% vs. 19%; p<0.01), and tetracyclines 
(e.g. doxycycline; 4% vs. 38%; p<0.01). Implementation of the multisite ASP was 
associated with an overall decrease in use of broad spectrum antimicrobials (e.g. third 
generation cephalosporins, fluoroquinolones and intravenous beta/lactamase inhibitor 
combinations; data not shown). Reporting on temporal changes to antimicrobial use 
patterns was beyond the scope of this study. 
 
 
Figure 4.4: Antimicrobial use for HCA-CDI cases compared with background 
antimicrobial use 
†Denotes statistical significance 
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Vancomycin and metronidazole were over-represented in HCA-CDI patients, but are also 
recommended for CDI treatment. Those two classes were further analysed. For 
vancomycin, the most commonly co-prescribed antimicrobial was piperacillin/tazobactam 
(11/25) with febrile neutropenia the commonest known indication (9/11). Vancomycin 
use was intravenous in all of those cases. For metronidazole, the most commonly co-
prescribed antimicrobial was ceftriaxone (13/35), predominantly for abdominal infections 
(10/13). There was an overall decrease in use of broad spectrum antimicrobials following 
implementation of the multisite ASP (data not shown). PPI use was documented in 
83/120 (69%) HCA-CDI patients compared with 343/730 (47%) patients audited as part 
of a local 2013 point prevalence survey (p<0.01). 
 
In non-severe HCA-CDI treated at the acute hospitals (n=95), oral metronidazole was 
initiated in 78 (82%) cases. Oral vancomycin plus oral metronidazole was used in eight 
(8%) cases, where metronidazole alone would have sufficed (Cheng et al., 2011). No 
therapy was given in nine non-severe cases, due to cessation of diarrhoea with or without 
identification of an alternative correctable cause. In the severe HCA-CDI group (n=8), 
oral metronidazole was initiated in 4 (50%) cases, where oral vancomycin, intravenous 
metronidazole or a combination was indicated. In those cases a relevant AMS 
intervention was made.  
 
4.6 Discussion 
Our study describes the relationship between HCA-CDI rates and a multisite ASP 
supported by a CDSS, education and antimicrobial restriction combined with targeted 
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audit and feedback. The effect of the ASP on HCA-CDI rates did not reach statistical 
significance, demonstrating that HCA-CDI rates remained stable during the study period. 
Targeted interventions may help to combat the waning of the initial impact of a program 
over time. We found that in an Australian non-metropolitan setting, LOS and hospital 
costs were significantly increased in HCA-CDI patients when compared with matched 
controls. Increased antimicrobial and PPI use in patients with HCA-CDI were consistent 
with previous reports (Slimings and Riley, 2014; Kwok et al., 2012). Although the initial 
treatment of non-severe HCA-CDI cases predominantly matched guidelines, there was 
concerning use of oral metronidazole in half of the severe cases (albeit with small 
numbers). This was similar to previous findings elsewhere (Jury et al., 2013), likely 
resulting from under-recognition of severity criteria (Cheng et al., 2011; Trubiano et al., 
2016). 
 
HCA-CDI has been associated with increased LOS and hospital costs (Gabriel and 
Beriot-Mathiot, 2014). Most studies evaluating these effects were either epidemiological 
studies (Pakyz et al., 2011; Campbell et al., 2013) or performed in the metropolitan 
setting (Feazel et al., 2014). To our knowledge this is the first study to combine 
evaluation of the burden of HCA-CDI with multisite ASP implementation in a regional 
and rural setting. Comparison with matched controls allowed for a pragmatic approach to 
identifying additional LOS and hospital costs associated with HCA-CDI (Kyne et al., 
2002; Vonberg et al., 2008). For those patients with LOS ≥ 8 days, there was a 42% 
increase in hospital costs in HCA-CDI patients compared with controls, despite similar 
LOS in those groups. This highlighted the increased cost of caring for HCA-CDI patients 
additional to greater LOS, and alleviated the potential for time-dependent biases. 
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There were several limitations to this study. We included all positive Clostridium difficile 
tests during the targeted intervention phase, as the frequency of daily diarrhoeal episodes 
was unreliably documented. Alternative causes of diarrhoea may have been present in 
some patients carrying Clostridium difficile. We could not attribute the increase in LOS 
and hospital costs to HCA-CDI alone. Alternative statistical methods such as multi-state 
modelling (van Kleef et al., 2014) to account for time-dependent biases, and propensity 
matching (Gabriel and Beriot-Mathiot, 2014) to accurately estimate the impacts of CDI 
have been proposed. To account for those limitations, we applied the case-control 
methodology in two additional subsets: the “long-stay” patients (≥8 days, the median 
time-to-onset of HCA-CDI) and only those treated for HCA-CDI. Those results were in 
line with our primary evaluation, emphasising the high LOS and cost burden of HCA-
CDI. As expected, gastrointestinal DRGs were overrepresented. In some cases the 
primary DRG may have been allocated to gastrointestinal due to CDI severity or duration.  
 
Community cases could not be accurately assessed with the current study resources. Of 
120 HCA-CDI cases, only 91 were eventually analysed for LOS and cost. Assessing the 
impact on HCA-CDI rates might have been confounded for antimicrobials (e.g. 
metronidazole, vancomycin) often given to treat CDI or co-administered with 
antimicrobials associated with HCA-CDI. Intravenous vancomycin has been associated 
with CDI (Hecht and Olinger, 1989); however, vancomycin was associated with CDI in 
this study only when combined with other antimicrobials. We did not evaluate 
appropriateness of prior antimicrobial use, in order to define avoidable HCA-CDI cases. 
Detailed demographic data and prior antimicrobial use were not collected for controls, as 
114 
 
this dataset was collected to allow for a post hoc analysis. Using background 
antimicrobial and PPI data allowed for larger numbers and accounted for the potential of 
bias due to under-reporting of those agents in control patients in whom CDI was not 
considered. However, detailed characteristics of patients from whom the background use 
data were derived were not available. The largest hospital accounted for two thirds of the 
total OBDs; hence its infection rate largely determined the overall rate. The response rate 
to emails was only 19%, limiting conclusions about their impact; however, responses 
were not requested in the initial email, and still some useful clinical feedback was 
received. Due to the hospitals’ geographic disparity, email remained the most pragmatic 
feedback method. 
  
Patient complexity in our hospitals may be lower compared with larger metropolitan 
hospitals, limiting generalisability to those settings. Further studies combining evaluation 
of ASPs with targeted CDI interventions would be useful, particularly in multisite and 
non-metropolitan settings. In this study we identified high risk antimicrobial classes that 
have formed targets for ongoing AMS activities. 
4.6.1 Conclusions 
Our study demonstrates the high burden of HCA-CDI in a non-metropolitan setting. 
While it confirms the association between high-risk antimicrobial use and HCA-CDI, it 
also identifies the possibility of under-recognition of CDI severity criteria during 
treatment initiation. Targeted audit and feedback interventions may be a useful way of 
consolidating the effects of a multisite ASP, contributing to sustainability, which remains 
one of the major challenges of contemporary AMS. 
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5.1 Summary statement 
This chapter provides an insight into the challenges associated with evaluating ASP 
implementation (involving an education campaign) across multiple hospital sites and 
health districts. The theme of multisite AMS education supported by technology is further 
explored in Chapters 6 and 7. Varying resources between hospitals necessitated a 
combined approach, whereby implementation was based around a CDSS and allowed for 
AMS support to be provided to the smaller and more remote sites with less on-site 
expertise. An evidence gap was identified around centrally-deployed decision support 
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technology to facilitate improved antimicrobial use. At a multi-health district level, CDI, 
infection-related LOS and mortality were examined as outcome measures for the ASP. 
Measurement of outcomes related to antimicrobial use was also explored in Chapter 2 
(renal toxicity and SSIs), Chapter 3 (30 day readmission rate and in-hospital mortality), 
and Chapter 4 (CDI). 
All results tables are provided at the end of the chapter (pages 148-161). 
 
5.2 Abstract 
5.2.1 Objective 
Studies evaluating ASPs supported by CDSSs have predominantly been conducted in 
single site metropolitan hospitals. This study aimed to examine outcomes of multisite 
ASP implementation supported by a centrally deployed CDSS. 
5.2.2 Methods 
An ITS study of a CDSS-supported multisite ASP was conducted across five hospitals in 
NSW, Australia from 2010 to 2014. Outcomes analysed were: effect of the intervention 
on targeted antimicrobial use, antimicrobial costs, HCA-CDI rates, infection-related LOS, 
and standardised mortality ratios (SMRs). 
5.2.3 Results 
Post-intervention, antimicrobials targeted for increased use rose from 223 to 293 
DDDs/1000 OBDs/month (+32%, p<0.01). Conversely, antimicrobials targeted for 
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decreased use fell from 254 to 196 DDDs/1000 OBDs/month (-23%; p<0.01). These 
effects diminished over time. Antimicrobial costs decreased initially (-AU$64,551/month; 
p<0.01), then increased (+AU$7,273/month; p<0.01). HCA-CDI rates decreased post-
intervention (-0.2 cases/10,000 OBDs/month; p<0.01). Proportional LOS reductions for 
key infections (respiratory 4.8 to 4.3 days, p<0.01; septicaemia 6.8 to 6.1 days, p<0.01) 
were similar to background LOS reductions (2.1 to 1.9 days). Similarly, infection-related 
SMRs (observed/expected deaths) decreased in line with background rates (respiratory 
1.1 to 0.75; septicaemia 1.25 to 0.8; background rate 1.19 to 0.90). 
5.2.4 Conclusions 
Implementation of collaborative multisite ASP supported by a centrally deployed CDSS 
was associated with changes in targeted antimicrobial use, decreased antimicrobial costs, 
decreased HCA-CDI rates, and no observable increase in LOS or mortality. Ongoing 
targeted interventions are suggested to promote sustainability. 
5.2.5 Keywords 
Antimicrobial stewardship, computerised clinical decision support system, health costs, 
Clostridium difficile, length of stay, mortality rate 
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5.3 Introduction 
ASPs aim to improve appropriateness of antimicrobial prescribing with the goals of more 
effectively treating and preventing infections, while curbing AMR and reducing adverse 
effects (Duguid and Cruickshank, 2010; Barlam et al., 2016). Studies examining the 
impact of ASPs have primarily been conducted in tertiary metropolitan hospitals (Cairns 
et al., 2013; Sick et al., 2013; Standiford et al., 2012; Nowak et al., 2012; Baysari et al., 
2016; Schuts et al., 2016). There is limited literature describing clinical outcomes from 
collaboratively implemented ASPs across multiple hospital sites (Ostrowsky et al., 2014; 
Lai et al., 2016; Cosgrove et al., 2012; Schuts et al., 2016). Previous single site ASP 
studies have demonstrated benefits using a CDSS, antimicrobial restriction, and 
prospective audit and feedback (Cairns et al., 2013; Sick et al., 2013; Nowak et al., 2012; 
Standiford et al., 2012; Davey et al., 2013). These benefits include a reduction in targeted 
antimicrobial use (Davey et al., 2013; Carling et al., 2003; Sick et al., 2013), 
antimicrobial drug acquisition costs (Ansari et al., 2003; Carling et al., 2003; Sick et al., 
2013), and HCA-CDI rates (Aldeyab et al., 2012; Carling et al., 2003). An evidence gap 
exists for implementation of ASPs across multiple sites using a centrally deployed CDSS 
(Barlam et al., 2016). 
  
Metrics for evaluating ASPs include antimicrobial use, drug costs, adverse effects such as 
HCA-CDI and AMR, LOS, and mortality (Morris et al., 2012; Khadem et al., 2012). 
Infection-related outcomes related to CAP, skin and soft tissue infections and septicaemia 
have been also been recommended (Morris et al., 2012). Although there are confounders 
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associated with their use as ASP metrics,  LOS and mortality are useful balancing 
measures to address potential unintended consequences (Davey et al., 2013).  
 
To our knowledge, no studies of multisite ASPs using a centrally deployed CDSS have 
included non-metropolitan hospitals. The aims of this study were to evaluate the impact 
of a CDSS-supported, multisite ASP on antimicrobial use, antimicrobial costs, HCA-CDI 
rates, infection-related LOS, and SMRs.  
 
 
5.4 Methods 
5.4.1 Setting 
In 2012 a multisite ASP supported by a centrally deployed CDSS was implemented in 12 
hospital sites (Figure 5.1) across the South Eastern Sydney and Illawarra Shoalhaven 
Local Health Districts, and Sydney Children’s Hospital, all in NSW, Australia. These 
districts cover a geographic area of 6,331 square kilometres and have an estimated 
population of 1.17 million, extending from central Sydney to three hours’ drive south 
(New South Wales Health, 2010). Comparable adult metrics were available for analysis in 
five hospitals, comprising 1900 beds, as shown in Figure 5.1. The remaining hospitals 
were not included in the study for the following reasons: small size, ASP implementation 
outside of study period, specialist (i.e. obstetrics, paediatrics) or subacute admissions 
(Figure 5.1). Those attributes would not allow comparison of outcomes such as 
antimicrobial use, LOS or HCA-CDI. The specialist paediatric hospital contributed to the 
development of guidelines for paediatric services within the other hospitals. Hospitals 
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shared AMS strategies, including a centrally deployed CDSS (Guidance MS®, 
Melbourne Health) (Guidance Group, 2013), educational material and similar 
antimicrobial formulary restrictions. Further information on case complexity and case 
mix of the included study hospitals is provided in Table 5.1.  
5.4.2 Intervention 
An ITS study was conducted combining data from five acute hospitals. The intervention 
point for the ASP was defined as the go-live date of the CDSS with concurrent 
dissemination of standardised antimicrobial prescribing guidelines at each site (May-July 
2012). This occurred in the setting of a 6-month lead-in period of prior education and 
antimicrobial guideline development (Figure 5.1). The fully modifiable CDSS, Guidance 
MS® is an intranet browser-based CDSS that guides prescribers on appropriate use and 
generates approvals for antimicrobials (Guidance Group, 2013). Antimicrobial restriction 
(a key component of our ASP) within the CDSS is determined on the basis of spectrum of 
action, potential toxicity or cost (Guidance Group, 2013). Implementation of the CDSS 
used project methodology (PRINCE2®, ILX Group, Mulgrave, Victoria, Australia) and 
was overseen by a multidisciplinary committee of medical, pharmacy, information 
technology (IT), and executive staff.  The committee met monthly via teleconference and 
collaborated closely throughout the project implementation period (May 2011 - May 
2012). This period was critical to optimise organisational readiness for implementation of 
a CDSS-supported ASP (Duguid and Cruickshank, 2010). 
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Figure 5.1: Population, clinical setting, nature and timing of interventions 
†Phone-based AMS with formulary restriction implemented Nov 2008 
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Figure 5.1 (cont): *Exclusions: delayed implementation, hospital sites had delayed recruitment of 
specialist staff and inadequate reporting of antimicrobial benchmarking data; data not comparable, 
specialist children’s and women’s hospitals with non-comparable patient and case mix; small sample size, 
antimicrobial use and cost data not reported to the National Antimicrobial Utilisation Surveillance Program 
(NAUSP); CDI, LOS and mortality data not analysed due to small sample size and high proportion of sub-
acute admissions 
 
Antimicrobial guidelines were based on national guidelines (Antibiotic Expert Group, 
2010), then standardised across the hospitals and incorporated into the CDSS. The 
development of guidelines, educational content and decision support was shared by adult 
and paediatric ID physicians and AMS pharmacists. This allowed for a standardised 
intervention that was tailored to hospital size and level of acuity (Figure 5.1), thereby 
reducing individual hospital workload, allowing access to clinical expertise at smaller 
sites and ensuring timely consensus on CDSS clinical content. Staffing (ID physicians, 
pharmacists and microbiologists) varied across the hospital sites, so intranet-based 
guidelines and an antibiotic advice hotline were used to promote access to program 
resources. Standardised bimonthly nationally benchmarked antimicrobial usage audits 
were reported to respective hospital AMS committees (South Australian Health, 2016). 
Prior to the study, AMS activities were restricted to phone-based advice, formal ID 
consults, selective antimicrobial sensitivity reporting, restriction of antifungals and 
reserve antibacterials (e.g. linezolid, tigecycline, colistin and daptomycin), and a phone-
based approval system at one study hospital (Figure 5.1). 
 
Study investigators classified the most commonly used antimicrobial classes into two 
categories, either targeted for increased or decreased use. Categorisation was based on the 
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following factors: local AMR patterns, local use compared with benchmarked hospitals 
(South Australian Health, 2016), risk of HCA-CDI and other side effects, compliance 
with antibiotic guidelines (Antibiotic Expert Group, 2010), and cost. Antimicrobials 
targeted for increased use were benzylpenicillin, doxycycline and aminopenicillins, 
whereas antimicrobials targeted for decreased use were third generation cephalosporins, 
macrolides, anti-pseudomonal beta-lactam/beta-lactamase inhibitor combinations, 
fluoroquinolones, and carbapenems. Additional antimicrobials were targeted for increased 
use in some settings, but decreased use in others. For example, local quality audits 
identified underdosing in surgical prophylaxis, but unnecessarily long duration of therapy 
in other settings such as cellulitis (data not shown). Such antimicrobials (i.e. first 
generation cephalosporins, flucloxacillin, aminoglycosides, and vancomycin) were only 
included in the overall antimicrobial use analysis. 
 
The infection control policies related to Clostridium difficile and hand hygiene were not 
subject to any major changes during the study period. Infection control measures 
recommended by local policies included: isolation in single rooms; use of disposable 
gowns and gloves; hand hygiene with alcohol-based hand rub and/or soap and water; and 
terminal cleaning with chlorine-based disinfectant. Diagnostic testing methods for 
Clostridium difficile were comparable across the health districts’ three main laboratories 
from May 2010, and included first line testing with targeted GDH antigen and toxins A 
and B (e.g. C. Diff Quik Chek Complete®, Techlab, Blacksburg, VA, USA). Discordant 
results occasioned the use of a PCR (e.g. GeneXpert®, Cepheid, Sunnyvale, CA, USA) 
test. All diarrhoeal stools were subjected to testing from December 2010 (seven months 
after the beginning of the pre-intervention period). A subset of the CDI data has been 
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published previously in a different context (Bond et al., 2016). Those data have been 
included here to allow comparison in the multisite setting. 
5.4.3 Outcomes 
The effect of the intervention was assessed by: (1) change in antimicrobials targeted for 
increased use (benzylpenicillin, doxycycline and aminopenicillins) expressed as DDDs 
per 1000 OBDs; (2) change in antimicrobials targeted for decreased use (third generation 
cephalosporins, macrolides, anti-pseudomonal beta-lactam/beta-lactamase inhibitor 
combinations, fluoroquinolones, and carbapenems; DDDs/1000 OBDs) (World Health 
Organisation, 2017); (3) change in total monthly antimicrobial costs (AU$). High cost 
antifungals (liposomal amphotericin, anidulafungin, caspofungin, posaconazole, and 
voriconazole) were analysed separately to the main antimicrobial group due to small 
variations in use accounting for large cost variations; (4) change in HCA-CDI rates, 
defined as a positive laboratory test for toxigenic Clostridium difficile plus diarrhoea 
onset greater than 48 hours after hospital admission (HCA-CDI cases per 10,000 OBDs) 
(Australian Council on Healthcare Standards, 2014); and (5) change in LOS and in-
hospital SMR for respiratory tract infections, cellulitis, kidney and urinary tract 
infections, and septicaemia, compared with background figures for all conditions 
(infectious and non-infectious combined). Confounders for each of the above measures 
were also investigated and reported where appropriate. Those included infection 
outbreaks, updated guidelines, changes to drug acquisition costs and administrative 
changes. 
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5.4.4 Data sources 
Adult inpatient data were included from May 2010 to July 2014. Antimicrobial use and 
acquisition cost data were obtained from pharmacy dispensing software, iPharmacy® 
Versions 5.5 and 5.6 (CSC, Sydney, Australia). Antimicrobial use data were processed by 
NAUSP (South Australian Health, 2016) using WHO classifications. OBD data were 
sourced from the hospitals’ performance units. HCA-CDI numbers were provided by the 
infection control teams in line with standardised surveillance and reporting (Australian 
Council on Healthcare Standards, 2014). LOS (using Australian refined DRGs) 
(Australian Institute of Health and Welfare, 2016) and SMRs (using principal diagnosis 
codes, based on International Classification of Diseases, 10th revision, Australian 
modification) (Australian Institute of Health and Welfare, 2016) were provided by the 
performance units for the following key infections: respiratory infections/inflammations 
(predominantly pneumonia), cellulitis, and kidney and urinary tract infections. Those 
were the commonest treatment indications for antimicrobials in the 2014 Australian 
NAPS (Australian Commission on Safety and Quality in Health Care, 2015). Septicaemia 
was also included due to its high mortality (Gauer, 2013). LOS and SMRs were compared 
for the time periods 1 July 2010 – 30 June 2012 and 1 July 2012 – 30 June 2014, as only 
data aligned with Australian financial years was available. Analysis of overall LOS 
excluded day case haemodialysis admissions. Comparative case complexity and case mix 
of the study hospitals was reported using National Weighted Activity Units (NWAUs) 
(National Health Funding Pool, 2016) and DRGs (Table 5.1) (Australian Institute of 
Health and Welfare, 2016). 
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5.4.5 Statistical analyses 
ITS analysis with segmented linear regression was used to examine the impact of the 
intervention on monthly antimicrobial use, costs and HCA-CDI, estimating the immediate 
effects of the intervention and changes in trend (Linden, 2015). To account for seasonal 
variations, 24 time points one month apart were used pre- and post-intervention (Ansari et 
al., 2003). To allow for statistical analysis of two years pre- and two years post-
intervention, the intervention point (go-live date of CDSS-supported ASP) was aligned 
for the five hospitals, with individual hospital data provided in Table 5.5 and Table 5.6. 
Definitions for ITS were: (1) initial level, model-predicted level (antimicrobial use, cost, 
HCA-CDI) 24 months pre-intervention; (2) initial trend,  model-predicted monthly trend 
pre-intervention; (3) change in level (immediate effect), model-predicted difference 
between the level at the end of the pre-intervention period and commencement of the 
post-intervention period (Cairns et al., 2013); (4) change in trend, model-predicted 
difference between initial (pre-intervention) monthly trend and post-intervention trend. 
Autocorrelation using Newey-West approximation for standard errors was investigated 
and an appropriate lag was used when necessary, in order to assess for similarity between 
observations (Linden, 2015). LOS was assessed using Mann-Whitney U-test. A logistic 
regression model was used to calculate the number of expected deaths using: age; sex; 
admission type (emergency or acute); admission source (acute transfer or other); principal 
diagnosis, and Charlson Comorbidity Index (0, 1-2, or 3+) (Charlson et al., 1987). 
Additional variables used in the expected deaths analysis related to vascular surgery, 
cardiac surgery, neurosurgery, trauma and transplant. Those figures were then used to 
calculate infection-related and total SMR (actual deaths/expected deaths). SMRs (pre- 
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and post-intervention) were expressed with 95% confidence intervals (CIs). Statistical 
significance was considered p<0.05. Statistical analyses were performed using Stata® 
Statistical Software: Release 14 (Statacorp 2015; College Station, TX, USA). 
5.4.6 Ethics 
Ethics approval was obtained from the districts’ Human Research Ethics Committees, 
approval number HE13/137 (Appendix E). 
 
 
5.5 Results 
5.5.1 Antimicrobial use 
Following the intervention, a rise in antimicrobials targeted for increased use of 70 
DDDs/1000 OBDs (+32%; p<0.01) was observed, followed by a decline in trend of 3.5 
DDDs/1000 OBDs per month (p<0.01). A concomitant reduction in antimicrobials 
targeted for decreased use of 58 DDDs/1000 OBDs (-23%; p<0.01) was observed, 
followed by a rise in trend of 3.4 DDDs/1000 OBDs per month (p<0.01;Figure 5.2). No 
significant change in level or trend was observed for overall antimicrobial use. There was 
a national shortage of benzylpenicillin in 2010-11; ampicillin was recommended as an 
alternative for most benzylpenicillin indications during this time. The national 
antimicrobial guidelines (Antibiotic Expert Group, 2010; Antibiotic Expert Groups, 2014) 
were updated in 2010 and again in 2014. 
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Figure 5.2: Impact of the AMS intervention on antimicrobial use 
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Figure 5.2 (cont): Abbreviations: DDDs, defined daily doses; OBDs, occupied bed days  
Targeted for increased use: benzylpenicillin, doxycycline, aminopenicillins (amoxycillin and ampicillin); 
targeted for decreased use: third generation cephalosporins (ceftriaxone, cefotaxime), macrolides 
(azithromycin, clarithromycin, erythromycin, roxithromycin), anti-pseudomonal penicillins 
(piperacillin/tazobactam, ticarcillin/clavulanic acid), fluoroquinolones (ciprofloxacin, moxifloxacin, 
norfloxacin); carbapenems (ertapenem, doripenem, imipenem/cilastatin, meropenem) total antimicrobials, 
all antimicrobials excluding antifungals and antivirals; vertical line is introduction of a CDSS-supported 
ASP, including antimicrobial restriction and education.  
 
5.5.2 Antimicrobial costs 
There was a significant reduction in total monthly antimicrobial costs of AU$64,551 (-
17%; p<0.01) post-intervention, followed by an increase in trend of AU$7,273 per month 
(p<0.01; Table 5.3). This corresponded to a reduction of AU$1.70/OBD post-intervention 
(-20%; p<0.01), with a subsequent increase in trend of AU$0.26/OBD per month 
(p<0.01). High cost antifungals demonstrated an immediate cost reduction (p<0.01), with 
no significant increase in trend. Some changes in acquisition costs were noted prior to the 
intervention, most notably a reduction in meropenem acquisition costs in mid-2011.  
5.5.3 HCA-CDI rates 
HCA-CDI rates were increasing pre-intervention from 2.8 to 6.2 cases/10,000 OBDs per 
month (p<0.01). A reduction was demonstrated post-intervention (-1.2 cases/10,000 
OBDs/month, p=0.15), followed by a decrease in trend (p<0.01; Table 5.3; Figure 5.3). 
There were no systemic changes to hand hygiene and cleaning policies during the study 
period. The rate of hand hygiene compliance had increased across facilities following 
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national initiatives prior to 2009. There were no notable HCA-CDI outbreaks from 2010-
2014.  
 
 
Figure 5.3: Impact of the AMS intervention on HCA-CDI rates 
Abbreviations: HCA-CDI, healthcare associated Clostridium difficile infection 
Two years of monthly HCA-CDI rates pre- and post-intervention; vertical line is introduction of a CDSS-
supported ASP. 
 
5.5.4 LOS 
Median LOS was reduced for respiratory infections (4.8 to 4.3 days, p<0.01), cellulitis 
(3.2 to 2.9 days, p<0.01), urinary and kidney infections (3.3 to 2.9 days, p<0.01), and 
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septicaemia (6.8 to 6.1 days, p<0.01; Table 5.4). Over the same time period, median LOS 
for all hospital admissions also decreased from 2.1 to 1.9 days (p<0.01). 
5.5.5 In-hospital SMR 
SMRs decreased for respiratory infections (1.10 [95%CI 1.01-1.20] to 0.75 [0.68-0.82] 
observed/expected deaths), urinary and kidney infections (0.78 [0.52-1.10] to 0.63 [0.42-
0.91]), and septicaemia (1.25 [1.12-1.38] to 0.80 [0.72-0.89]).  Reductions in those 
infection-related SMRs were in line with the reduction in background SMR (1.19 [1.15-
1.23] to 0.90 [0.87-0.93]; Table 5.4). A small increase was observed for cellulitis (0.55 
[0.28-0.95] to 0.66 [0.38-1.05]). 
 
5.6 Discussion 
To our knowledge, this is the first study to evaluate implementation of a multisite ASP 
supported by a centrally deployed CDSS. We found improvements in antimicrobial use, 
demonstrated by changes in antimicrobials targeted for increased and decreased use. 
There were significant reductions in antimicrobial costs and HCA-CDI rates. Safety of 
the intervention was supported by decreased or unchanged LOS and SMRs for key 
infections during the study period. The long-term impact of the intervention on 
antimicrobial use and cost diminished over time, which suggests that ongoing program 
reinforcement and targeted interventions may be required to alleviate “AMS fatigue”. 
Changes in overall antimicrobial use prior to the main intervention probably resulted from 
an intensive education campaign to optimise antimicrobial use across the hospitals, with 
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heightened awareness of the impending change among clinicians. The importance of 
readiness assessments prior to implementation was recognised, along with shared 
interventions across the study hospitals. Those included AMS ward rounds with post-
prescription review and feedback, consensus guidelines, departmental education, and 
antimicrobial restriction. 
 
Some studies have evaluated ASPs across multiple hospital sites (Ostrowsky et al., 2014; 
Antoine et al., 2006; Schuts et al., 2016) and the utility of an individual site CDSS for 
improvement in antimicrobial prescribing (Cairns et al., 2013; Kaushal et al., 2003; 
Buising et al., 2008; Thursky, 2006); however, the combination of these two approaches 
is novel. Furthermore, this collaborative ASP was applied to non-metropolitan settings 
with an established structure of support from a larger hospital. Pooling data across five 
hospitals enhanced the potential to identify effects of the ASP. Few randomised studies 
have been conducted to determine the effect of ASPs (Davey et al., 2013; Schuts et al., 
2016). Our study used interrupted time series analysis, which is considered an alternative 
pragmatic approach with strong quasi-experimental design (Fowler et al., 2007). 
Comparison with control hospitals would have strengthened the study design; however, 
there were none available in the health districts due to widespread implementation of the 
ASP. 
 
Our study demonstrates that shared knowledge and expertise can be used to effectively 
implement an ASP across multiple hospital sites spanning a wide geographic area. The 
economies of scale enjoyed by the multisite approach allowed for collective interventions 
to be employed with reduced workload at individual hospital sites. Multisite 
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implementation also alleviated some of the potential disadvantages of the CDSS, such as 
resources required for implementation and maintenance (Barlam et al., 2016). An 
additional benefit of extensive multisite intervention was consistency in antimicrobial 
prescribing guidelines, facilitating the training of medical officers rotating through the 
facilities within the districts’ different hospitals. A consistent, multisite approach was also 
anticipated to enhance prescriber confidence and facilitate the quality improvement 
culture necessary to effect longer term improvements in antimicrobial prescribing (Broom 
et al., 2014; Charani et al., 2011). 
 
ASPs are a key element of the approach to reducing HCA-CDI (Leffler and Lamont, 
2015). Importantly, our intervention was associated with a reduction in HCA-CDI rates, 
as well as a decrease in trend that persisted over time. This occurred in the context of 
increasing community CDI rates (Slimings et al., 2014). 
 
The specialist paediatric hospital and paediatric wards from study sites were not included 
in this analysis. Non-comparability of standard adult metrics such as DDDs results in 
difficulty benchmarking antimicrobial use in children (Porta et al., 2012). HCA-CDI 
cannot easily be assessed in the paediatric population due to asymptomatic carriage in 
infants and lower rates of symptomatic CDI in children (Sammons et al., 2013). Although 
quantitative paediatric data were not included in this study, paediatric antimicrobial 
guideline and CDSS development were important for multisite ASP implementation 
across the network of small rural to large metropolitan hospitals.  
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Maintaining cost effectiveness is of concern to administrators (McGowan, 2012). Placing 
drug costs as the primary measure of cost analysis does not take into account changes in 
acquisition costs (e.g. when drugs come off patent). In addition, the most appropriate 
antimicrobial is not necessarily the lowest in price. Identifying other methods of cost 
benefit analysis is justified, such as the impact of healthcare associated infections, and the 
increased cost of treating resistant organisms (Goff, 2011). Some cost savings were 
attributed to reductions in drug acquisition costs, such as for meropenem in 2011. 
Paradoxically, the intervention was associated with increased drug costs in some 
instances. Benzylpenicillin, targeted for increased use, had a daily cost at usual dosing 
(1.2g intravenously 6 hourly) of AU$25, compared with ceftriaxone (targeted for 
decreased use; AU$1.30 for 1g intravenously daily). In addition, the post-intervention 
cost increase may have been driven by high cost antifungal use where treatment of a 
small number of patients may result in a significant increase in drug costs. Building 
works at some of the sites, leading to increased prophylaxis and treatment of invasive 
fungal infections, may have led to this increase. However, antifungals were not a main 
target of the collaborative ASP as they were already highly restricted prior to the 
intervention. Costs of the intervention were not analysed as part of this study; there were 
costs associated with purchasing the CDSS, and additional pharmacy and ID resources in 
supporting the ASPs.  
 
There were some other limitations to this study. Antimicrobial use patterns may also have 
been affected by unforeseen drug shortages and changes to infection control practices. 
There were no systematic changes to the infection control policies across the districts 
during the study period, and no recognised outbreaks of CDI occurred during this time. 
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Some measures were not included due to a lack of comparable pre- and post-intervention 
data across sites; these included the impact of antimicrobial stewardship ward rounds, 
point prevalence survey results and AMR patterns. Antimicrobials analysed included only 
those targeted for increased (e.g. benzylpenicillin) or decreased (e.g. ceftriaxone) use. Not 
all antimicrobial classes were reported individually, such as glycopeptides (e.g. 
vancomycin) and first generation cephalosporins (e.g. cephazolin, cephalexin). Although 
often targeted in ASPs, based on national guidelines (Antibiotic Expert Group, 2010) 
there were instances where these classes were targeted for either increased or decreased 
use. As such, it was not clear whether the ASP would result in a change to use. Reserve 
antibacterial agents such as linezolid and daptomycin were already highly restricted prior 
to the intervention, requiring prior physician approval before use.  
 
The effect of the intervention was not uniform across the sites. Reasons for this variability 
may have included differences in maturity of existing antimicrobial stewardship 
initiatives prior to the introduction of the CDSS, disparate levels of acuity, and variable 
patterns of resistance. Pre-existing AMS initiatives at all sites consisted of selective 
microbiology reporting, limited ID and microbiology phone support, and some 
departmental education, with one site additionally using a phone-based approval system 
(Figure 5.1). Variation in case complexity and case mix between study hospitals (Table 
5.1) may have justified some differences in antimicrobial use. Additionally, seasonal 
variation was evident in the antimicrobial use patterns. Those confounders may have been 
alleviated by using combined antimicrobial use data with sufficient pre- and post-
intervention time points for the ITS analysis. Data on antimicrobial use, cost and HCA-
CDI data could not be aligned perfectly in time with LOS and mortality data due to report 
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limitations; however, the maximum lag (for one hospital) was only 6 weeks over a 48 
month period.  Infection-related and overall LOS decreased after the intervention, which 
may have been due to increased use of hospital in the home services. There may have 
been potential confounders, such as changes to funding and hospital admission models 
that affected LOS and SMR during the intervention which were difficult to quantify. 
However, LOS and SMR were included as important balancing measures as they could 
potentially be negatively impacted by changed patterns of antimicrobial use. Statewide 
programs were also introduced by the NSW Clinical Excellence Commission through 
2010-2014 to improve management of deteriorating patients (Between the Flags program) 
and recognition and management of sepsis (Sepsis Kills program) (Clinical Excellence 
Commission, 2016). Those initiatives potentially contributed to the improvements in LOS 
and SMR in the post-intervention period. 
  
We anticipate that our findings would be generalisable to healthcare facilities with 
potential for utilising shared resources, such as those with existing professional or 
political networks. Additional studies using prospective methodological approaches in 
different settings would help to validate our results. 
5.6.1 Conclusions 
Implementation of a multisite ASP supported by a centrally deployed CDSS was 
associated with significant changes to targeted antimicrobial use, containment of 
antimicrobial expenditure and reduction in HCA-CDI, without obvious adverse effects. 
Ongoing targeted interventions involving education and behaviour change are required to 
sustain the benefits of ASPs on hospital antimicrobial use. 
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5.8 Tables 
Table 5.1: Case complexity and case mix of study hospitals for the Australian financial year 2013 – 2014 
Hospital Total 
acute 
episodes 
Total acute  
NWAU(16) 
Average  
NWAU(16) per 
acute episode 
Top five DRGs by volume 
Prince of Wales 32,699 49,513 1.51 Chest pain; cellulitis; other digestive system diagnosis; respiratory infection/ 
inflammation; injuries 
 
Shellharbour 8,213 11,246 1.37 Respiratory infection/ inflammation; schizophrenia disorders; chronic obstructive 
airway disease; hernia procedures; personality disorder and acute reactions 
 
Shoalhaven 10,970 12,678 1.16 Uncomplicated neonatal admission; vaginal delivery; respiratory infection/ 
inflammation; chronic obstructive airway disease; caesarean delivery 
 
St George 39,234 57,138 1.46 Uncomplicated neonatal admission; vaginal delivery; chest pain; respiratory 
infection/ inflammation; oesophagitis and gastroenteritis 
 
Wollongong 36,951 50,813 1.38 Uncomplicated neonatal admission; vaginal delivery; respiratory infection/ 
inflammation; cellulitis; caesarean delivery 
 
Australian financial year, 1 July 2013 to 30 June 2014; total acute episodes excludes haemodialysis, due to a large number of episodes without significant 
antimicrobial use; NWAU(16), National weighted activity unit (2015/16), a measure of comparing and valuing each public hospital service, to determine the 
overall complexity and relative resource payment for services funded on an activity basis. DRGs, Australian-refined diagnosis related group.  
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Table 5.2: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use 
 Pre-intervention Post-intervention 
Antimicrobial Initial 
level 
LCI UCI Initial 
trend 
LCI UCI p 
value 
Change 
in level 
LCI UCI p 
value 
Change 
in trend 
LCI UCI p 
value 
 
Combined targeted 
for increased use 
 
 
182a 
 
170 
 
195 
 
1.7a 
 
0.7 
 
2.8 
 
<0.01 
 
71a 
 
43 
 
98 
 
<0.01 
 
-3.5a 
 
-5.3 
 
-1.7 
 
<0.01 
Combined targeted 
for decreased use 
 
316 298 334 -2.6 -4.1 -1.2 <0.01 -58 -87 -29 <0.01 3.4 1.4 5.3 <0.01 
Total antimicrobial 
use 
1125a 1033 1184 -3.4a -8.9 2.1 0.22 -29a -129 71 0.57 3.55a -2.6 9.7 0.25 
 
Antimicrobial use (level) expressed as average defined daily doses/1000 occupied bed days for five hospitals, as reported to NAUSP; trends: positive value represents 
increase, negative value represents decrease; 95% confidence intervals expressed as LCI (lower confidence interval) and UCI (upper confidence interval); aadjusted for first 
order autocorrelation; targeted for increased use: benzylpenicillin, doxycycline, aminopenicillins (amoxycillin, ampicillin); targeted for decreased use: third generation 
cephalosporins (ceftazidime, cefotaxime, ceftriaxone); macrolides (azithromycin, clarithromycin, erythromycin, roxithromycin); anti-pseudomonal penicillins 
(piperacillin/tazobactam, ticarcillin/clavulanic acid); fluoroquinolones (ciprofloxacin, moxifloxacin, norfloxacin); carbapenems (meropenem, ertapenem, doripenem, 
imipenem/cilastatin); individual hospital data provided in Table 5.5. 
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Table 5.3: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare associated Clostridium difficile infection 
 Pre-intervention Post-intervention  
Variable Initial 
level 
LCI UCI Initial 
trend 
LCI UCI p 
value 
Change 
in level 
LCI UCI p 
value 
Change 
in trend 
LCI UCI p 
value 
                
Totalb costs 
($AU) 
463375a 417101 509649 -3196a -5759 -633 0.02 -64551a -106056 -23044 <0.01 7273a 3899 10649 <0.01 
Costs per 
OBD ($AU) 
9.9 8.7 11.1 -0.07 -0.14 -0.01 <0.01 -1.7 -2.6 -0.8 <0.01 0.26 0.18 0.34 <0.01 
Antifungalc 
costs ($AU) 
92575 67721 117429 2021 376 3666 0.02 -50270 -86637 -13903 <0.01 1117 -1504 3738 0.40 
HCA-CDI 
per 10,000 
OBDs 
2.8 1.7 3.9 0.14 0.06 0.22 <0.01 -1.2 -2.8 0.4 0.15 -0.2 -0.3 0.1 <0.01 
 
Abbreviations: OBD, occupied bed day; $AU, Australian dollars; HCA CDI, healthcare associated Clostridium difficile infection. 
aadjusted for first order autocorrelation; trends: positive value represents increase, negative value represents decrease; bantibacterial, antifungal, antiviral chigh cost 
antifungals: liposomal amphotericin, anidulafungin, caspofungin, posaconazole, voriconazole; individual hospital data provided in Table 5.6. 
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Table 5.4: Length of stay and standardised mortality ratio by clinical infection group 
 Length of stay  Standardised mortality ratio 
 July 10 – June 12 July 12 – June 14  July 10 – June 12 July 12 – June 14 
Outcome 
measure 
Episodes Median LOS 
(IQR), days 
Episodes Median LOS  
(IQR), days 
p value Standardised 
mortality ratio      
(95% CI) 
Actual/ 
expected 
deaths 
Standardised 
mortality ratio      
(95% CI) 
Actual/ 
expected 
deaths 
          
Respiratory 
infections 
 
5,489 4.8 (2.8-7.8) 5640 4.3 (2.5-7.1) <0.01 1.10 (1.01-1.20) 534/485 0.75 (0.68-0.82) 436/584 
Cellulitis 
 
3,696 3.2 (1.6-5.8) 3757 2.9 (1.2-5.0) <0.01 0.55 (0.28-0.95) 12/22 0.66 (0.38-1.05) 17/26 
Urinary and 
kidney 
infections 
  
4,323 3.3 (1.2-5.2) 4364 2.9 (1.0-5.2) <0.01 0.78 (0.52-1.10) 30/39 0.63 (0.42-0.91) 29/46 
Septicaemia 
 
1,610 6.8 (4.0-11.7) 2441 6.1 (3.5-10.9) <0.01 1.25 (1.12-1.38) 350/281 0.80 (0.72-0.89) 359/450 
Overall 
 
224,021 2.1 (0.6-5.6) 242,383 1.9 (0.5-5.0) <0.01 1.19 (1.15-1.23) 3795/3193 0.90 (0.87-0.93) 3647/4063 
 
Abbreviations: LOS, length of stay; IQR, interquartile range; CI, confidence interval  
Respiratory infections/inflammations, code E62; cellulitis, code J64; urinary and kidney infections, code, L63; septicaemia, code T60; overall LOS excludes haemodialysis 
day admissions. Codes for LOS used Australian refined diagnosis related group definitions; codes for SMR used principal diagnosis codes, based on International 
Classification of Diseases, 10th revision, Australian modification. 
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Table 5.5a: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use, by hospital 
Prince of Wales Hospital 
  Pre-intervention Post-intervention 
 Antimicrobial Initial 
level 
LCI UCI Initial 
trend 
LCI UCI p 
value 
Change 
in level 
LCI UCI p 
value 
Change  
in trend 
LCI UCI p 
value 
                 
Targeted for 
increased  
use 
Benzylpenicillin 19a 11 28 0.5 -0.1 1.2 0.1 4.9 -8.6 18.4 0.5 -0.3 -1.2 0.6 0.5 
Doxycycline 10a 5 15 2 1.5 2.5 <0.01 4.4 -6.8 15.6 0.4 -1.8 -2.6 -0.9 <0.01 
Aminopenicillins 146a 129 163 -0.8 -1.8 0.3 0.15 3.0 9.3 47.5 <0.01 0.4 -1.0 1.7 0.6 
Combined 
 
175a 148 202 1.78 0.1 3.4 0.04 38 14.0 61.4 <0.01 -1.68 -4.1 0.68 0.15 
 
 
Targeted for 
decreased  
use 
 
3rd gen 
cephalosporins 
 
75a 
 
68 
 
83 
 
-0.6 
 
-1.0 
 
-0.3 
 
<0.01 
 
1.7 
 
-4.7 
 
8.2 
 
0.6 
 
0.8 
 
0.2 
 
1.5 
 
0.01 
Macrolides 95a 80 111 -0.6 -1.6 0.4 0.2 -13 -35 8.8 0.2 0.4 -1.2 1.9 0.6 
Anti-pseudomonal 
penicillins 
28a 23 33 0.7 0.4 1.0 <0.01 -4.9 -13 3.3 0.24 -0.67 -1.1 -0.2 <0.01 
Fluoroquinolones 72 62 81 -1.8 -1.4 -0.2 0.01 -0.2 -12 12 0.98 0.1 -1 1.1 0.87 
Carbapenems 25 17 34 0.4 -0.2 1.0 0.2 3.4 -7.4 14 0.5 -0.5 -1.3 0.3 0.25 
Combined 
 
296 270 322 -0.9 -2.7 0.8 0.3 -13 -47 21 0.4 0.1 -2.4 2.5 0.9 
Total antimicrobial 
use 
1109a 1078 1140 0.8 -3.2 1.6 0.5 69 20 119 <0.01 3.6 -0.8 8.1 0.1 
Antimicrobial use (level) expressed as average defined daily doses/1000 occupied bed days, as reported to NAUSP; 95% confidence intervals expressed as LCI (lower 
confidence interval) and UCI (upper confidence interval); trends: positive value represents increase, negative value represents decrease.  
aadjusted for first order autocorrelation; aminopenicillins, amoxycillin, ampicillin; third generation cephalosporins, ceftriaxone and cefotaxime; macrolides, azithromycin, 
clarithromycin, roxithromycin, erythromycin; anti-pseudomonal penicillins, piperacillin-tazobactam and ticarcillin-clavulanic acid; fluoroquinolones, ciprofloxacin, 
moxifloxacin and norfloxacin; carbapenems, ertapenem, doripenem, imipenem/cilastatin, meropenem. 
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Table 5.5b: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use, by hospital 
Shellharbour Hospital 
  Pre-intervention Post-intervention 
 Antimicrobial Initial 
level 
LCI UCI Initial 
trend 
LCI UCI p 
value 
Change 
in level 
LCI UCI p 
value 
Change  
in trend 
LCI UCI p 
value 
                 
Targeted for 
increased  
use 
Benzylpenicillin 13 -1.1 26 0.17 -0.8 1.2 0.7 35 17 53 <0.01 -1.4 -2.7 -0.1 0.03 
Doxycycline 22a 8 35 5.2 3.9 6.5 <0.01 74 33 115 <0.01 -7 -10 -4 <0.01 
Aminopenicillins 98a 80 117 -0.2 -1.6 1.2 0.75 53 25 81 <0.01 -1.3 -2.9 0.3 0.1 
Combined 
 
132a 96 168 5.2 2.5 7.8 <0.01 162 99 226 <0.01 -9.9 -14.2 -5.6 <0.01 
 
 
Targeted for 
decreased  
use 
 
3rd gen 
cephalosporins 
 
94 
 
78 
 
110 
 
-1.2 
 
-2.9 
 
0.6 
 
0.19 
 
-29 
 
-59 
 
2 
 
0.06 
 
2.1 
 
0.3 
 
3.9 
 
0.02 
Macrolides 295 259 331 -6.1 -8.7 -3.4 <0.01 -65 -127 -3.4 0.04 5.7 2.9 8.4 <0.01 
Anti-pseudomonal 
penicillins 
17 13 21 0.03 -0.3 0.3 0.88 -8 -15 -1 0.02 0.25 -0.2 0.7 0.28 
Fluoroquinolones 55 35 75 -0.001 -1.6 1.6 1 -30 -58 -1 0.04 0.7 -1.3 2.6 0.5 
Carbapenems 5 2 7 -0.05 -0.2 0.1 0.57 -1.5 -5 2 0.41 0.2 -0.1 0.5 0.18 
Combined 
 
466 400 530 -7.3 -13 -1.2 0.02 -133 -245 -22 0.02 8.9 1.9 16 0.01 
Total 
antimicrobial use 
1295a 1191 1399 -8 -18 3 0.14 -42 -252 167 0.7 6.7 -5.3 18 0.27 
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Table 5.5c: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use, by hospital 
Shoalhaven Hospital 
  Pre-intervention Post-intervention 
 Antimicrobial Initial 
level 
LCI UCI Initial 
trend 
LCI UCI p 
value 
Change 
in level 
LCI UCI p 
value 
Change 
in trend 
LCI UCI p 
value 
                 
Targeted for 
increased  
use 
Benzylpenicillin 36 22 49 0.03 -1.1 1.2 1 9 -13 31 0.8 -0.2 -1.5 1.1 0.7 
Doxycycline 108a 71 143 0.4 -1.7 2.6 0.7 54 26 81 <0.01 -1.1 -3.5 1.3 0.4 
Aminopenicillins 202a 190 214 -2.4 -3.3 -1.5 <0.01 19 -11 49 0.2 2.2 0.2 4.1 0.03 
Combined 
 
344a 302 387 -2.0 -4.4 0.5 0.12 82 32 131 <0.01 0.8 -3.0 4.6 0.68 
 
 
Targeted for 
decreased  
use 
 
3rd gen 
cephalosporins 
 
54 
 
42 
 
67 
 
0.3 
 
-0.5 
 
1.0 
 
0.5 
 
-16 
 
-27 
 
-6 
 
<0.01 
 
-0.5 
 
-1.4 
 
0.4 
 
0.24 
Macrolides 170 153 187 -3.2 -4.4 -1.9 <0.01 -40 -84 3 0.07 5.1 -0.3 11 0.06 
Anti-pseudomonal 
penicillins 
21 16 26 -0.01 -0.3 0.3 0.97 -5 -12 1.7 0.14 0.63 -0.02 1.3 0.06 
Fluoroquinolones 66 57 75 -1 -1.7 -0.3 <0.01 -13 -30 3.4 0.12 0.85 -0.2 1.9 0.12 
Carbapenems 9a 6 11 -0.2 -0.3 -0.01 0.04 -2 -6.5 2.5 0.37 0.4 0.1 0.8 0.02 
Combined 
 
320 293 346 -4.1 -5.8 -2.3 <0.01 -77 -128 -27 <0.01 6.5 0.9 12 0.02 
Total 
antimicrobial use 
1508a 1391 1625 -15 -24 -7 <0.01 -104 -249 40 0.15 17 8 27 <0.01 
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Table 5.5d: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use, by hospital 
St George Hospital 
  Pre-intervention Post-intervention 
 Antimicrobial Initial 
level 
LCI UCI Initial 
trend 
LCI UCI p 
value 
Change 
in level 
LCI UCI p 
value 
Change  
in trend 
LCI UCI p 
value 
                 
Targeted for 
increased  
use 
Benzylpenicillin 20a 14 27 0.7 0.2 1.2 <0.01 -16 -24 -7 <0.01 -0.1 -0.7 0.4 0.6 
Doxycycline 1.4a -2.9 5.6 1.1 0.84 1.43 <0.01 -0.1 -8.5 8.3 0.98 -1.0 -1.6 -0.5 <0.01 
Aminopenicillins 75a 69 81 2.0 1.28 2.69 <0.01 8.1 -6.8 23.0 0.3 -3.8 -4.7 3.0 <0.01 
Combined 
 
96a 85 107 3.8 2.8 4.9 <0.01 -7.6 -27.8 12.6 0.45 -5.0 -6.3 -3.8 <0.01 
 
 
Targeted for 
decreased  
use 
 
3rd gen 
cephalosporins 
 
44 
 
37 
 
50 
 
0.5 
 
0 
 
1.06 
 
0.051 
 
-4.0 
 
-14 
 
6.1 
 
0.43 
 
-0.9 
 
-1.5 
 
-0.3 
 
<0.01 
Macrolides 80 68 90 0.9 -0.1 1.9 0.09 -6.4 -28 15 0.56 -2.0 -3.4 -0.7 <0.01 
Anti-pseudomonal 
penicillins 
18a 15 20 0.8 0.6 1.0 <0.01 -7 -12 -2 <0.01 -0.08 -0.4 0.2 0.6 
Fluoroquinolones 29a 24 34 0.2 -0.1 0.5 0.13 -5 -9 -1 0.02 -0.1 -0.5 0.2 0.43 
Carbapenems 13a 10 15 0.1 -0.02 0.3 0.09 3.2 -2.4 8.8 0.25 -0.1 -0.4 0.2 0.5 
Combined 
 
183 165 202 2.5 0.8 4.3 <0.01 -19 -54 15 0.27 -3.3 -5.4 -1.2 <0.01 
Total 
antimicrobial use 
633 590 676 14 11 18 <0.01 -43 -98 12 0.12 -17 -20 -13 <0.01 
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Table 5.5e: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use, by hospital 
Wollongong Hospital 
  Pre-intervention Post-intervention 
 Antimicrobial Initial 
level 
LCI UCI Initial 
trend 
LCI UCI p 
value 
Change 
in level 
LCI UCI p 
value 
Change  
in trend 
LCI UCI p 
value 
                 
Targeted for 
increased  
use 
Benzylpenicillin 20 15 26 -0.3 -0.7 0.06 0.1 18 11 25 <0.01 -0.05 -0.6 0.5 0.8 
Doxycycline 30a 19 40 1.2 0.1 2.3 0.03 35 8 61 0.01 -2.5 -4 -1 <0.01 
Aminopenicillins 114a 104 124 -1.2 -2.1 -0.3 0.01 27 11 44 <0.01 0.8 -0.3 1.9 0.15 
Combined 
 
164a 143 186 -0.3 -2.3 1.8 0.8 80 39 120 <0.01 -1.8 -4.4 0.8 0.18 
 
 
Targeted for 
decreased  
use 
 
3rd gen 
cephalosporins 
 
51 
 
42 
 
61 
 
-0.3 
 
-0.9 
 
0.4 
 
0.4 
 
-8 
 
-17 
 
1 
 
0.08 
 
0.56 
 
-0.2 
 
1.3 
 
0.12 
Macrolides 123 110 137 -1.9 -3.0 -0.9 <0.01 -13 -34 8.5 0.23 1.5 0.4 2.5 <0.01 
Anti-pseudomonal 
penicillins 
49a 41 58 -0.3 -0.9 0.2 0.24 -7 -15 1.5 0.1 0.7 0.05 1.3 0.04 
Fluoroquinolones 73 63 83 -1 -1.8 -0.3 <0.01 -16 -30 -4 0.01 1.3 0.5 2.1 <0.01 
Carbapenems 19a 15 23 0.01 -0.2 0.2 0.87 -3 -10 3 0.3 0.6 0.2 1.0 <0.01 
Combined 
 
316 283 349 -3.6 -6.0 -1.2 <0.01 -48 -88 -7 <0.01 4.6 1.8 7.4 <0.01 
Total antimicrobial 
use 
1081a 1008 1156 -7 -15 0.2 0.06 -22 -159 114 0.74 6.4 -1.8 14.6 0.12 
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Table 5.6a: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare-associated Clostridium difficile infection 
rates, by hospital 
Prince of Wales Hospital 
 Pre-intervention Post-intervention 
Variable Initial 
level 
LCI UCI Initial 
trend 
LCI UCI p 
value 
Change 
in level 
LCI UCI p 
value 
Change 
in trend 
LCI UCI p 
value 
Total costs ($AU) 
 
174984a 135818 214149 -2006 -4201 188 0.07 -7440 -37329 22449 0.62 2853 297 5410 0.03 
Total costs per OBD 
($AU) 
12 10 14 -0.15 -0.3 -0.003 0.045 -1.5 -3.5 0.5 0.15 0.55 0.35 0.75 <0.01 
Antifungalb costs 
($AU) 
56110a -705 2803 87 -1218 1391 0.9 -13288 -34951 8375 0.22 1049 -
705 
2803 0.23 
HCA CDI per  
10000 OBDs (n) 
5.5 3.6 7.5 0.08 -0.05 0.2 0.2 0.4 -3.2 4.0 0.8 -0.24 -0.5 -0.01 0.04 
 
Abbreviations: OBD, occupied bed day; $AU, Australian dollars; HCA CDI, healthcare associated Clostridium difficile infection. 
aadjusted for first order autocorrelation; bhigh cost antifungals, liposomal amphotericin, caspofungin, voriconazole, posaconazole, anidulafungin. 
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Table 5.6b: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare-associated Clostridium difficile infection 
rates, by hospital 
Shellharbour Hospital 
 Pre-intervention Post-intervention 
Variable Initial 
level 
LCI UCI Initial 
trend 
LCI UCI p 
value 
Change 
in level 
LCI UCI p value Change 
in trend 
LCI UCI p 
value 
Total costs ($AU) 
 
12274 10351 14196 -37 -196 123 0.65 -2708 -6074 657 0.11 36 -175 247 0.73 
Total costs per OBD 
($AU) 
4.3a 3.5 5.0 -0.02 -0.08 0.05 0.6 -0.85 -2 0.3 0.15 0.05 -0.02 0.11 0.16 
Antifungalb costs  
($AU) 
-88 -129 31 51 -29 130 0.2 -1177 -2893 540 0.17 -49 129 31 0.22 
HCA CDI per  
10000 OBDs (n) 
1.1 -1.2 3.4 0.1 -0.02 0.25 0.09 -2.5 -5.6 0.5 0.1 -0.1 -0.3 0.1 0.4 
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Table 5.6c: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare-associated Clostridium difficile infection 
rates, by hospital 
Shoalhaven Hospital 
 Pre-intervention Post-intervention change 
Variable Initial 
level 
LCI UCI Initial 
trend 
LCI UCI p 
value 
Change  
in level 
LCI UCI p 
value 
Change 
in trend 
LCI UCI p 
value 
Total costs ($AU) 
 
28629 21020 36238 -624 -1037 -210 <0.01 89 -4122 4299 0.97 639 201 1077 <0.01 
Total costs per OBD 
($AU) 
8.5 6.2 109 -0.2 -0.3 -0.1 <0.01 0.14 -1.1 1.4 0.83 0.24 0.1 0.4 <0.01 
Antifungalb costs 
($AU) 
4409a 23 386 -213 -368 -58 <0.01 2225 404 4046 0.02 204 22.5 386 0.03 
HCA CDI per  
10000 OBDs (n) 
1.7 -0.3 3.7 0.1 -0.04 0.3 0.14 -0.1 -3.6 3.4 0.95 -0.2 -0.4 0.1 0.17 
 
  
161 
 
Table 5.6d: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare-associated Clostridium difficile infection 
rates, by hospital 
St George Hospital 
 Pre-intervention Post-intervention change 
Variable Initial 
level 
LCI UCI Initial 
trend 
LCI UCI p  
value 
Change 
in level 
LCI UCI p 
value 
Change 
in trend 
LCI UCI p 
value 
Total costs ($AU) 
 
104693a 84724 124662 1688 206 3170 0.03 -61611 -85528 -37694 <0.01 828 -873 2529 0.33 
Total costs per OBD 
($AU) 
7.1a 5.95 8.33 0.19 0.02 0.22 0.02 -4.7 -6.5 -2.9 <0.01 0.1 -0.01 0.23 0.06 
Antifungalb costs 
($AU) 
11112 -6465 28689 1998 390 3606 0.02 -46943 -74954 -18932 <0.01 -300 -2011 1411 0.73 
HCA CDI per  
10000 OBDs (n) 
4.1 1.9 6.3 0.2 0.07 0.36 <0.01 -1.9 -4.5 0.7 0.15 -0.4 -0.6 -0.2 <0.01 
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Table 5.6e: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare-associated Clostridium difficile infection 
rates, by hospital 
Wollongong Hospital 
 Pre-intervention Post-intervention change 
Variable Initial 
level 
LCI UCI Initial 
trend 
LCI UCI p  
value 
Change 
in level 
LCI UCI p  
value 
Change 
in trend 
LCI UCI p  
value 
Total costs ($AU) 
 
142796 122788 162803 -2218 -3396 -1040 <0.01 7120 -19333 33573 0.6 2917 1138 4667 <0.01 
Total costs per OBD 
($AU) 
12.3 10.6 14.1 -0.2 -0.3 -0.1 <0.01 0.5 -1.6 2.6 0.6 0.27 0.12 0.41 <0.01 
Antifungalb costs  
($AU) 
21032 -1051 1476 98 -713 908 0.8 8912 -6418 24242 0.25 212 -1051 1476 0.74 
HCA CDI per  
10000 OBDs (n) 
1.6 0.5 2.6 0.15 0.06 0.24 <0.01 -1.9 -4.1 0.33 0.09 -0.08 -0.21 0.06 0.25 
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6.1 Summary statement 
This chapter investigates a novel e-learning approach for education on antimicrobial use. 
The theme builds on the use of technology to enable multisite education as discussed in 
Chapter 5. The potential benefits of the e-learning approach include: applicability to rural 
and regional settings, availability on mobile devices, and targeting of multiple health 
professional groups. Qualitative feedback is also employed, a theme that was additionally 
reported in Chapters 3 and 4. Further comparative investigation into the impact of the e-
learning tool is described in Chapter 7. 
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6.2 Abstract 
6.2.1 Background 
Traditional approaches to health professional education are being challenged by increased 
clinical demands and decreased available time. Web-based e-learning tools offer a 
convenient and effective method of delivering education, particularly across multiple 
health care facilities. However, the effectiveness of this model for health professional 
education needs to be explored in context. 
6.2.2 Objectives 
The aims of this study were to (1) determine health professionals’ experience and 
knowledge of clinical use of vancomycin, an antibiotic used for treatment of serious 
infections caused by MRSA and (2) describe the design and implementation of a web-
based e-learning tool created to improve knowledge in this area. 
6.2.3 Methods 
We conducted a study on the design and implementation of a video-enhanced, web-based 
e-learning tool between April 2014 and January 2016. A web-based survey was 
developed to determine prior experience and knowledge of clinical vancomycin use 
among nurses, doctors, and pharmacists. The Vancomycin Interactive (VI) involved a 
series of short video clips interspersed with interactive question and answer scenarios, 
where only the correct response allowed for progression to the next section. Dramatic 
tension and humor were used as tools to engage users. Health professionals’ knowledge 
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of clinical vancomycin use was obtained from website data; qualitative participant 
feedback was also collected. 
6.2.4 Results 
From the 577 knowledge survey responses, pharmacists (N=70) answered the greatest 
number of questions correctly (median score 4/5), followed by doctors (N=271; 3/5) and 
nurses (n=236; 2/5; p<0.001). Survey questions on target trough concentration range 
(75%; 433/577) and rate of administration (65%; 375/577) were answered most correctly, 
followed by timing of first level (49%; 283/577), maintenance dose (42%; 242/577), and 
loading dose (38%; 219/577). Self-reported “very” and “reasonably” experienced health 
professionals were also more likely to achieve correct responses.  
The VI was completed by 163 participants during the study period. The rate of correctly 
answered VI questions on first attempt was 65% for nurses (N=63), 68% for doctors 
(N=86), and 82% for pharmacists (N=14; p<0.001), reflecting a similar pattern to that of 
the knowledge survey. Knowledge gaps were identified for loading dose (39% correct on 
first attempt; 64/163), timing of first trough level (50%; 82/163), and subsequent trough 
levels (48%; 78/163). Of the 163 participants, we received qualitative user feedback from 
51 participants following completion of the VI. Feedback was predominantly positive 
with themes of “entertaining,” “engaging,” and “fun” identified; however, there were 
some technical issues identified relating to accessibility from different operating systems 
and browsers. 
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6.2.5 Conclusions 
A novel web-based e-learning tool with interactive video content was successfully 
developed combining game design principles and humor to improve user engagement. 
Knowledge gaps were identified for different health professionals that allowed for 
targeting of future education strategies. The VI provides an innovative model for 
delivering web-based education to busy health professionals in different locations. 
6.2.6 Keywords 
Nursing education; pharmacy education; medical education; continuing education; 
vancomycin; survey methods; anti-bacterial agents. 
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6.3 Introduction 
6.3.1 Internet-based learning 
The development of IBL for healthcare professionals has increased in recent years (Liu et 
al., 2016). One reason for advancement of IBL is the existence of barriers associated with 
implementation of face-to-face health professional education, including increased clinical 
demands and decreased available time (Cook et al., 2010). These barriers become more 
evident where education is required across multiple facilities that are separated by long 
distances. Consequently, there is a requirement for more effective and accessible ways of 
improving knowledge and competence in health professionals (Liu et al., 2016). To date, 
IBL approaches have shown positive effects on health education outcomes through 
overcoming the above barriers (Cook et al., 2008). 
 
Serious games have been defined as “interactive computer applications, with or without 
significant hardware components” that are designed to entertain while achieving changes 
in knowledge or skills. Methods to improve their entertainment value include dramatic 
tension, humour and challenge (Thompson, 2012). User engagement can also be 
improved through the inclusion of a narrative (Lu et al., 2016). Humour as an aid to 
nursing and medical education has been described in the literature (Baid and Lambert, 
2010; Ziegler, 1999), while the use of games as a medium for humour may increase 
learners’ interest and motivation to learn (Baid and Lambert, 2010). As distinct from e-
learning with limited user interaction (Graafland et al., 2014a), serious games can provide 
greater engagement with the educational content. 
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Use of serious game methodologies to deliver health professional education has been 
reported in previous studies (Graafland et al., 2014b; Wang et al., 2016; Castro-Sanchez 
et al., 2014). Educational and design frameworks are recommended for the development 
of games for health professional education (Akl et al., 2013; Graafland et al., 2014a). 
Strategies include application of knowledge in a safe environment that resembles real life 
(Akl et al., 2013), a degree of interactivity (Cain and Piascik, 2015), and entertainment 
(Thompson, 2012). These topics were considered in development and assessment of the 
e-learning tool in this study.  
 
Most e-learning tools in health care have targeted specific groups, such as medical or 
nursing students, physicians or nurses (Boeker et al., 2013; Johnsen et al., 2016; 
Williams, 2014; Youngblood et al., 2008). We developed the VI to target nurses, doctors 
and pharmacists, the three main groups involved in use of medicines in hospitals. The 
specific educational content of the VI was clinical use of the glycopeptide antibiotic, 
vancomycin, given intravenously in hospitals for treatment of infections caused by 
MRSA. MRSA infections have high mortality and are resistant to conventional treatment 
with safer antibiotics such as penicillins, which usually do not require such specific 
administration and monitoring. Vancomycin is a commonly used antibiotic for treatment 
of MRSA infections (Rybak et al., 2009), but there are problems associated with its use. 
Those include the requirement for a loading dose (initial higher single dose) in serious 
infections, side effects when administered too rapidly, and the need to monitor 
vancomycin plasma levels (Antibiotic Expert Groups, 2014). As part of our ASP (Duguid 
and Cruickshank, 2010), local quality improvement activities identified gaps in 
competence around clinical use of vancomycin. Three main topics were identified from 
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those local activities and from previous studies: (1) dosing, including loading and 
maintenance (Swartling et al., 2012; Lomaestro, 2011; Phillips et al., 2016); (2) 
administration, such as compatible fluids and rate of infusion (Crowley et al., 2007; 
Phillips et al., 2016); and (3) TDM, including appropriate timing of blood sampling, 
target trough levels and required actions based on reported levels (Coleman and Wilson, 
2015; Phillips et al., 2016; Cardile et al., 2015).  
6.3.2 Aims of this study 
The aims of this study were: (1) to report the design and implementation of a web-based, 
interactive e-learning tool providing education on the dosing, administration and TDM of 
vancomycin, (2) to assess health professionals’ pre-intervention knowledge of 
vancomycin use in order to inform development of the e-learning tool, and (3) to assess 
health professionals’ initial acceptance of the VI. 
 
6.4 Methods 
6.4.1 Setting  
This prospective design and implementation study of a video-enhanced, web-based e-
learning tool took place in ISLHD and South Eastern Sydney Local Health District 
(SESLHD), located in NSW, Australia. These health districts cover a geographic area of 
6,331 square kilometres and have an estimated population of 1.17 million, reaching from 
central Sydney to three hours’ drive south (New South Wales Health, 2010). The 
districts’ 14 hospitals contain a total of 2500 beds and range from small rural facilities to 
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large tertiary metropolitan hospitals. A timeline of design, implementation and evaluation 
is shown in Figure 6.1.  
 
 
Figure 6.1: Timeline of VI design, implementation and evaluation 
6.4.2 Web-based vancomycin knowledge survey 
An anonymous open web-based survey was created using Survey Monkey® (Palo Alto, 
California, USA) to determine confidence, experience and knowledge of vancomycin, 
prior to the VI. The survey was developed locally by the AMS and educator pharmacists 
as part of routine activities, with input from the ID team. Clinical content was based on 
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the Australian Therapeutic Guidelines: Antibiotic, Version 15, 2014 (Antibiotic Expert 
Groups, 2014) and the Australian Injectable Drugs Handbook, Version 6, 2015 (Society 
of Hospital Pharmacists of Australia Publications Reference Group, 2015). Use of these 
references was required as part of the Australian hospital accreditation standards 
(Australian Commission on Safety and Quality in Health Care, 2011). Survey participants 
were nurses, doctors and pharmacists from the two health districts. A four-point Likert 
scale was used to determine levels of experience, confidence and knowledge on dosing, 
administration and TDM of vancomycin (Table 6.1). The survey was advertised using 
email and the districts’ fortnightly newsletters. The survey link was open from 1 February 
2015 to 30 June 2015 and participation was voluntary. Only one attempt was allowed on 
each question and users were directed to further reading material at completion of the 
survey. Nurses were expected to correctly answer questions on fluid compatibility and 
administration rate, since they were mainly responsible for administration of medicines in 
hospitals. Doctors were anticipated to correctly answer questions relating to dosing and 
TDM, arising from their role as prescribers. Pharmacists were expected to have a working 
knowledge of all aspects of clinical vancomycin use. The response rate to the survey was 
calculated from the number of respondents and the number of recipients on staff email 
groups. 
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Table 6.1: Vancomycin knowledge survey questions 
1. What is your profession? 
2. How much experience do you have with calculating doses of vancomycin? 
3. What do you think is the correct loading dose for vancomycin? 
4. What is an appropriate maintenance dose for vancomycin for a patient with a 
creatinine clearance of greater than 90mL/min? 
5. How confident are you to determine the administration rate for vancomycin? 
6. At what rate should vancomycin be administered to avoid red man syndrome? 
7. How confident are you to provide advice on vancomycin monitoring? 
8. When should the first level be taken for a dose of 1g 12hrly? 
9. What is the usual target range for vancomycin plasma trough levels? 
10. Did you refer to any resources to answer these questions? 
 
6.4.3 Design and implementation of the VI 
Similar to the survey, clinical content of the VI was developed locally, based on the 
Therapeutic Guidelines: Antibiotic (Antibiotic Expert Groups, 2014) and the Australian 
Injectable Drugs Handbook (Society of Hospital Pharmacists of Australia Publications 
Reference Group, 2015). The vancomycin knowledge survey informed in part the VI’s 
educational content in the post-production phase, allowing finalisation of the multiple 
choice questions. An entertaining web-based educational tool was selected in the early 
development stage (mid-2013; Figure 6.1) for two reasons. The first was that there was 
already a health district requirement for staff to complete between 10 and 20 hours’ 
mandatory training per year on other topics, and study investigators did not wish to 
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contribute to the burden of further web-based mandatory training. Rather, a brief, 
targeted, and light-hearted educational tool was thought to be more acceptable and 
beneficial for staff. Secondly, large distances between hospital sites meant that face-to-
face education of health professionals was very resource intensive. The learning 
objectives of the VI for target users (nurses, doctors and pharmacists) were to improve 
knowledge of vancomycin dosing, administration and TDM. The VI did not address 
clinical indications for vancomycin, dosing in specialist areas such as intensive care and 
renal dialysis, use of continuous infusions or surgical prophylaxis.  
 
A single interactive video was produced due to financial constraints; there was the 
expectation that all professional groups should have rudimentary knowledge of clinical 
vancomycin use. The VI (Copyright ISLHD) was hosted on the open website 
www.vancomycin.com.au (Bond and Crowther, 2015). Using the serious game design 
concepts of interactivity and entertainment, we presented a case study resembling real life 
interaction between a patient and a health professional. Dramatic tension between the two 
characters created the basis for the plot, along with the unprofessional behaviour of the 
modelled health professional. The interaction was also designed to be humorous, 
particularly through the special effect of “shrinking” the health professional, and 
references to William Shakespeare’s plays (Figure 6.2 and Figure 6.3). The concept was 
intended to appeal to health professionals who may feel they are at the mercy of their 
patients, a theme that emerged during the script-writing process. 
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Figure 6.2: Filming of the VI 
 
The user interface consisted of video clips interspersed with interactive question and 
answer scenarios placed at the specific points, so that technical content felt organic to the 
narrative (Figure 6.4; Table 6.2). A correct answer allowed progression to the next 
section, whereas an incorrect answer resulted in a shaking screen and a sound effect. Data 
captured from answers to the interactive questions allowed for subsequent analysis. Only 
data from the targeted health professionals were included in the analysis; students and 
other participants were excluded. Additional questions in the VI, as distinct from the 
survey, related to compatibility of vancomycin with various fluids and clinical actions in 
response to different trough levels. Completion of the VI took approximately 10 minutes 
based on user testing. 
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Table 6.2: Vancomycin Interactive questions 
1. What is an appropriate loading dose for Mrs Jones? 
2. What is an appropriate regular dose for Mrs Jones? 
3. What fluids should vancomycin be administered in? (more than one correct 
answer) 
4. At what rate do you need to administer the vancomycin? 
5. When should the first vancomycin level be taken for a patient receiving 1g 
12hrly? 
6. What is the target trough level? 
7. If the level comes back as 35mg/L what may this mean? More than one answer 
may apply. 
8. The first level comes back as 20mg/L. What should the next dose for this 
patient be and what is the dose interval? 
9. If the level comes back as 26mg/L, what should the next dose and dose interval 
be for this patient? 
10. The course length is likely to be 7 days based on the clinical response of the 
patient. When should the next level be taken? More than one answer may apply. 
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Figure 6.3: Dramatic tension created the basis for the VI’s plot 
 
 
Figure 6.4: Example of user interface for an interactive question from the VI 
 
Quotes for production were obtained from three developers in accordance with NSW 
Health policy, with financial support provided internally by the Clinical Governance Unit 
of the health district. Content development began in April 2014, and the video was filmed 
using professional actors in November 2014. Post-production modifications were made to 
the video up until release in July 2015. In early 2015 the website was established to 
promote improved access to the VI, and to include additional clinical content not 
contained in the VI. Testing of content and usability was performed by pharmacists and 
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ID doctors (n=8) at the study site, with feedback provided by email to the study 
investigators. Feedback from testers predominantly related to accuracy of the clinical 
content in the context of the narrative, and informed the final iteration of the VI. The first 
phase of dissemination and advertisement (email, newsletters, link on intranet homepage) 
to ISLHD staff occurred on 27 July 2015 (Figure 6.1) with the initial target audience 
estimated from organisational records to be 1000 staff. General release of the VI outside 
of ISLHD occurred on 17 November 2015. The final production cost was AUD$15,000; 
time devoted to content development, testing, advertising, implementation, and evaluation 
was not included in those costs as it fell within usual activities for the pharmacy and 
infectious diseases department staff members involved in development of the VI. 
6.4.4 User acceptance evaluation 
Following release of the VI, qualitative survey responses were assessed to inform the 
investigators about user acceptability and suggestions for improvement. The qualitative 
survey was open between 1 December 2015 and 31 January 2016, in order to conclude 
prior to the annual intake of new junior doctors in February 2016 (Figure 6.1).  
6.4.5 Outcome measures 
The primary outcome measure was comparative vancomycin knowledge between health 
professions and self-reported levels of confidence and experience. Vancomycin 
knowledge responses from website data (not linked at a participant level) were also 
assessed and compared with the knowledge survey. In addition, qualitative feedback on 
the VI was evaluated using a five-point Likert scale and free text responses that were 
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grouped into key themes. Assessments were derived from survey responses and VI 
website data. Technical issues around compatibility with desktop and mobile operating 
systems and web browsers were also assessed. Reporting of outcomes on quantitative 
post-intervention survey data, clinical measures of quality vancomycin use such as 
therapeutic vancomycin plasma levels, and clinical outcomes related to vancomycin 
treatment was beyond the scope of this study.  
6.4.6 Statistical analyses 
Chi-square and Fisher’s exact tests were used for proportions. Chi-square for trend was 
used to determine trend between professions for knowledge questions. Kruskal-Wallis 
and Mann-Whitney U-tests were used to examine total survey scores. For continuous 
data, normality was assessed using the Shapiro Wilk Statistic. A skewed distribution was 
denoted by p<0.05. Kruskal Wallis and follow up Wilcoxon rank-sum tests were used to 
investigate between subjects effects with non-normal distributions. A multivariate 
analysis was performed to examine influential factors on correct survey responses. For 
each item a logistic regression was conducted followed by a multiple regression on the 
total score. For profession, nurses were allocated to the reference group, and self-reported 
“no experience/confidence” was used at the reference for the experience analysis. 
Statistical significance was accepted as p<0.05. Additionally, a mediation analysis 
(Preacher and Hayes, 2008) was carried out to explore the mediating effects of 
vancomycin experience on the association between profession and knowledge (reflected 
by the total number of correct responses). For the mediation analysis, significance was 
determined by the 95% confidence of the regression coefficient, b. If the 95% CI did not 
contain 0 it was considered significant. The extent of mediation was reported as a 
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percentage, where a higher percentage reflects greater mediation. Statistical analyses were 
performed using Stata statistical software: Release 14 (Statacorp LP, College Station, TX, 
USA). 
6.4.7 Ethics 
Ethics approval was granted by the Joint UOW ISLHD Health and Medical Human 
Research Ethics Committee (EC00150; approval number HE15/005; Appendix F). The 
VI website contained a disclaimer that anonymous data collected from the video could be 
used for research purposes. 
 
6.5 Results 
6.5.1 Vancomycin knowledge survey prior to release of the VI 
The response rate to the survey was 27% (577 responses from 2,147 email recipients).  
The response rates by profession were 24% (236/967) for nurses, 25% (271/1,070) for 
doctors and 64% (70/110) for pharmacists (p<0.001).  
 
As shown in Table 6.3, the median knowledge survey score for nurses was 2 (IQR 1-3), 
compared with 3 (IQR 3-4) for doctors and 4 (IQR 3-4) for pharmacists (p<0.001). 
Pharmacists had greater total scores than both doctors (p<0.001) and nurses (p<0.001), 
while doctors had greater total scores than nurses (p<0.001). For nurses, the most 
correctly answered questions were on administration rate (64% correct) and target trough 
range (58% correct), while only 19% of nurses answered the loading dose question 
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correctly. The most correctly answered question by doctors was on target trough range 
(86% correct). Pharmacists answered all responses correctly greater than 80% of the time. 
 
Table 6.3: Number of correct responses to web-based vancomycin knowledge survey, n 
(%) 
Survey question Nurse 
n=236 
Doctor 
n=271 
Pharmacist 
n=70 
p value Total 
n=577 
Loading dose 46 (19) 112 (41) 59 (84) <0.001 217 (38) 
Maintenance dose 58 (25) 126 (46) 58 (83) <0.001 242 (42) 
Administration rate 152 (64) 160 (59) 62 (89) <0.001 374  (65) 
First level timing 70 (30) 155 (57) 59 (84) <0.001 284 (49) 
Target trough range 136 (58) 234 (86) 65 (93) <0.001 435 (75) 
Median total score 
(IQR) 
2 (1-3) 3 (3-4) 4 (3-4) <0.001     3 (2-4) 
Abbreviation: IQR, interquartile range 
 
Multivariate analysis (Table 6.4) showed that for the loading dose question, pharmacists 
and doctors were more likely to achieve a correct response than nurses. A smaller 
variation between professions was seen for the administration rate question, with the 
comparison between pharmacists and nurses reaching significance. In addition, self-
reported “very” and “reasonably” experienced health professionals were more likely to 
achieve a correct response. Similar associations between professions and experience 
levels were seen for maintenance dose, first level timing and trough level range (Table 
6.4). Pharmacists self-reported more experience and confidence than doctors or nurses, 
which influenced the likelihood of a correct response. 
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Table 6.4: Multivariate analysis of vancomycin knowledge survey responses (n=577)  
Topic  Profession Experience/confidence 
Nurse  
ref 
Doctor Pharm 1  
ref 
2 3 4 
Loading 
dose 
OR  
(95% CI) 
- 2.6  
(1.7-4.1) 
16.8  
(7.9-35.7) 
- 1.4 
(0.8-2.7) 
4.6 
(2.4-8.6) 
11.1 
(3.3-36.9) 
p value - <0.001 <0.001 - 0.25 <0.001 <0.001 
Maint 
dose 
OR 
(95% CI) 
- 2.5  
(1.7-3.8) 
12.1  
(5.9-24.7) 
- 1.0  
(0.6-1.8) 
2.2 
(1.2-3.8) 
3.3  
(1.1-9.6) 
p value - <0.001 <0.001 - 0.85 0.01 0.03 
Admin 
rate 
OR 
(95% CI) 
- 1.0  
(0.6-1.4) 
2.9  
(1.3-6.4) 
- 2.1  
(1.4-3.3) 
4.7  
(2.9-7.6) 
5.7  
(0.2-1.1) 
p value - 0.82 0.01 - 0.001 <0.001 <0.001 
Level 
timing 
OR 
(95% CI) 
- 2.7  
(1.9-4.1) 
8.5  
(4.0-17.7) 
- 3.6  
(2.1-5.9) 
6.8  
(4.0-11.6) 
4.0  
(1.4-10.9) 
p value - <0.001 <0.001 - <0.001 <0.001 0.01 
Trough 
range 
OR 
(95% CI) 
- 3.9  
(2.5-6.1) 
5.6  
(2.1-15.1) 
- 3.4  
(2.1-5.6) 
5.7  
(3.2-10.0) 
5.7  
(1.2-26.5) 
p value - <0.001 0.001 - <0.001 <0.001 0.03 
Total 
correct 
b 
(95% CI) 
- 0.8  
(0.6-1.1) 
1.7  
(1.4-2.1) 
- 0.9a  
(1.4-2.1) 
p value - <0.001 <0.001 - <0.001 
Abbreviations: ref, reference group for multivariate analysis; maint dose, maintenance dose; 
admin rate; administration rate; level timing, timing of first level; trough range, target range for 
plasma trough level, total correct; Pharm, Pharmacist (all levels); OR, odds ratio; CI, confidence 
interval; Experience/confidence: 1, none; 2, a little; 3, moderate; 4, very experienced/confident. b, 
regression coefficient; aaverage of responses to three vancomycin experience/confidence 
questions, therefore a multiple regression was performed for Total correct.  
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Subsequent mediation analysis revealed that vancomycin experience significantly 
mediated the effect of profession on total score (total indirect effect: b = 0.63, bias-
corrected 95% CI 0.44 – 0.85). Approximately 58% of the profession effect was mediated 
by experience, where a higher percentage value indicates greater mediation.  
6.5.2 Vancomycin Interactive 
Responses to the VI were analysed using background website data received from 27 July 
to 14 November 2015, with ISLHD as the target population group.  The initial dropdown 
question asking the user’s profession was answered by 389 participants; 163 health 
professionals (42% of those answering the initial profession question) completed all ten 
questions (Table 6.5). The rate of correctly answered questions on first attempt was 65% 
for nurses, 68% for doctors and 82% for pharmacists, significantly higher in the 
pharmacist group (p<0.001). Notably low numbers of correct responses were identified 
for the following three questions, averaged over the three professional groups: loading 
dose (39% correct), timing of first level (50%), and timing of subsequent levels (48%). 
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Table 6.5: Number (%) of correct answers on first attempt by nurses, doctors and 
pharmacists from VI data 
Question Nurse 
n=63 
Doctor 
n=86 
Pharmacist 
n=14 
p value Total 
n=163 
1 – Loading dose  19 (30) 36 (42) 9 (64) 0.047 64 (39) 
2 – Maintenance dose 50 (79) 59 (69) 11 (79) 0.32 120 (74) 
3 – Compatible fluids 53 (84) 67 (78) 11 (79) 0.76 131 (80) 
4 – Administration 
rate 
56 (89) 55 (64) 14 (100) <0.001 125 (77) 
5 – Timing of first 
level 
20 (32) 49 (57) 12 (86) <0.001 81 (50) 
6 – Target trough level 47 (75) 72 (84) 12 (86) 0.34 131 (80) 
7 – Level of 35mg/L 43 (68) 68 (79) 14 (100) 0.02 125 (77) 
8 – Level of 20mg/L 49 (78) 81 (94) 13 (93) 0.01 143 (88) 
9 – Level of 26mg/L 46 (73) 55 (64) 12 (86) 0.20 113 (69) 
10 – Subsequent levels 27 (43) 45 (52) 7 (50) 0.52 79 (48) 
Average score 65% 68% 82% <0.001 68% 
p-values obtained using Chi-square for trend. 
6.5.3 Comparison of responses between VI and web-based survey  
The rates of correct response from the VI were significantly higher than the knowledge 
survey for maintenance dose (74% VI vs. 42% survey; p<0.001) and administration rate 
questions (77% VI vs. 65% survey; p=0.004). There was a slightly higher correct 
response rate for the question on target trough level (80% VI vs. 75% survey; p=0.186). 
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Uniformly low correct response rates were observed for the questions on loading dose 
(39% for VI vs. 38% for survey; p=0.701) and the timing of first level (50% VI vs. 49% 
survey; p=0.89). The question on timing of levels subsequent to the first level in the VI 
was answered correctly in 48% of cases; there was no equivalent question in the survey.   
6.5.4 User acceptance evaluation of the VI 
Among the 163 VI participants, 51 (31%) responses were received. Responses were 
predominantly positive, as shown in Table 6.6. 
 
Table 6.6: Qualitative responses (%) following participation in the VI  
Survey statement/question Strongly  
agree 
Agree Neutral Disagree Strongly 
disagree 
Using the VI has enhanced my knowledge (n=51) 11 (22) 29 (57) 8 (16) 3 (6) 0 (0) 
Using the VI has improved my performance 
(n=50) 
8 (16) 28 (56) 12 (24) 2 (4) 0 (0) 
 
When users were asked, “What’s good about the VI in comparison to other e-learning 
modules?” 28 free text responses were received. Four responses (14%) related to not 
being able to load the video. Key themes from the remaining 24 responses (86%) were 
“entertaining”, “engaging”, “a lighter approach to learning”, “more real life”, and “held 
attention”. To the question, “Does the training provided by the VI meet your needs? If 
not, what can be improved?”, 23 free text responses were received. Sixteen respondents 
(70%) reported, “yes it met needs”; two (10%) stated issues loading VI; three users (13%) 
requested printable resources; one user was “not sure”; and one user requested more 
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information to be available when answering questions. All qualitative survey responses 
are provided in Table 6.7. 
 
Table 6.7: Qualitative survey feedback on the Vancomycin Interactive  
What was good about the Vancomycin Interactive in comparison to other e-
learning modules? (28 responses) 
 could not view 
 engaging 
 entertaining 
 Entertaining 
 entertaining easy to understand 
 fun and immediate answers available 
 Funny, not too much information 
 held attention. not just boring power point slides 
 i learnt stuff 
 Informative and entertaining 
 Interesting and memorable (due to jokes and cased based learning) 
 It concentrated on vancomycin 
 It was an entertaining lesson 
 it was engaging & entertaining :-) 
 It was fun and had a lighter approach to learning which was very nice! It was 
still very informative and educational, but the fun nature of Shirley made it 
more enjoyable to complete. 
 It was short and specific for vancomycin 
 it was very knowledgable session. it improves my confidence. the main thing is 
we are familiar with this medication and we quiet often uses at ward. 
 It wouldnt work on my work computer 
 more real life 
 no idea it wouldn’t load 
 Provides a real world context 
 Step by step followed by questions 
 Unable to do vancomycin interactive. 
 Very entertaining 
 Video 
 Was interesting and interactive 
 Was short and funny 
 Was very interesting…..Fun way of learning with the jingle 
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Table 6.7 (cont) 
Did the training provided by the Vancomycin Interactive meet your needs? If not, 
what can be improved? (23 responses) 
 yes (n=16) 
 a few case studies with some monitoring of levels would be useful 
 could not view 
 Good to be able to print a chart with formulas and normal levels  
 I think so, not sure if available but would like a summary of key points that can 
be printed out at end 
 It would be better to have more information before questions e.g. for dosing etc. 
Or at least have some explanation as to why the questions were wrong. 
 no idea it wouldn't load 
 not sure 
 
 
6.6 Discussion 
6.6.1 Principal findings 
We have reported on the design, implementation and user evaluation of a novel web-
based e-learning tool for education of health professionals on clinical use of the antibiotic 
vancomycin. The VI was developed for non-commercial use and targeted three health 
professional groups across multiple hospital sites. Responses from the survey that 
preceded the VI demonstrated a global lack of knowledge on the safe and effective use of 
vancomycin among nurses and doctors, justifying an IBL approach that was suitable for 
disparate geographical locations. Pharmacists were shown to be more knowledgeable on 
clinical vancomycin dosing, administration and TDM.  
 
As expected, self-reported levels of confidence and experience were correlated with 
increased likelihood of correct responses to the knowledge survey questions. Responses 
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from the web-based knowledge survey and VI data were only similar for three of the five 
common questions, loading dose, timing of first level and the target trough level (Table 
6.1 and Table 6.2). This may suggest that respondents equally understood those three 
questions in the VI and the knowledge survey.  Responses to two questions, maintenance 
dose and administration rate, were significantly better in the knowledge survey compared 
with the VI. This could be caused by the respondents’ different understanding about the 
survey questions presented in the two media or difference in knowledge level between the 
participants in the two surveys. Following implementation, qualitative survey responses 
demonstrated that the VI was well received by users, and was considered to be an 
engaging and entertaining method of improving knowledge. A small number of responses 
highlighted technical issues relating to not being able to load the video content, which 
were generally resolved through software upgrades. 
 
Numerous studies have reported the development and evaluation of serious games for 
training health professionals, but few have targeted multiple professions (Wang et al., 
2016; Graafland et al., 2012; Bergeron, 2008; Taekman and Shelley, 2010). One study 
reported development of a serious game on appropriate antibiotic use, but this was not 
specific to any particular antibiotic (Castro-Sanchez et al., 2014). Vancomycin was 
chosen as the topic for our web-based tool due to its frequency of use, and complexities 
associated with treatment of serious MRSA infections, the requirement for loading doses, 
TDM and subsequent dose adjustment. The VI in this study adopted some principles of 
serious game design (Graafland et al., 2014a), including interactivity and entertainment, 
and combined those with humour (Ziegler, 1999) to engage multi-professional users. 
Knowledge responses from the VI are promising, and further research is needed to 
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determine the reasons for difference in responses to questions between the classical 
knowledge survey and knowledge responses from VI website data. 
 
Feedback from the majority of the participants suggested that the VI enhanced their 
vancomycin knowledge (79%) and improved their performance (72%). This supports the 
VI as a resource to provide healthcare professionals with training on clinical use of 
vancomycin. Qualitative responses were generally positive, further supporting the use of 
the VI for health professional education. The main challenges for implementation of the 
VI related to developing clinical content for the video that would remain applicable to all 
three professional groups, without creating a tool that would take too long to complete. 
Advertising the tool using different media was also challenging, as the tool was made 
available across two health districts with multiple hospitals, and the target professional 
groups may have preferred to receive alerts regarding content in different ways. 
 
The creation of a brief, web-based, entertaining educational tool was the purpose of the 
project, whereby no further mandatory training burden was placed on staff. As distinct 
from existing local mandatory learning modules, the VI was intended for use among 
clinical staff involved in vancomycin use. Employing serious game design concepts may 
provide greater educational benefit than traditional computer-based learning methods 
through the use of greater interactivity, entertainment and scoring; however, further 
published comparisons are required (Wang et al., 2016).   Our results suggest that 
pharmacists have the greatest level of knowledge on clinical vancomycin use. Therefore, 
in order to deliver the best learning outcomes for health professionals in this area, it is 
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recommended to combine face-to-face teaching with VI learning, using pharmacists as 
educators in the future. 
6.6.2 Limitations of this study 
We studied the logistics and design of an web-based e-learning tool incorporating 
interactive video content for health professional education relating to clinical use of the 
antibiotic vancomycin. Post-intervention knowledge and clinical outcomes were not 
reported here; these form the basis of ongoing research that will be reported separately. 
The use of an open website allowed for potential diffusion worldwide, since users outside 
our organisations may have found the VI using an internet search engine. In August 2015 
the website was also shared on a professional network with members outside the targeted 
health district. As a result, there was some unintended use of the video prior to its general 
release. However, the greatest number of web sessions was from ISLHD, and employees 
of the target ISLHD hospitals may not have been physically located in the region while 
completing the VI.  
 
Question design within the VI was limited to multiple choice and multiple answer 
questions. Further variation in question types such as open questions, as previously 
reported (Johnsen et al., 2016), could be made in future versions to improve immersion 
and interactivity. The inclusion of a formal testing process immediately before and after 
the e-learning tool may also have added some informative value on its effect and could 
inform future improvements. In addition, further scoring methodology, such as time 
limitation, competition and  increasing difficulty could improve the robustness of the 
design (Wang et al., 2016). The Hawthorne effect may have introduced bias into the 
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study, whereby participants’ behaviour may have been altered through their awareness of 
being measured. This bias may have been limited by participation being anonymous, and 
the primary intended aim for users being to further their vancomycin knowledge, rather 
than participation in a research project. Detailed economic analysis of the study was 
limited by the project forming part of usual educational activities for study investigators. 
As such, the total project cost was likely greater than the reported production cost. 
 
There was relatively low uptake of the VI among clinical staff during the study period 
despite broad advertisement; this limited statistical power of the study and highlighted the 
challenge of using a new e-learning tool for delivery of non-compulsory training material 
to health professionals. Reasons for this probably related to the following: (1) the VI was 
not mandatory learning, so health professionals who did not regularly use vancomycin 
may not have been motivated to participate; (2) competing education priorities in those 
health professionals not otherwise intrinsically motivated to participate; (3) lack of time 
out from clinical responsibilities; (4) the likelihood that multiple staff completed the VI 
together, meaning that the VI’s reach might have been greater than the results 
demonstrated; (5) the tool was not targeted towards a specific profession; and (6) not 
being able to access the VI using hospital computers, which may have hampered 
widespread use by health professionals during office hours. However, there were only 
four reports of the VI not loading from 51 survey responses, suggesting that the majority 
of participants could access the VI. While the free access website allowed for 
participation during working hours, there may have been less motivation to perform 
work-related education in this setting. It was expected that the greatest amount of 
participation would occur during working hours on hospital computers. Clinical 
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indications for vancomycin were not addressed by the VI, as its primary purpose was to 
improve knowledge once the decision to prescribe had been made. 
 
Our study presented a model for adopting serious game concepts in combination with 
humour to develop and conduct web-based health professional education in a light-
hearted, interactive and entertaining way. This model may be useful in settings where use 
of face-to-face education is limited by resources and geography. As the VI learning 
material was made available around the world, it showcased another significant benefit of 
open e-learning resources. Health professionals and health care organisations with the 
same learning needs can reuse the material we have published rather than expending 
resources to develop similar material. 
6.6.3 Conclusions 
We demonstrated a novel web-based e-learning tool that used humour and some game 
design principles to deliver health professional education on the commonly used 
antibiotic vancomycin. The VI was well accepted by users, and was thus useful for 
delivering the intended health professional education. Future learning needs for different 
professional groups were identified through both the web-based knowledge survey and VI 
data. This will allow tailoring of face-to-face education programs, in addition to 
subsequent versions of the VI that will embed robust gaming methodology. Further 
research will be aimed at measuring the effect on knowledge of the VI compared with a 
traditional email intervention, and examining the impact of the VI on clinical vancomycin 
use. 
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7.1 Summary statement 
This chapter further investigates the use of technology for providing education to health 
professionals in relation to antimicrobial use, a theme that builds on those described in 
Chapters 5 and 6. The VI is compared with a standard educational email intervention in 
terms of clinical vancomycin knowledge use. The outcome measure of vancomycin 
plasma levels is also evaluated in relation to the VI. Clinical outcomes of antimicrobial 
use as balancing measures have also been explored in Chapters 2, 3, 4, and 5.  
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7.2 Abstract 
7.2.1 Background 
IBL for health professional education is increasing. It offers advantages over traditional 
learning approaches, as it enables learning to be completed at a time convenient to the 
user and improves access where facilities are geographically disparate. We developed and 
implemented the VI e-learning tool to improve knowledge on the clinical use of the 
antibiotic vancomycin, which is commonly used for treatment of infections caused by 
MRSA. 
7.2.2 Objectives 
The aims of this study were to evaluate the effect of the VI e-learning tool on: (1) survey 
knowledge scores and (2) clinical use of vancomycin among health professionals. 
7.2.3 Methods 
We conducted a comparative pre-post intervention study across the 14 hospitals of two 
health districts in New South Wales, Australia. A knowledge survey was completed by 
nurses, doctors and pharmacists before and after release of a web-based e-learning tool. 
Survey scores were compared with those obtained following a traditional educational 
intervention in the form of an email update. Survey questions related to dosing, 
administration and monitoring of vancomycin. Outcome measures were survey 
knowledge scores among the three health professional groups, vancomycin plasma trough 
levels and vancomycin approvals recorded on a CDSS. 
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7.2.4 Results 
Survey response rates were 27% (577/2147) pre-intervention and 8% (177/2147) post-
intervention. The VI was associated with an increase in knowledge scores among nurses 
(mean 1.67 out of 5 to 2.35/5; p<0.001) but not among other professional groups. The 
comparator email update was associated with an increase in knowledge scores among the 
overall respondent group (mean 2.85/5 to 3.3/5; p=0.02) and among doctors (mean 2.83/5 
to 3.29/5; p=0.04). Participants who referred to web-based resources while completing 
the e-learning tool achieved higher overall scores than those who did not (p<0.001). The 
e-learning tool was not shown to be significantly more effective than the comparator 
email in the clinical use of vancomycin, as measured by plasma levels within the 
therapeutic range. 
7.2.5 Conclusions 
The e-learning tool was associated with improved knowledge scores among nurses, 
whereas the comparator email was associated with improved scores among doctors. This 
implies that different strategies may be required for optimising the effectiveness of 
education among different health professional groups. Improvements to design and 
evaluation methodology are proposed to increase the likelihood of a demonstrable effect 
from e-learning tools in the future. 
7.2.6 Keywords 
Nursing education; pharmacy education; medical education; continuing education; survey 
methods; anti-bacterial agents. 
200 
 
7.3 Introduction 
7.3.1 Internet-based learning 
Traditional face to face approaches to health professional education are being challenged 
by busy trainee schedules, involving increased clinical demands and decreased available 
time (Cook et al., 2010; Wang et al., 2016). These barriers can be addressed through the 
use of internet-based learning (IBL) approaches, which can be completed at a time 
convenient to the user (Cook et al., 2008). IBL may also be useful where health 
professional education is required across geographically disparate hospital locations. 
Effective IBL tools should provide entertainment and supply the user with knowledge, 
skills or attitudes useful in real life (Bergeron, 2006). Recently there has been 
considerable development in novel IBL methodologies for health professional education 
(such as serious games) with common topics relating to surgical skills training, critical 
care and emergency triage (Graafland et al., 2012; Wang et al., 2016). Some studies 
showed improvements in test scores (Wang et al., 2016); however, study design was 
heterogeneous, and none focused on the antibiotic vancomycin as an educational target.  
7.3.2 Vancomycin education 
Vancomycin is the main antibiotic used for treatment of infections caused by MRSA 
(Antibiotic Expert Groups, 2014). Problems associated with vancomycin use across 
multiple professions include the requirement for a loading dose in serious infections, side 
effects when administered too rapidly, and the need to monitor vancomycin plasma levels 
(or concentrations) (Antibiotic Expert Groups, 2014). Therefore, several studies have 
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described interventions to improve clinical use of vancomycin (Phillips et al., 2016; 
Melanson et al., 2013; Swartling et al., 2012; Coleman and Wilson, 2015; Hamad et al., 
2015; Crowley et al., 2007; Dib et al., 2009; Li et al., 2012). Specific topics addressed in 
those studies were dosing (Phillips et al., 2016; Swartling et al., 2012; Hamad et al., 2015; 
Li et al., 2012), administration (Phillips et al., 2016) and therapeutic drug monitoring 
(TDM) (Phillips et al., 2016; Melanson et al., 2013; Swartling et al., 2012; Coleman and 
Wilson, 2015; Crowley et al., 2007; Dib et al., 2009). Educational targets were nurses, 
doctors, or pharmacists, with one TDM study conducting multidisciplinary interventions 
(Crowley et al., 2007). In a previous study we described the design and implementation 
process of a web-based e-learning tool (Vancomycin Interactive; VI©) that employed 
serious game design concepts including interactivity and entertainment to provide 
education on vancomycin (Bond et al., 2017). To our knowledge, the current study is the 
first to compare outcomes of a vancomycin e-learning tool with a standard didactic email 
intervention. 
7.3.3 Aims of this study 
The aims of this study were to assess the VI e-learning tool versus standard email update 
for: (1) effects on health professionals’ vancomycin knowledge; and (2) effects on quality 
of vancomycin use measured by both vancomycin plasma trough levels and approvals for 
use recorded on a computerised clinical decision support system (CDSS) (Guidance 
Group, 2013). 
 
202 
 
7.4 Methods 
This comparative pre-post intervention study took place in ISLHD (intervention site; 
1000 total beds; 700 acute beds) and SESLHD (comparator site; 1500 total beds; 1200 
acute beds), located in New South Wales (NSW), Australia (Figure 7.1). These health 
districts cover a geographic area of 6,331 km2 and have an estimated population of 1.17 
million, reaching from central Sydney to 3 h drive south (New South Wales Health, 
2010). The districts’ 14 hospitals range from small rural facilities to large tertiary 
metropolitan hospitals.  The comparator site was selected due the following: a shared 
information technology platform with the intervention site; geographical proximity, and 
existing clinical and professional networks.  
 
 
Figure 7.1: Map of intervention and comparator sites 
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7.4.1 Pre-and post-intervention vancomycin knowledge survey  
An anonymous web-based survey was created using Survey Monkey® (SurveyMonkey 
Inc, Palo Alto, CA) to determine pre-intervention experience/confidence and knowledge 
of vancomycin use among nurses, doctors and pharmacists across two health districts 
(Bond et al., 2017). A four-point Likert scale was used to determine levels of experience 
and confidence relating to knowledge questions on dosing, administration and monitoring 
of vancomycin (Table 6.1). Post-intervention, a second survey with the same questions 
was sent to the intervention and comparator sites. User testing indicated that pre-
intervention survey would take around two minutes to complete and the post-intervention 
surveys would take three minutes, since additional user feedback was sought on the VI 
and comparator email. Requests for survey participation are included as Figure 7.2 and 
Figure 7.3. A survey question on resources used to answer the survey was also analysed. 
 
“Dear health professional (nurse, doctor, pharmacist), 
Please take two minutes to complete a brief knowledge survey on the dosing, 
administration and monitoring of vancomycin.  
This survey will help us to develop a vancomycin learning module targeted to your 
needs at SESLHD and ISLHD Hospitals. 
https://www.surveymonkey.com/s/vancomycin 
We would be grateful for your time to answer 10 quick questions.  
Thank you” 
 
Figure 7.2: Pre-intervention survey request emailed to staff at intervention/ comparator 
sites 
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Dear colleague, 
Please take 3 minutes to complete this second survey on the anti-MRSA antibiotic 
vancomycin. We would love to know if the VI/vancomycin email update was useful, 
and how we can improve antibiotic education in the future. Answers will remain 
confidential. 
To complete the survey please click: https://www.surveymonkey.com/r/vancomycin 
Thanks!” 
 
Figure 7.3: Post-intervention survey request emailed to staff at intervention/ comparator 
sites 
7.4.2 VI and clinical email update 
Educational content was developed locally for the VI on dosing, administration and TDM 
of vancomycin (Antibiotic Expert Groups, 2014; Society of Hospital Pharmacists of 
Australia Publications Reference Group, 2015). The learning objectives of the VI for 
target users (nurses, doctors and pharmacists) were to improve knowledge of vancomycin 
dosing, administration and TDM. The VI (ISLHD) (Bond and Crowther, 2015) depicted a 
case study involving interaction between a patient and a health professional, both played 
by professional actors. The user interface consisted of video clips interspersed with 
interactive question and answer scenarios (Table 6.2). User testing indicated that the VI 
would take approximately 10 minutes to complete. An email (taking 2-3 minutes to read) 
with the same clinical content and learning objectives was developed as a comparator 
intervention (Figure 7.4). To allow for the differences in the two media, there were some 
minor variations in clinical content between the VI and email that related to 
administration of vancomycin. 
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Release and advertisement of the VI (email, newsletters, link on intranet homepage) to 
the intervention site occurred on 27 July 2015. The clinical email update was then sent to 
nurses, doctors and pharmacists at the comparator site (Figure 7.4). Following completion 
of the second survey, the VI website was also advertised to the comparator site. 
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“Dear health professional (nurse, doctor, pharmacist), 
There have been some important updates to the adult guidelines for dosing, 
administration and monitoring of intravenous vancomycin, commonly used for the 
treatment and prevention of infections caused by MRSA.  
Please see below for the key points: 
 
DOSING 
A loading dose is recommended, particularly in patients with serious infections who 
are critically ill. A dose of 25-30 mg/kg is appropriate in most situations. 
For maintenance doses of vancomycin in an average weight patient (70kg): 
 Creatinine clearance 
(mL/min)  
Starting maintenance 
dosage 
Timing of trough  
plasma level 
more than 90 1.5 g 12-hourly before the fourth dose 
60 to 90 1 g 12-hourly before the fourth dose 
20 to less than 60 1 g 24-hourly before the third dose 
less than 20 1 g 48-hourly 48 hours after the first 
dose 
-      For intermittent dosing of vancomycin, an appropriate maintenance dose is 15-20 
mg/kg (actual bodyweight). Use the Cockcroft-Gault formula or online calculator to 
approximate creatinine clearance. 
 
ADMINISTRATION 
Vancomycin should be administered by slow infusion at a rate of 10 mg/min. 
 
MONITORING 
-      The recommended trough level for vancomycin is 15 to 20 mg/L for most 
infections. 
-      Before interpreting the result, check that the timing of the trough sample was 
appropriate (i.e. before the last dose was given). In patients receiving vancomycin 
12hrly, do not wait for the trough concentration result before giving the next scheduled 
dose. 
-      Adjustment of vancomycin dosage in adults: 
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 Trough 
plasma level 
Dosage adjustment 
less than 10 
mg/L 
Increase dosage by adjusting either the dose or the dose interval. 
 
10 to 14 
mg/L 
For patients with uncomplicated infection who are clinically 
improving, maintain current dosage. For patients with complicated 
infection, increase dosage by adjusting either the dose or the dose 
interval to achieve a trough concentration of 15 to 20 mg/L. 
15 to 20 
mg/L 
Maintain current dosage. 
21 to 25 
mg/L 
Maintain current dosage, or reduce dosage by adjusting either the 
dose or the dose interval, or withhold dose. 
more than 25 
mg/L 
Withhold dose until trough concentration is less than 20 mg/L and 
seek expert advice. 
 For any questions please contact …” 
Clinical content based on Therapeutic Guidelines: Antibiotic, Version 15 (Antibiotic 
Expert Groups, 2014). 
 
Figure 7.4: Clinical email update sent to staff at the comparator sites  
 
7.4.3 Vancomycin trough plasma levels and approvals on the CDSS 
Vancomycin plasma levels from a four month period before and a two month period after 
the VI and comparator email were analysed to determine changes in the proportion of 
levels in the therapeutic range. The post-intervention period was limited to two months in 
order to conclude prior to the annual intake of new junior doctors. Criteria for dose 
adjustment were as follows: (1) 0-9 mg/L, increase dose; (2) 10-14 mg/L, maintain or 
increase dose depending on severity of infection and clinical status; (3) Maintain current 
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dose (4) 20-25 mg/L, maintain or reduce dose depending on severity of infection and 
clinical status; (5) >25 mg/L, withhold dose until trough level less than 20 mg/L and seek 
expert advice (Antibiotic Expert Groups, 2014). The number of vancomycin levels as a 
proportion of the total number of vancomycin CDSS approvals was also analysed to 
determine frequency of vancomycin use. Pharmacy dispensing software did not allow for 
patient-level data on vancomycin dispensing to be analysed, as vancomycin was 
distributed as ward stock in some hospitals. Hence, vancomycin CDSS approvals were 
used as a surrogate indicator for total vancomycin use. 
7.4.4 Outcome measures 
We compared total vancomycin knowledge survey scores pre- and post-intervention, 
within and between intervention and comparator sites. The number of vancomycin levels 
in the therapeutic range, the median number of vancomycin levels and ratio of 
vancomycin levels to CDSS vancomycin approvals between sites were also analysed. 
7.4.5 Statistical analyses 
Chi-square and Fisher’s exact tests were used for proportions. For continuous data, 
normality was assessed using a Skewness/Kurtosis statistic (D'Agostino et al., 1990). A 
skewed distribution was denoted by p<0.05. Kruskal-Wallis and follow up Wilcoxon 
rank-sum tests were used to investigate between effects with non-normal distributions. 
Multivariate analysis was performed to examine influential factors (profession, site, pre- 
or post-intervention) on correct survey responses. Statistical analyses were performed 
using Stata statistical software: Release 14 (Statacorp LP, College Station, TX, USA). 
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7.4.6 Ethics  
Ethics approval was granted by the Joint UOW and ISLHD Health and Medical Human 
Research Ethics Committee (EC00150), approval number HE15/005 (Appendix F). The 
VI website contained a disclaimer that anonymous data collected from the video could be 
used for research purposes. 
 
7.5 Results 
7.5.1 Vancomycin knowledge survey 
The response rate to the pre-intervention survey was 27% (577 responses from 2147 
email recipients).  The response rates by profession were 24% (236/967) for nurses, 25% 
(271/1070) for doctors and 64% (70/110) for pharmacists (p<0.001); previously reported 
(Bond et al., 2017). Post-intervention, there were 177 survey responses (8% response 
rate), comprising 88 nurses, 69 doctors and 20 pharmacists (p<0.001). 
 
Univariate analysis demonstrated that pre-intervention, there was a higher median survey 
score for the comparator site (median 3/5; IQR 2-4; mean 2.85) than for the intervention 
site (2/5; IQR 1-3; mean 2.51; p=0.01). Post-intervention survey scores were also higher 
for the comparator site (median 3/5; IQR 2-4; mean 3.3) than for the intervention site 
(median 3/5; IQR 2-4; mean 2.71; p=0.06). 
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The median knowledge survey score for nurses increased post-VI (p<0.001; Table 1). No 
significant differences pre- and post-VI were observed for doctors, pharmacists or for 
combined health professionals. At the comparator email site, the median knowledge 
survey score increased post-intervention for combined health professionals (p=0.02) and 
for doctors (p=0.04). 
7.5.2 Resources used to answer survey questions 
To the question, “Did you refer to any resources to answer these questions?,” 595/754 
(79%) participants responded “no”. Out of those 595, 424 (71%) self-reported that they 
guessed some or all of the answers, whereas 171 (29%) reported that they knew the 
answers. The remaining 159/754 (21%) respondents self-reported that they referred to 
resources for answering the questions. The resources quoted were local guidelines 
(49/159 [31%]) and the Australian Medicines Handbook or Therapeutic Guidelines: 
Antibiotic (110/159 [69%]). 
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Table 7.1: Pre- and post-intervention median knowledge survey score, n (IQR)  
Profession VI intervention site Comparator email site 
Pre; n=278 Post; n=107 p 
value 
Pre; n=299 Post; n=70 p  
value 
Nurse 2/5 (1-2) 
Mean: 1.67 
2/5 (1-3) 
Mean: 2.35 
<0.001 2 (1-3) 
Mean: 2.30 
3 (2-4) 
Mean: 2.71 
0.17 
Doctor 3 (2-4) 
Mean: 3 
4 (2-4) 
Mean: 3.29 
0.28 3 (2-4) 
Mean: 2.83 
4 (2-4) 
Mean: 3.29 
0.04 
Pharmacist 5 (4-5) 
Mean: 4.24 
4 (4-5) 
Mean: 3.89 
0.40 5 (4-5) 
Mean: 4.39 
5 (4-5) 
Mean: 4.27 
0.87 
Total  
score 
2/5 (1-4) 
Mean: 2.51 
3/5 (2-4) 
Mean: 2.71 
0.24 3 (2-4) 
Mean: 2.85 
3 (2-4) 
Mean: 3.3 
0.02 
 
7.5.3 Multivariate analysis of knowledge survey scores  
Several factors were associated with an increased knowledge survey score. Compared 
with nurses, pharmacists (regression coefficient 1.93; 95% confidence interval 1.63-2.23; 
p<0.001) and doctors (coeff 0.89; 95% CI 0.70-1.09; p<0.001) had increased likelihood 
of a higher survey score. Post-intervention survey participation was also associated with a 
higher score (coeff 0.41; 95% CI 0.20-0.62; p<0.001) than pre-intervention. Referring to 
online resources was associated with a higher score compared with responses where 
participants self-reported that they knew or guessed the answers (coeff 0.98; 95% CI 
0.75-1.20; p<0.001). The comparator site was not significantly associated with increased 
likelihood of higher survey scores (coeff 0.16; 95% CI -0.02-0.34; p=0.08). 
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7.5.4  Vancomycin TDM 
From 1 January to 30 April 2015 there were 429 vancomycin trough plasma levels taken 
at the intervention site (ISLHD; 1000 beds) and 1571 levels for the comparator site 
(SESLHD; 1700 beds). During the post-intervention period 1 December 2015 to 31 
January 2016, there were 151 levels reported at the intervention site and 316 levels at the 
comparator site. As shown in Table 7.2, there were no significant post-intervention 
differences in the proportion of vancomycin levels in the sub-therapeutic (0-9mg/L), 
therapeutic (10-14, 15-20, 21-25 mg/L) or supra-therapeutic (>25 mg/L) ranges. There 
were increases in the number of levels in the high-therapeutic range (20-25 mg/L) at both 
sites; however, those differences did not reach statistical significance. There were no 
significant pre-post intervention differences in median vancomycin levels at the 
intervention site or comparator site (Table 7.2). 
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Table 7.2: Pre- (4 months) and post-intervention (2 months) vancomycin plasma trough 
levels for intervention and comparator sites, n (%)  
Trough level (mg/L) VI intervention site Comparator email site 
Pre 
n=429 
Post 
n=151 
p 
value 
Pre 
n=1571 
Post 
n=316 
p 
value 
0-9 (sub-therapeutic) 48 (11) 17 (11) 0.98 259 (16) 50 (16) 0.77 
10-14 (low therapeutic) 91 (21) 28 (19) 0.49 362 (23) 62 (20) 0.18 
15-20 (therapeutic) 168 (39) 54 (35) 0.46 515 (33) 98 (31) 0.54 
21-25 (high therapeutic) 72 (17) 36 (24) 0.06 260 (17) 66 (21) 0.06 
>25 (supra-therapeutic) 50 (12) 16 (11) 0.73 175 (11) 40 (13) 0.44 
Median trough level 
(IQR) 
18 (13-21) 17 (13-22) 0.62 16 (12-21) 17 (12-22) 0.14 
VI, Vancomycin Interactive; IQR, interquartile range. 
7.5.5 Vancomycin trough plasma levels compared with vancomycin CDSS 
approvals  
The proportion of vancomycin trough levels to vancomycin CDSS approvals at the 
intervention site decreased from 429/399 pre-intervention (1.1 levels for every 
vancomycin approval) to 151/196 post-intervention (0.8 levels/approval). At the 
comparator site, the proportion of vancomycin levels to vancomycin CDSS approvals 
decreased from 1571/399 pre-intervention (3.9 levels/approval) to 314/199 post-
intervention (1.6 levels/approval).  
 
214 
 
7.6 Discussion 
7.6.1 Principal findings 
This study compared the educational effect of an interactive web-based e-learning tool 
with a comparator email update. Altogether, the e-learning tool did not result in improved 
knowledge survey scores or clinical vancomycin use when compared to the email. 
However, the e-learning tool was associated with improved survey scores among nurses, 
whereas the comparator email update was associated with improved scores among 
doctors. Multivariate analysis showed that survey scores did not differ between the 
intervention and comparator sites. Not unexpectedly, pharmacists and doctors had higher 
overall knowledge scores than nurses due to the greater number of questions considered 
relevant to those groups. Participants who referred to web-based resources while 
completing the survey had higher survey scores than those who did not. 
Concerningly, only about one third of pre- and post-intervention vancomycin levels taken 
at both sites fell within the recommended therapeutic range of 15-20 mg/L. This figure 
rose to 73% when the ranges 10-14 mg/L, 15-20mg/L and 21-25 mg/L were combined, 
which includes all potential recommended therapeutic ranges (Antibiotic Expert Groups, 
2014). The proportion of vancomycin levels to CDSS approvals decreased at both sites, 
perhaps signifying a reduction in the ordering of unnecessary levels, or shorter 
vancomycin courses requiring fewer levels. A greater proportion of levels/approvals was 
observed at the comparator site in both pre- and post-intervention phases, which may 
have resulted from differences in acuity between sites. 
In previous studies, strategies for improving the clinical use of vancomycin have included 
use of loading doses (Li et al., 2012), implementation of guidelines (Swartling et al., 
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2012), education (Phillips et al., 2016; Coleman and Wilson, 2015; Dib et al., 2009), and 
clinical decision support systems (Hamad et al., 2015; Crowley et al., 2007; Melanson et 
al., 2013).  None of those educational interventions incorporated a web-based e-learning 
tool, and the predominant methodology was uncontrolled pre-post intervention at single 
hospital sites. One study has reported development of a serious game to improve general 
antimicrobial prescribing but it did not focus on vancomycin (Castro-Sanchez et al., 
2014). A review of educational games for health professionals emphasised the need for 
more research with improved study methodology (Akl et al., 2013). Our study differed in 
its multisite approach, comparison of e-learning tool with a standard email intervention, 
and targeting of multiple health professional groups.  
7.6.2 Interpretation of results 
The difference in efficacy between the VI (improved nurses’ scores) and the email 
(improved doctors’ scores) may have arisen from nurses’ increased familiarity and 
engagement with online learning modules, whereas for doctors a didactic learning style 
may be more suitable. Additionally, the short time to read a clinical update email may 
have been more convenient for doctors. Referring to resources was associated with 
improved survey scores, which emphasises the importance of guideline access in the 
clinical setting. Some aspects of our study design may be applicable to facilities where 
there are geographic barriers to use of face-to-face education, such as rural and regional 
hospitals. Some improvements to the structure of the VI through greater application of 
serious game methodology are proposed (Table 7.3), including more interactivity, scoring 
and competition (Graafland et al., 2014; Thompson, 2012). Those features could result in 
a greater level of user acceptance and effectiveness. 
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7.6.3 Study limitations 
There were some underlying differences in baseline vancomycin knowledge between 
intervention and comparator sites as detected in the univariate analysis; however, those 
did not retain significance in the multivariate analysis. Also, the total number of 
vancomycin levels at the comparator site was considerably higher, which may be due to 
differences in case mix (number of acute beds), antimicrobial use and background 
educational culture. However, the proportion of satisfactory levels (i.e. those in 
therapeutic range) did not differ between the sites. Furthermore, similar sizeable 
reductions in the number of vancomycin levels ordered were experienced at both sites. 
Some of this reduction may have been associated with seasonal variation of vancomycin 
use, although unlike other antibiotics, vancomycin is not typically associated with strong 
seasonal variation (Australian Commission on Safety and Quality in Health Care, 2015). 
The low response rate to the post-intervention survey limited the power of pre-post 
intervention comparisons.  Potential reasons for this reduction include the perception of 
staff that the post-intervention survey request concerned the pre-intervention survey, 
despite clarifications that were provided in the email title and text, and appropriate 
advertisement in staff newsletters. We note that the proportions of different health 
professionals were similar in the two time periods. In addition, the denominator included 
all targeted health professionals including those not involved in the day-to-day clinical 
use of vancomycin, which is likely to have reduced the response rate.  
The higher scores from the post-intervention survey may have resulted from participant 
bias; i.e. only more experienced and enthusiastic staff may have responded to the second 
survey. Time-dependent bias may also have influenced some of the improvement in 
217 
 
survey scores, whereby increased time in a clinical role may have resulted in greater 
knowledge of vancomycin use over the study period. A crossover design might have 
partially alleviated this factor, but was not possible in our case due to the rotation of 
junior doctors between the two sites.  
There were some minor variations in clinical content between the VI and email; however, 
they related only to administration of vancomycin and references used for development of 
content were the same for both interventions. Participants who referred to guidelines 
while completing the survey attained higher scores than those who did not. Although this 
was unavoidable in a pragmatic study, it was still a desirable outcome as those 
participants were using recommended national or local guidelines. The time to complete 
the e-learning tool (10 minutes) was longer than the email update (2-3 minutes); the 
duration of the email may have been more appropriate in a busy clinical context. As 
reported in our previous study (Bond et al., 2017), there was low uptake of the VI during 
the study period, and we did not measure the number of comparator emails read by staff. 
There may have been some word of mouth leakage of the VI to the comparator site; 
however, study data collection was completed prior to the junior doctor rotation. Given 
the use of paper medications charts, the number of CDSS approvals was used as a 
surrogate for vancomycin prescribing. We did not examine quality measures of 
vancomycin use such as time to first therapeutic level, levels obtained at steady-state, or 
clinical outcomes associated with the intervention; further research aims to examine these 
effects. Linkage of survey-participant responses was desirable but was not achievable 
within the ethical requirement for an anonymous survey. Based on those limitations and 
the mixed results of our study, we propose a checklist that, subject to validation, may 
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improve the likelihood of demonstrating significant effects from an e-learning tool (Table 
7.3). 
 
Table 7.3: Proposed development and evaluation checklist for health professional e-
learning tools  
 Perform qualitative research prior to design to determine learning needs of the target 
group 
 Target clinical content to a specific health professional group 
 Apply a theoretical educational framework to include serious game design elements 
such as entertainment, interactivity, scoring, and competition 
 Use identifiable surveys where possible to allow individual linkage of pre- and post-
intervention survey results 
 Allow for sufficient time post-intervention to collect data on knowledge and user 
acceptability 
 Limit time required to complete the application (<5 minutes) in the context of a busy 
clinical environment and acknowledging competing education priorities 
 Improve access to the e-learning tool through open access websites, development of the 
tool as an app and shortcuts through the local intranet 
 Record pre- and post-intervention data that can suggest both effectiveness and non-
effectiveness, including quantitative clinical outcomes 
 Develop a comprehensive advertisement and dissemination  plan, to include email, 
social media, newsletters, hospital grand rounds, quick links on hospital computers 
 Optimise search engine capacity 
 Select appropriate site for comparison with  the e-learning tool 
 Comprehensive beta-testing by target end users 
 Collect relevant from the e-learning tool’s data feed 
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7.6.4 Conclusions 
Different health professional groups can be educated by using different targeted learning 
approaches. Significant challenges can be experienced during design and evaluation of 
comparative e-learning research. Further studies should aim to improve structural 
elements of e-learning tools and enhance evaluation through an approach governed by a 
newly proposed checklist. 
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8 General discussion 
8.1 Preamble 
The research in this thesis by journal article compilation has extended current knowledge 
of antimicrobial stewardship. The three primary aims were achieved during the course of 
this research project. Firstly, an educational approach to improving antimicrobial use was 
developed and evaluated at the individual, department, hospital and health district level. 
Prevention of infection, treatment of infection and a serious adverse effect of 
antimicrobial use were presented to demonstrate the value of this approach. Secondly, 
AMS education and evaluation strategies applicable to multisite and rural and regional 
settings were developed. Clinically meaningful outcome measures were targeted, such as 
duration of antimicrobial therapy, LOS and mortality. Thirdly, technology for improving 
ASPs was developed, implemented and evaluated, including: a CDSS to enhance 
education and reporting, use of email in research and development of a web-based e-
learning tool for education of health professionals. The results suggest that: common 
educational methods can be used to improve hospital antimicrobial use across different 
clinical settings and organisational levels; patient-related outcomes should be measured in 
addition to processes when evaluating AMS interventions; and technological innovations 
can enhance the effectiveness of ASPs. 
 
This concluding chapter provides an overview of project findings, followed by an outline 
of the implications, strengths and limitations of this work. Recommendations for future 
research are presented, followed by the thesis conclusions. 
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8.2 Overview of findings 
Improving antimicrobial use in humans forms an important part of the Australian national 
strategy to address AMR (Australian Government, 2015). Hospital AMS initiatives 
should be targeted towards high-use areas, such as surgical prophylaxis and treatment of 
common infections such as CAP (Duguid and Cruickshank, 2010; Australian 
Commission on Safety and Quality in Health Care, 2015). In Chapter 2, an educational 
approach was employed to discontinue prophylactic gentamicin use for insertion and 
removal of urinary catheters in orthopaedic surgery patients. Use of gentamicin in this 
setting was considered inappropriate according to national guidelines (Antibiotic Expert 
Group, 2010), but was an embedded practice at the time of intervention. The requirement 
for peer education and review, and the potential for medico-legal considerations to 
influence behaviour change among senior doctors were outlined in this chapter. 
 
CAP remains a leading cause of hospitalisation and death worldwide (Postma et al., 
2015). Inappropriate use of antimicrobials for the treatment of CAP can result in 
emergence of resistant pathogens such as MRSA (Paterson, 2004). Chapter 3 reported an 
approach for improving antimicrobial treatment of CAP that included use of timely 
measurement and feedback to individual clinicians via email, education at departmental 
meetings, and auditing of compliance with guidelines. Based on those interventions, a 
reduction in median duration of CAP therapy was demonstrated, driven by shorter 
courses of oral antimicrobials. Excessive duration of therapy is one of the most common 
reasons for inappropriate antimicrobial use in Australia (Australian Commission on 
Safety and Quality in Health Care, 2015), so this was targeted in addition to initial choice 
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of therapy. Furthermore, a significant reduction in the inappropriate use of the broad 
spectrum antibiotic ceftriaxone was demonstrated. 
 
As inappropriate use of antimicrobials for prevention and treatment of infections can 
result in adverse effects such as HCA-CDI, a project examining the relationship between 
AMS and CDI was conducted (Chapter 4). The purpose of this chapter was to determine 
whether the combination of a health district-wide ASP and a targeted education and 
feedback initiative would result in a reduction in HCA-CDI rates. In addition, the burden 
of HCA-CDI in terms of LOS and hospital costs was investigated. Although a reduction 
in monthly HCA-CDI rates was observed using ITS analysis, this did not reach statistical 
significance. A case-control analysis showed that there was a significant burden on the 
patient in terms of additional length of hospital stay related to HCA-CDI, and also a cost 
burden for the health service. These findings reinforce the importance of developing 
AMS strategies to reduce HCA-CDI, including a reduction in inappropriate antimicrobial 
use (Leffler and Lamont, 2015). 
 
As most of the available literature on AMS outcomes is derived from tertiary 
metropolitan hospitals (Schuts et al., 2016), there is an evidence gap for programs that 
can be applied to rural and regional facilities, and multiple hospitals. Chapter 5 reported 
AMS outcomes from two neighbouring health districts with varying resource levels. A 
shared strategy of antimicrobial education and restriction was facilitated by a centrally 
deployed CDSS, demonstrating that technology can be used to support AMS in hospitals 
with disparate size and locations (Baysari et al., 2016). Antimicrobial use, costs, HCA-
CDI, infection-related LOS and mortality were selected as outcomes; those have been 
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previously reported in the published literature (Baysari et al., 2016). Significant changes 
to patterns of antimicrobial use were observed, along with reductions in antimicrobial 
costs and HCA-CDI. Although LOS and mortality were not substantially reduced when 
compared with background rates, these were included as important balancing measures 
that may have been negatively impacted by changing patterns of antimicrobial use (Davey 
et al., 2013; Davey et al., 2017). Some of the initial impact of the shared program 
diminished over time, suggesting that ongoing novel approaches to AMS education may 
be required. One such approach in the form of an e-learning tool was described in 
Chapters 6 and 7. 
 
The challenges of providing continuing health professional education, such as increased 
clinical demands, resource limitations and competing mandatory online training modules, 
are further exacerbated in health districts with multiple hospitals spread across a wide 
geographic area. Use of newer technological approaches to education may provide a 
solution. Chapter 6 described the design and implementation of a novel educational 
approach for improving knowledge on use of the anti-MRSA antimicrobial vancomycin. 
As an online e-learning tool, this approach was well received by users and offered an 
alternative to resource-intensive face-to-face education. It became evident from survey 
data that there were shortcomings in clinical vancomycin knowledge, particularly among 
nurses and doctors. Those shortcomings have provided opportunities to further explore 
vancomycin education strategies. 
 
Chapter 7 examined the e-learning approach to education, through comparison with an 
email update to clinicians. Post-intervention knowledge survey scores increased for 
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nurses following the e-learning tool, but were not significantly different for doctors or 
pharmacists. This suggests that nurses may be better suited to receiving antimicrobial 
education in this format. The comparator email was associated with an increase in 
knowledge survey scores among the total participant group and among doctors. This 
probably arose from both the shorter time requirement and the didactic nature of the 
educational e-mail.  Those survey participants who used educational resources to answer 
questions achieved higher scores than those who did not refer to resources. Pharmacists 
were more likely to achieve higher survey scores than doctors and nurses, thus they are 
well placed to facilitate additional targeted education to those professional groups. No 
significant differences were observed at the intervention and comparator sites pre- and 
post-intervention of therapeutic vancomycin plasma levels. 
8.3 Implications 
The research described in this thesis has a number of implications. It provides a model for 
evaluation of an ASP across a rural and regional health district comprising multiple 
hospitals. Where there are existing political or professional links between hospital sites, 
the reported quality improvement methodology is pragmatic and transferable to different 
clinical settings. For example, the research methodology described in Chapter 2 relates to 
orthopaedic surgery, but could just as easily be applied to other specialties where there is 
inappropriate antimicrobial prophylaxis. Equally, Chapter 3 relates to CAP, but could be 
applied to other common treatment indications with clear guidelines and evidence for 
appropriate antimicrobial use, such as cellulitis or UTIs. 
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AMR is a real and present global threat to human health (World Health Organisation, 
2011). Thus, there is a requirement for culture change in organisations, with the ultimate 
aim of improving patient outcomes through better antimicrobial use. The work contained 
in this thesis provides realistic methods for achieving change in culture. Furthermore,, 
sharing of AMS expertise across hospitals and health districts resulted in improved equity 
of program resources, such as those projects reported in Chapters 4, 5 and 6. 
  
A current educational strategy for improving clinical knowledge relating to vancomycin 
has been provided on an open and free website for any person or organisation around the 
world who wants to use it (Chapters 6 and 7). The sharing of research methods, data and 
expertise forms part of the culture within Australian AMS networks. 
8.4 Strengths  
The research described in this thesis has addressed a knowledge gap in antimicrobial 
stewardship, namely how to successfully implement a strategy for education and 
evaluation across multiple hospitals sites, incorporating smaller rural and regional 
hospitals. Different clinical aspects, with a strong grounding in the literature, were 
addressed in the chapters, and the use of technology was investigated as a means of 
overcoming barriers to antimicrobial education. In addition, educational approaches were 
targeted at different organisational levels, including individual, departmental, hospital, 
health district, and multiple health districts. 
 
Constructed as a thesis by journal compilation, common themes were present through the 
chapters, and current standards for evaluation methodology were used where appropriate. 
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An example is ITS analysis, the quasi-experimental evaluation technique described in 
Chapters 4 and 5. 
 
The reporting of meaningful outcomes is an aspect of current AMS research that requires 
improvement (Schuts et al., 2016; Davey et al., 2017). Additionally, there is a shortage of 
standard definitions for outcome measures (Moehring et al., 2017), which creates a 
barrier to pragmatic AMS research. Although process measures such as antimicrobial use 
patterns and costs are useful in describing the effectiveness of interventions, the focus 
should primarily be on patient safety. In this way, AMS becomes firmly embedded within 
the framework of clinical governance. Outcome measures selected for inclusion in this 
research project broadly align with a recent expert consensus, based on: association with 
improved antimicrobial prescribing, improved patient care, utility in targeting AMS 
efforts, and feasibility for monitoring within an eMR (Moehring et al., 2017). Markers of 
patient safety were reported in all of the individual research projects: renal function and 
SSI rates in Chapter 2; 30 day readmission rate and mortality in Chapter 3; CDI and LOS 
in Chapter 4; CDI, infection related LOS and mortality in Chapter 5; and vancomycin 
therapeutic levels, as a measure of both treatment effectiveness and drug toxicity in 
Chapter 7. Chapter 6 reported design and implementation of an e-learning tool, and 
therefore did not address patient-related outcome measures. 
 
Meaningful statistical significance was achieved in some components of all of the studies. 
Where possible, qualitative measures were also described (Chapters 3, 4 and 6). 
Examples included email feedback and qualitative survey responses. This allowed for a 
more comprehensive understanding of the cultural drivers of hospital antimicrobial use. 
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8.5 Limitations 
Detailed descriptions of limitations relating to the individual research projects were 
provided in Chapters 2, 3, 4, 5, 6 and 7. There were some overarching limitations, often 
inherent to pragmatic clinical research projects.  
 
Small sample sizes potentially compromised statistical significance and may have 
hampered applicability of results to similar populations. The uncontrolled before-and-
after intervention study designs necessarily constrained conclusions about the impact of 
interventions on outcomes. Conclusions on the effect of changes in antimicrobial use on 
patient outcomes were also impacted by the existence of a complex health system with 
multiple external confounders, such as community-acquired infections, variations in drug 
acquisition costs and infection control practices. The retrospective study methodology in 
Chapter 5 was used as a pragmatic way of assessing outcomes of AMS, where a 
prospective study would have been unachievable due to parallel clinical commitments 
during the implementation phase. Antimicrobial resistance was not included as an 
outcome measure for this research project as a longer ASP timeline would be required to 
effect meaningful changes to resistance patterns (Yong et al., 2010). 
 
Multisite methodology was one of the strengths of this research with the exceptions of 
Chapters 2 and 3 where clinical data were only presented from the tertiary referral 
hospital. This was despite attempts by the candidate to collect data at one or more of the 
smaller sites. Lack of on-site personnel, and a busy clinical load prevented adequate data 
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collection. The methodology for those studies remains applicable to a multisite approach, 
as described in suggestions for future research (Section 8.6).  
 
In the research related to the VI (Chapters 6 and 7), the pre- and post-intervention surveys 
were not linked, limiting the statistical analysis to grouped comparisons. Also, low survey 
response rates, particularly post-intervention, hampered conclusions about the 
effectiveness of the VI. This project was also the only one to compare different 
educational methods, those being an e-learning tool and an email (Chapter 7). 
 
Assessing the appropriateness of prescribing of antimicrobials according to the 
recommendations in the Australian Therapeutic Guidelines: Antibiotic (Antibiotic Expert 
Group, 2010) was an important part of this research. Midway through the research, a new 
version of the Therapeutic Guidelines: Antibiotic was released (Antibiotic Expert Groups, 
2014). However, there were no changes to the recommendations for antimicrobial use 
related to the projects described in Chapters 2, 3 or 4. Chapter 5 was a retrospective 
analysis based on the 2010 version of the guidelines, and Chapters 6 and 7 were 
constructed around clinical content that was derived only from the 2014 version.  
8.6 Suggestions for future research 
This research demonstrated changes in antimicrobial use patterns over time, and the effect 
on patient outcome measures. A number of questions have arisen that can guide further 
research. The effect of AMS on patterns of antimicrobial resistance at various 
organisational levels presents novel research opportunities, particularly in the multisite, 
non-metropolitan setting. As the majority of study methodologies were uncontrolled, 
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there is also an opportunity to conduct studies with design features that include 
prospective data collection and randomisation, and further multisite research that can 
capture data from the smaller rural hospitals. An emerging area in AMS is mixed methods 
research, whereby qualitative components provide a deeper insight into the effectiveness 
of interventions and help to inform quantitative evaluation. This would be of particular 
use in assessing technological advances. There is also the potential to further explore 
much sought after outcome data such as clinical cure rates and mortality. 
8.7 Conclusions 
With the increasing prevalence of antimicrobial resistance, there is an urgent need to 
develop ways to improve use of antimicrobials in humans. In hospitals, where patients are 
treated for severe and complex infections, antimicrobial stewardship offers a system for 
improving patient outcomes while addressing antimicrobial resistance at a broader level. 
In that context, this research has achieved the following meaningful contributions:  
(1) An educational model for discontinuing unnecessary gentamicin use in the setting of 
orthopaedic surgery was implemented without evident harm to patients.  
(2) An intervention leading to a significant reduction in antimicrobial duration of therapy 
for patients with community-acquired pneumonia, without any negative impact on 30-day 
readmission rates and mortality. 
(3) The burden of Clostridium difficile infection as a consequence of antimicrobial use 
was shown by significant increases in patient length of stay and hospital costs. 
(4) A multisite educational model resulted in significant improvements in antimicrobial 
use and was associated with reductions in Clostridium difficile infection, infection-related 
lengths of stay and mortality.  
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(5) An innovative educational method in the form of the Vancomycin Interactive e-
learning tool identified that different educational strategies can be suited to particular 
health professionals. Through addressing barriers to traditional educational methods, this 
freely available online e-learning tool offers a potential model for future antimicrobial 
education.   
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9 Appendices 
Appendix A 
Literature search methodology 
An initial search for the available literature, using a censorship date of 30 June 2013 was 
employed using the following strategy on Pubmed: 
((antimicrobial[ti] OR antifungal[ti] OR antibiotic[ti]) AND (utilisation[ti] OR 
utilization[ti] OR usage[ti] OR stewardship[ti] OR "management team"[ti]) OR 
"antimicrobial use"[ti] OR "antibiotic use"[ti] OR "antifungal use"[ti]) OR (("anti-
bacterial agents"[MeSH] OR "antifungal agents"[MeSH]) AND "Physician's Practice 
Patterns"[MeSH]). 
As an “antimicrobial stewardship” MeSH term was not available, the search strategy from 
the recent Cochrane review by Davey and colleagues (2013) was analysed to determine 
the most closely related MeSH terms, which included “anti-bacterial agents’, “anti-fungal 
agents” and “Physician's Practice Patterns”. Searches for antiviral agents and other 
antimicrobials were excluded from this literature review. 
Literature for this review was searched for using the following hierarchy (University of 
Illnois at Chicago, 2013): meta-analyses and systematic reviews; randomised controlled 
trials; cohort studies; case-control studies; case series, case reports; editorials, expert 
opinion. 
Subsequent searches for the subtopics within the review were analysed from within this 
search strategy, with a recent review article on each topic acting as a check for 
completeness of the review. The majority of studies in this field were of low quality 
238 
 
according to the evidence pyramid, mainly consisting of uncontrolled observational 
before-and-after studies. A 2013 Cochrane review identified 507 full text articles on the 
improvement of antibiotic prescribing in hospital inpatients (Davey et al., 2013). Of these, 
300 were excluded on the basis of the study design, which included inadequate time 
series analyses and uncontrolled before-and-after studies. Some of these studies were 
included, because their structure provided insight into the type of projects that were 
carried out as part of this thesis. 
 
Search terms used for Chapter 2 were: “orthopaedic surgery”, “orthopedic surgery”, 
“surgical prophylaxis”, “antimicrobial/s”, “antibiotic/s”, “antimicrobial stewardship”, 
“antibiotic stewardship”, “urinary catheter/s”, “catheter-associated bacteriuria”, “urinary 
tract infection/s”, and “prophylaxis”. 
 
Search terms used for Chapter 0 were: “community-acquired pneumonia”, “antimicrobial 
stewardship”, “antimicrobial/s”, and “antibiotic/s”. 
 
Search terms used for Chapter 4 were: “Clostridium difficile”, “antibiotic/s”, 
“antimicrobial/s”, “proton pump inhibitor/s”, “length of stay”, “health costs”, 
“antimicrobial stewardship”, and “antibiotic stewardship”. 
 
Search terms used for Chapter 5 were: “antimicrobial/s”, “Clostridium difficile”, “length 
of stay”, “health costs”, “multisite”, “multi-site”, “mortality”, “antimicrobial 
stewardship”, and “antibiotic stewardship”. 
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Search terms used for Chapters 6 and 7 were: “nursing education”, “pharmacy 
education”, “medical education”, “continuing education”, “vancomycin”, “antimicrobial 
stewardship”, “online learning”, and “serious game”. 
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Appendix B 
Ethics materials and data collection form reported in Chapter 2. 
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Orthopaedic surgical prophylaxis project data collection form 
Bed Name MRN Opn Surgeon 
and Reg 
OpDate MSU 
Preop 
(MRSA?) 
Cr 
Pre 
Cr 
Pst 
Date ABx – 
In/Pre 
(Wt) 
ABx – 
Out/Post 
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Appendix C 
Ethics materials and data collection form reported in Chapter 0. 
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CAP project data collection form 
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1a. Patient audit number: _______          1b. MRN: ___________ 1c. Site: ________ 
 
2. Initials (eg. JoSm): First _ _   Last _ _ 
 
3a. Date of birth: __________________          3b.  Sex:  M F 
 
4a. Arrival date: ________ 4b. Arrival time:________    4c. Admitted:   Y    N    U 
 
Exclusion criteria: 
< 18 years of age 
Immunosuppressed (HIV positive or concurrent chemo/immunosuppressant therapy) 
Cystic fibrosis 
Bronchiectasis 
Exacerbation of COPD or asthma if not involving pneumonia 
Suspected or confirmed tuberculosis 
Aspiration or hospital-acquired pneumonia 
Discharged from hospital within the previous 14 day period 
Patients transferred from another hospital 
 
5. Placement after ED: Discharge       HITH Ward   ICU/HDU  Transfer       
Other 
 
Doctor’s diagnosis:  Pneumonia Chest infection     Other: _____________   
Unknown 
 
Dr’s assessment of severity: Mild   Moderate Severe        Unknown 
 
CAP confirmed on Chest X-ray report: Yes    Equivocal     No    Not done    
Unknown 
 
SMART-COP severity score (on first observations): 
Result  Score 
S systolic BP < 90mmHg (2 points):   
M multilobar involvement (1 point):   
A albumin < 35g/L (1 point)   
R respiratory rate 25br/min or more (30br/min in 
>50yrs) (1 point) 
  
T tachycardia 125bpm or more (1 point)   
C confusion (acute) (1 point)   
O Oxygen low- PaO2<70 (<60 for over 50yrs)  
O2 sat 93% or less (90% or less for > 50 yrs)(2 
pts) 
  
P pH < 7.35 (2 points)   
      SMART-COP score (greater than or equal to 5 = 
severe) 
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Symptoms:   Cough – Y   N   U        Sputum – Y  N  U    Fever – Y   N   U         
Dyspnoea – Y   N   U 
 
Severity score documented:   Y   N   Unknown Which score/result: 
_________________ 
 
Sputum sample taken: Yes     No     Unknown   
 
Sputum result:  Pathogen(s)_____________     Negative     Contaminated 
 
Allergies/Adverse drug reactions  ________________________________  
 
Type of reaction: _____________________________________________ 
 
Antibiotics given prior to ED (or “none”): __________________________________ 
 
Initial antibiotic regimen 
Antibiotic Dose Frequency Correct, 
Low, 
High, 
Unclear 
Route Right 
drug? 
* 
ID/micro 
approved? 
       
       
       
       
 * Completely, Partially, Not at all, Unclear 
 
Antibiotic: who ordered it:  AMO  AMO'sReg   AMO'sJMO   EDCons   EDReg   
EDJMO   Unk 
 
Who charted it:  AMO  AMO'sReg   AMO'sJMO   EDCons   EDReg   
EDJMO   Unk 
 
Medication changed by team:   Yes   No   Unk    Date: _______ To what: 
____________________ 
 
20a. Total duration ABx in hospital: _______ days      20b. Days of ABx given at D/C: 
________ days 
 
21a. Discharge date: _______   21b. Date of death (if applicable): 
____________ 
 
       22. Final diagnosis/es: __________________________________________________ 
23.Comments:____________________________________________________________
________________________________________________________________________ 
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Ethics materials and data collection form reported in Chapter 4. 
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Clostridium difficile project data collection form 
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1a. Patient audit number: _______                   1b. Site: ________ 
 
2a. Initials (eg. JoSm): First _ _   Last _ _          2b. MRN: ___________ 
 
3a. Date of birth: __________________          3b. Sex:  M   F   Other 
 
4a. Date admitted: __________________       4b. Date discharged: __________________ 
 
5a. Admitting consultant: _________________________ 5b. Unit: 
___________________ 
 
6a. Date of diagnosis: ___________________ 6b. Micro Episode no. 
_______________ 
 
7a. Was C. diff diarrhoea the reason for admission?  Y / N / U 
 
7b. If NO, reason: ______________________________________________ 
 
8. Date of discharge for most recent admission (if applicable): ___________________ 
 
9. Primary classification:      a. HCA-inpatient   b. HCA-outpatient definite (within 4 
weeks of discharge) 
   
 c. HCA-O probable (4-8 weeks)   d. HCA-O possible (8-12 weeks)    e. Nursing 
home    f. Community 
 
10. If health care associated:   a. Hospital of likely origin ______________b. Ward: 
___________ 
 
 c. Consultant: ________________________  d. Unit: 
______________________ 
 
11. Potential risk factors   Y/N/U  Drug + dose + 
indication/procedure if Yes 
 a. Current PPI use   _____ 
 _______________________________ 
 b. Current H2 antagonist  _____ 
 _______________________________ 
 c. Antiperistaltic use   _____ 
 _______________________________ 
 d. GI surgery within 30 days  _____ 
 _______________________________ 
 
12. Co-morbidities   Y/N/U 
 a. Current malignancy    _____ 
 _______________________________ 
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 b. Immunosuppressive drugs  _____ 
 _______________________________ 
 c. Immunosuppressive illness  _____ 
 _______________________________ 
 
13. Other important risk factors / co-morbidities / contributory factors 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________ 
14. Current antibiotic use  
 a. Antibiotic use at time of diagnosis  Y / N / U 
 b. Name of antibiotic  IV/Oral  Dose/Frequency/Duration      
Indication 
      _______________  ______  ______________________    
______________ 
      _______________  ______  ______________________    
______________ 
      _______________  ______  ______________________    
______________ 
      _______________  ______  ______________________    
______________ 
 
15. Previous antibiotic use 
 a. Antibiotic use 1 month prior to diagnosis Y / N / U 
 b. Name of antibiotic  IV/Oral  Dose/Frequency/Duration      
Indication 
      _______________  ______  ______________________    
______________ 
      _______________  ______  ______________________    
______________ 
      _______________  ______  ______________________    
______________ 
      _______________  ______  ______________________    
______________ 
  
 c. If off antibiotics at diagnosis, date last antibiotic stopped: 
__________________ 
 
16. Initial Treatment 
 a.     Drug   IV/Oral         Date started
 Dose/Frequency/Intended duration 
     _______________  ______         __________
 _____________________________ 
     _______________  ______         __________
 _____________________________ 
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     _______________  ______         __________
 _____________________________ 
 
17a. Did AMS recommend changing treatment?  Y / N / U 
17b. AMS-recommended treatment 
 a.      Drug   IV/Oral         Date started
 Dose/Frequency/Intended duration 
     _______________  ______         __________
 _____________________________ 
     _______________  ______         __________
 _____________________________ 
     _______________  ______         __________
 _____________________________ 
 
18. Were other antibiotics withdrawn within 48 hours of diagnosis? 
 a. Completely (stat)   b. Completely (< 48hrs)   c. Partially   d. Changed   e. Not at 
all   f. Unknown 
 
19a. ICU required?  Y / N / U  19b. Surgery required?   Y / N / U 
 
20. Mortality 
 a. 7 days: Alive / Died / Unk    b. Discharge: Alive / Died / Unk    c. 30 days: 
Alive / Died / Unk 
 
21. Comments 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________________________________________ 
________________________________________________________________________
____________________   
 
Please return to Stuart Bond, Pharmacy, 4222 5646 or pager #263 
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